Molecular genetic analysis of familial breast cancer in South Africa by Agenbag, Gloudi
  
Molecular Genetic Analysis of Familial 
Breast Cancer in South Africa 
 
 
 
By 
 
Gloudi Agenbag 
 
 
 
 
 
Thesis presented in partial fulfilment of the requirements for the degree of  
Master of Science (MSc) in Genetics at the University of Stellenbosch. 
 
 
 
Studyleader:  Prof L Warnich 
Co-studyleader:  Dr MJ Kotze 
 
 
 December 2005 
 
 
 DECLARATION 
 
I, the undersigned, hereby declare that the work contained in this thesis is my own original work and 
that I have not previously in its entirety or in part submitted it at any university for a degree. 
 
Signature:  _________________________________ Date:  _____________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University http://scholar.sun.ac.za
   
  
ABSTRACT  
 
Breast cancer is a major cause of morbidity and mortality as it is the most common invasive cancer in 
women worldwide.  The lifetime risk for South African women to develop breast cancer is one in 31.  
A family history of the disease is a well-established risk factor and germline mutations in the BRCA1 
(breast cancer one) and BRCA2 (breast cancer two) tumour suppressor genes markedly increase the risk 
of developing breast cancer.  A few hundred mutations spanning the entire coding sequences of both 
genes have already been reported.  Numerous other breast cancer susceptibility loci have been 
identified, but results from association studies are discrepant.  The checkpoint kinase gene, CHEK2, 
and specifically the CHEK2*1100delC variant has, however, consistently been implicated as a 
candidate low-penetrance breast cancer allele.  To date, few comprehensive molecular-genetic studies 
have been completed for the various South African breast cancer populations.   
 
The aim of this study was to determine the BRCA1 and BRCA2 mutation spectrum and prevalence in 
two South African populations, namely Mixed Ancestry and Caucasian.  The frequency of the 
CHEK2*1100delC mutation was also investigated.  The patient group comprised 101 unrelated patients 
(98 women and 3 men), presenting with invasive breast cancer.  Patients with a moderate family history 
of breast cancer (n=48) were screened for the CHEK2*1100delC allele and the coding sequences of the 
BRCA1 (partly completed in a previous study) and BRCA2 genes.  Patients without a family history of 
the disease (n=53) were only screened for the CHEK2*1100delC allele.  Mutation detection was done 
using combined single-strand conformation polymorphism and heteroduplex analysis (SSCP/HA), 
followed by DNA sequencing of the identified variants.  Due to its size (~5kb), exon 11 of BRCA2 was 
sequenced directly after amplification, in seven overlapping fragments. 
 
Three deleterious BRCA1 mutations, 1623_1627delTTAAA, E881X and 5313delC have previously been 
identified in three patients from the study population.  No additional pathogenic mutations have been 
detected in this gene during this study.  Two deleterious BRCA2 mutations, 6677_6678insTA and 
8162delG, were identified in two and three patients respectively.  Overall, BRCA1 and BRCA2 
mutations have been identified in 17% of the Mixed Ancestry patients and in 15.8% of the Caucasian 
patients.  Together BRCA1 and BRCA2 mutations account for 16.7% of breast cancer in the study 
population.  In addition, a number of silent polymorphisms as well as variants of unknown functional 
significance, both known and novel, were identified.   
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The E881X variant, which has been reported as an Afrikaner founder mutation (Reeves et al. 2004), 
was identified in one patient of Mixed Ancestry, but none of the published European founder mutations 
have been detected in our patient group.  This suggests a unique mutation spectrum for South African 
breast cancer patients.  The prevalence of the BRCA2 mutations, 8162delG and 6677_6678insTA, has 
to be elucidated within a larger study group.  Haplotype analysis will reveal whether these patients 
have a common ancestor.  Our findings do not suggest the presence of the CHEK2 variant in South 
African breast cancer patients, but a larger study population has to be analysed to confirm this. 
 
The results of this study are in agreement with those from other populations, indicating that less than 
20% of breast cancers that occur in individuals with a moderate-risk for developing breast cancer are 
due to BRCA1 and BRCA2 mutations.  By determining the contribution of BRCA1 and BRCA2 
mutations to breast cancer in this group of patients, one can assess the appropriateness of predictive or 
diagnostic DNA testing in the clinical setting.     
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OPSOMMING 
 
Borskanker is ’n belangrike oorsaak van morbiditeit en sterftes aangesien dit die mees algemene vorm 
van kanker in vroue wêreldwyd is.  Die risiko vir ŉ Suid-Afrikaanse vrou om borskanker te ontwikkel 
is een in 31.  ’n Familiegeskiedenis van die siekte is ’n bevestigde risikofaktor, en kiemlyn-mutasies in 
die BRCA1 (“breast cancer one”) en BRCA2 (“breast cancer two”) gewasonderdrukker gene verhoog 
die risiko om borskanker te ontwikkel aansienlik.  ’n Paar honderd mutasies in die koderende volgordes 
van beide gene is reeds gerapporteer.  Talryke ander borskanker vatbaarheidslokusse is reeds 
geïdentifiseer, maar resultate van assosiasie-studies is teenstrydig.  Die sel-sikluskontrolepunt geen, 
CHEK2, en meer spesifiek die CHEK2*1100delC variant, is konsekwent aangedui as ’n moontlike lae- 
penetrasie borskanker-alleel.  Tot op hede is min omvangryke molekulêre genetika studies gedoen oor 
borskanker in die onderskeie Suid-Afrikaanse bevolkingsgroepe. 
 
Die doel van hierdie studie is om die BRCA1 en BRCA2 mutasiespektrum en voorkoms te bepaal in 
twee Suid-Afrikaanse bevolkingsgroepe, naamlik Gemengde Herkoms (Kleurling) en Kaukasiër.  Die 
frekwensie van die CHEK2*1100delC mutasie is ook vasgestel.  Die pasiëntegroep het bestaan uit 101 
onverwante individue (98 vroulik en 3 manlik) met borskanker.  Pasiënte met ’n familiegeskiedenis van 
borskanker (n=48) is gesif vir die CHEK2*1100delC alleel en vir die koderende volgordes van die 
BRCA1 (gedeeltelik afgehandel in ’n vorige studie) en BRCA2 gene.  Pasiënte sonder ’n 
familiegeskiedenis van die siekte (n=53) is slegs gesif vir die CHEK2*1100delC alleel.  Mutasie- 
opsporing is gedoen met behulp van enkelstring konformasie polimorfisme en heterodupleks analise 
(SSCP/HA), gevolg deur DNS-volgordebepaling van die geïdentifiseerde variante.  As gevolg van sy 
grootte (~5kb), is ekson 11 van BRCA2 in sewe oorvleuelende fragmente geanaliseer deur middel van 
direkte volgordebepaling ná amplifikasie.  
 
Drie patogeniese BRCA1 mutasies, 1623_1627delTTAAA, E881X en 5313delC, is voorheen 
geïdentifiseer in drie pasiënte uit die studiegroep.  Geen bykomende mutasies is opgespoor in die geen 
gedurende hierdie studie nie.  Twee patogeniese BRCA2 mutasies, 6677_6678insTA en 8162delG, is 
geïdentifiseer in twee en drie pasiënte onderskeidelik.  In die geheel is BRCA1 en BRCA2 mutasies 
geïdentifiseer in 17% van die Gemengde Herkoms pasiënte en in 15.8% van die Kaukasiër pasiënte.  
Gesamentlik is BRCA1 en BRCA2 mutasies verantwoordelik vir 16.7% van borskanker in die 
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studiegroep.  Daarbenewens is ’n aantal bekende en nuwe polimorfismes, asook variante waarvan die 
funksionele betekenis onbekend is, geïdentifiseer.   
 
Die E881X variant, wat gerapporteer is as ’n Afrikaner stigtermutasie (Reeves et al. 2004), is 
geïdentifiseer in een pasiënt van Gemengde Herkoms, maar geen algemeen bekende Europese 
stigtermutasies is gevind in die pasiënt groep nie.  Dit dui op ’n unieke mutasiespektrum vir Suid-
Afrikaanse borskankerpasiënte.  Die voorkoms van die BRCA2 mutasies, 8162delG en 
6677_6678insTA, behoort bepaal te word in ’n groter studiegroep.  Haplotipe analise sal aan die lig 
bring of hierdie pasiënte ’n gemeenskaplike voorouer het.  Die bevindings van hierdie studie toon nie 
die teenwoordigheid van die CHEK2 variant in die Suid-Afrikaanse bevolking nie, maar ’n groter 
studiegroep moet ondersoek word om dit te bevestig.   
 
Die resultate van hierdie studie is in ooreenstemming met studies in ander bevolkings, wat daarop dui 
dat minder as 20% van borskankers wat voorkom in individue met ’n matige risiko vir borskanker, as 
gevolg van BRCA1 en BRCA2 mutasies is.  Met die vasstelling van die bydrae wat BRCA1 en BRCA2 
mutasies lewer tot borskanker in die pasiëntgroep, kan die toepaslikheid van DNS-toetsing in ’n 
kliniese omgewing vasgestel word. 
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List of Abbreviations and Symbols 
 
%    Percentage 
®    Registered trademark 
°C    Degrees Celsius 
A    Adenine (in DNA sequence) 
Acetic acid   CH3COOH 
Acrylamide   C3H5NO 
AC±T     Adriamycin, Cytoxan and Taxol or Taxotene (chemotherapy) 
ADH    Atypical ductal hyperplasia 
AF-2    Activation function domain of ER-α 
AI    Aromatase inhibitors 
Ala    Alanine (amino acid) 
ALH    Atypical lobular hyperplasia 
Alu    Short interspersed nuclear element, characterised by the AluI restriction  
enzyme 
APS    Ammonium persulphate 
AR    Androgen receptor 
Arg    Arginine (amino acid) 
Asn    Asparagine (amino acid) 
ASO    Allele specific oligonucleotides 
Asp    Aspartic acid (amino acid) 
ATM    Ataxia telangiectasia mutated 
ATR     Ataxia telangiectasia and RAD3 related 
Aurora-A   Aurora kinase A (Aurora2/STK15/BTAK) 
BACH1    BRCA1-associated carboxyl-terminal helicase  
BAP1    BRCA1-associated protein 
BARD1    BRCA1-associated RING domain 
BASC     BRCA1-associated genome surveillance complex  
BC    Breast cancer 
BIC    Breast Cancer Information Core 
Bisacrylamide   N,N’-methylene-bis-acrylamide: C7H10O2N2 
BLM    Bloom syndrome (DNA helicase RecQ protein-like-3, RECQL3) 
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Boric acid   H3BO3 
bp    Base pair 
BRAF35   BRCA2-associated factor 
BRC    BRCA2 repeat motif 
Brca1    BRCA1 murine homolog  
BRCA1    Breast cancer susceptibility gene 1 
Brca2    BRCA2 murine homolog 
BRCA2    Breast cancer susceptibility gene 2 
BRCA3    Breast cancer susceptibility gene 3  
BRCA2DBD   BRCA2 DNA/DSS1-binding domain 
BRCT     BRCA1 carboxyl-terminal 
BRIP1     BACH1-BRCA1-associated C-terminal helicase-1 
Bromophenol blue   3’,3’’,5’,5’’-tetrabromophenolsulfonephthalein: C19H10Br4O5S 
BTAK    Breast tumour amplified kinase (Aurora-A/STK15) 
C    Cytosine (in DNA sequence) 
cAMP    3’5’-cyclic adenosine monophosphate 
Canis familiaris  Dog 
CANSA   Cancer Association of South Africa 
CCD    Charge-coupled device 
Cdc2    Cell cycle division 2 
Cdc25A   Cell cycle division 25A 
Cdc25C   Cell cycle division 25C 
CDK2    Cyclin-dependent kinase 2    
cDNA    Complementary deoxyribonucleic acid 
CDS1    CDP-deacylglycerol synthase 1 
CDP    Phospatidate cytidylyltransferase 1 
CH3COOH   Acetic acid 
CHEK2/CHK2   Checkpoint kinase 2 gene 
CMF     Combination of Cytoxan, Methotrexate and 5-Fluorouracil (chemotherapy) 
COMT    Catechol-O-methyltransferase 
CSGE     Conformation sensitive gel electrophoresis 
CtBP    C-terminal-binding protein 
CtIP    CtBP-interacting protein 
CYP    Cytochrome P450 superfamily 
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D    Aspartic acid (amino acid) 
dATP    2’-Deoxyadenosine-5’-triphosphate 
DCIS    Ductal carcinoma in situ 
dCTP    2’-Deoxycytidine-5’-triphosphate 
ddNTP    Dideoxynucleotide triphosphate 
del    Deletion 
DGGE    Denaturing gradient gel electrophoresis 
dGTP    2’-Deoxyguanosine-5’-triphosphate 
dH2O    Distilled water 
dHPLC    Denaturing high-performance liquid chromatography 
DNA    Deoxyribonucleic acid 
dNTP    Deoxynucleotide triphosphate 
DPD2    Dopamine receptor D2 
DS    DNA sequencing 
DSB    Double strand break 
dsDNA    Double-stranded DNA 
DSS1    Deleted in split-hand/split-foot 1 region 
dTTP    2’-Deoxythumidine-5’-triphosphate 
DZ    Dizygotic 
E    Glutamic acid (amino acid) 
EDTA    Ethylenediamine tetra-acetic acid: C10H16N2O8 
e.g.    Exempli gratia (Latin abbreviation for “for example” 
ER    Estrogen receptor 
ERD    Estrogen receptor down-regulators 
et al.     Et alia (Latin abbreviation for “and others”) 
EtBr    Ethidium bromide (2,7-diamino-10-ethyl-9-phenyl-phenanthridinium  
bromide): C21H20BrN3 
EtOH    Ethanol: CH3CH2OH 
F    Phenylalanine (amino acid) 
FANCD1   Fanconi anaemia complementation group 1  
FCCM    Fluorescent chemical cleavage of mismatch 
FH    Familial hypercholesterolemia 
FHA    Fork head associated 
FNAB    Fine needle aspiration biopsy 
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Formaldehyde   HCHO 
Formamide   HCONH2 
G    Glycine (amino acid) 
g    Gram 
G    Guanine (in DNA sequence) 
G1-phase   Growth phase 1 of cell cycle    
G2-phase   Growth phase 2 of cell cycle 
GADD45   Growth-arrest- and DNA damage-inducible 45    
gDNA    Genomic deoxyribonucleic acid 
Gln    Glutamine (amino acid) 
Glu    Glutamic acid (amino acid) 
Gly    Glycine (amino acid) 
Glycerol   C3H5(OH)3 
GSTM1   Glutathione S-transferase-μ1 
GSTT1    Glutathione S-transferase-θ 1 
H    Histidine (amino acid) 
H2AX    histone species 
HA    Heteroduplex analysis 
HBCC    Hereditary breast and colorectal cancer 
HCHO    Formaldehyde 
He    Heterozygous 
HER-2    HER-2 protein, derived from human EGFR (epidermal growth factor  
receptor) 2, also known as c-erbB-2 or neu 
His    Histidine (amino acid) 
Ho    Homozygous 
HR    Homologous recombination 
HRAS1    Harvey rat sarcoma viral oncogene homolog 1 
HRT    Hormone replacement therapy 
HWE    Hardy-Weinberg equilibrium 
I    Isoleucine (amino acid) 
ICAM    Intracellular adhesion molecule 
IDC NOS   Ductal carcinoma not otherwise specified 
i.e.    Id est (Latin abbreviation for “that is”) 
ILC    Invasive lobular carcinomas 
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Ile    Isoleucine (amino acid) 
Inc    Incorporated 
ins    Insertion 
in utero    Latin abbreviation for “in the uterus” 
in vitro    Latin abbreviation for “in a test tube” 
IR    Ionizing radiation 
IVS    Intervening sequence 
K    Lysine (amino acid) 
kb    Kilo base pair 
kD    Kilo Dalton 
L    Leucine (amino acid) 
LCIS    Lobular carcinoma in situ 
LDLR    Low-density lipoprotein receptor 
Leu    Leucine (amino acid) 
LH    Luteinizing hormone-releasing 
LKB1    Serine/threonine protein kinase 11 (STK11) 
LOH    Loss of heterozygosity 
Lys    Lysine (amino acid) 
M    Methionine (amino acid)  
M    Molar (moles per litre) 
M    Pathogenic mutation 
melt-MADGE   Melt-point analysis by microplate-array diagonal-gel electrophoresis 
Met    Methionine (amino acid) 
mg/ml    Milligrams per millilitre 
MIM    Mendelian Inheritance in Man 
ml    Millilitre 
mm    Millimetre 
mM    Millimolar 
M-phase   Mitotic phase of cell cycle 
MPLA    Multiplex ligation-dependent probe amplification 
MRE11    Mitotic recombination 11 
MRI    Magnetic resonance imaging 
mRNA    Messenger ribonucleic acid 
MSH1    Bacterial Muts homolog 1 
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MSH2    Bacterial Muts homolog 2 
MSH6    Bacterial Muts homolog 6 
MTHFR   Methylenetetrahydrofolate reductase  
Mus musculus   House mouse 
MvaI    Restriction endonuclease isolated from Micrococcus varians RFL19, with  
recognition site 5’-CC↓WGG-3’ 
MYC    Myelocytomatosis viral oncogene homolog 
MZ    Monozygotic 
N    Asparagine (amino acid) 
n    Sample size 
NAT1    N-acetyltransferase 1 
NAT2    N-acetyltransferase 2 
NBR1     Next to BRCA1 one gene 
NBR2     Next to BRCA1 two gene 
Nbs1    Nijmegen breakage syndrome 1 
NCBI    National Center for Biotechnology Information 
ng    Nanogram 
ng/μl    Nanograms per microlitre 
NHEJ    Non-homologous end joining 
NLS    Nuclear localization signal 
NOS    Not otherwise specified 
NuMA    Nuclear mitotic apparatus 
OB1    Oligonucleotide/oligosaccharide-binding 1 
OB2    Oligonucleotide/oligosaccharide-binding 2 
OB3    Oligonucleotide/oligosaccharide-binding 3 
OCCR    Ovarian cancer cluster region 
OR    Odds ratio 
p    Chromosome short arm 
p    Pagination (page number) 
P    Polymorphism  
P    Probability 
P    Proline (amino acid) 
P/CAF    p300/CBP-associated factor 
PBS    Phosphate buffered saline 
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PCR    Polymerase chain reaction 
pH    Potential of Hydrogen 
PM5    Polymorphism 5 
PM6    Polymorphism 6 
PM7    Polymorphism 7 
pmol/μl    Picomolar per microlitre 
PR    Progesterone receptor 
Pro    Proline (amino acid) 
pS2    Presenilin 2 
PTEN    Phosphatase and tensin homolog 
PTT    Protein truncation test 
q    Chromosome long arm 
Q    Glutamine (amino acid) 
R    Arginine (amion acid) 
RAD51    Eukaryotic homolog of bacterial RecA 
RAD53    Saccharomyces cerevisiae homolog of human CHEK2 
RB    Retinoblastoma 
rcf    relative centrifugal force 
RFLP    Restriction fragment length polymorphism 
RING     Zinc-chelating domain 
RNA    Ribonucleic acid 
ROS    Reactive oxygen species 
S    Serine (amino acid) 
SDS    Sodium dodecyl sulphate: C12H25NaSO4 
Ser    Serine (amino acid) 
SERM    Selective estrogen receptor modulators 
Silver nitrate   AgNO3 
S-phase    DNA synthesis phase of cell cycle 
SSA    Single-strand annealing 
SSCP    Single strand conformation polymorphism 
ssDNA    Single-stranded DNA 
STK11    Serine/threonine protein kinase 11 (LKB1) 
STK15    Serine/threonine protein kinase 15 (Aurora-A/BTAK) 
T    Threonine (amino acid) 
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T    Thymine (in DNA sequence) 
Taq    DNA polymerase (EC 2.7.7.7) isolated from Thermus aquaticus 
TBE    Tris borate-EDTA buffer (5X TBE: 0.089M Tris; 0.089M boric acid;  
0.002M EDTA) 
TDLU    Terminal duct lobular units 
TEMED    N,N,N’,N’-tetrametylethylenediamine 
Temp    Temperature 
TFPGA    Tools for Population Genetic Analysis 
TGGE     Thermal gradient gel electrophoresis 
Thr    Threonine (amino acid) 
TP53    Tumour protein 53 
Tris    2-Amino-2-(hydroxymethyl)-1,3-propanediol: C4H11NO3 
Trp    Tryptophan (amino acid) 
™    Trademark 
U    Units 
UK    United Kingdom 
Urea    CH4N2O 
US    United States 
UTR    Untranslated region 
UV    Ultraviolet 
UV    Unclassified variant 
V    Valine (amino acid) 
V    Volts 
v/v    Volume per volume 
VDR    Vitamin D receptor 
Versus    Latin abbreviation for “against” 
VNTR    Variable number of tandem repeat 
W    Adenine or Thymine (in DNA sequence) 
w/v    Weight per volume 
WT    Wild type 
X    Stop codon (UAA, UAG or UGA) 
XRCC1   X-ray repair cross-complementation group 1 
XRCC2   X-ray repair cross-complementation group 2 
XRCC3   X-ray repair cross-complementation group 3 
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 IX
Xylene cyanole   Xylene cyanole FF: C25H27N2NaO6S2   
ZBRK1    Zinc finger and BRCA1 interacting protein with a KRAB domain 1 
α    Alpha 
β    Beta 
μ    Mu 
μg/ml    Micrograms per millilitre 
μM    Micromolar 
ψBRCA1   BRCA1 pseudogene 
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lanes (M) of each gel, with the 500bp band indicated.  Lanes A1 to M2 represent the 
different fragments for exon 11, with the negative control loaded in the third lane of 
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molecular marker is loaded in the first lane (M).  Lanes 1 to 3 represent the exon 10 
fragment of the CHEK2 gene, with the negative control loaded in lane 4.      p95 
 
Figure 4.16   Electrophoresis performed on a Mighty Small polyacrylamide gel to determine which 
program was optimal for PCR amplification.  Lane 1 and 2: touch-down PCR program 
D (65→60°C); lane 3 and 4: two-step PCR program C (65/60°C); lane 5 and 6: touch-
down PCR program D (64→59°C); lane 7 and 8: two-step PCR program C (64/60°).  
Lane 3 is indicative of a single amplification product, all other lanes represent non-
specific amplification of homologous sequences.  Amplification was unsuccessful of the 
sample loaded in lane 4.             p96 
 
Figure 4.17   Results obtained from the automated sequencing in the sense (5’→3’) direction of the 
CHEK2 exon 10 fragment with.  The bases discriminating the exon 10 fragment on 
chromosome 22 from the pseudogene on chromosome 15 are indicated.                     p97 
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1.  INTRODUCTION 
 
Mammary carcinoma (breast cancer MIM #114480) refers to cancer of the breast epithelial tissue, a 
histopathologically, etiologically and genetically heterogeneous disease.  Currently it is the most 
common invasive cancer in women worldwide, with incidence rates the highest in industrialized 
nations such as the United States, Australia and countries in Western Europe (Ghafoor et al. 2003).  
Although the mortality rate has decreased during the 20th century, incidence has increased (Althuis et 
al. 2005).  This trend can only partly be accounted for by the increased use of early diagnostic and 
screening techniques.  The risk of a woman developing breast cancer during her lifetime is one in seven 
among women from the United States (Jemal et al. 2005), one in nine among British women (UK 
National Statistics Online www.statistics.gov.uk) and one in 66 among Japananese women (Japan 
National Cancer Centre www.ncc.go.jp).  The lifetime risk for South African women to develop breast 
cancer is one in 31 (CANSA statistics www.cansa.org.za).  Two-thirds of breast cancers are detected in 
postmenopausal women.   
 
Breast cancer remains a major cause of morbidity and mortality worldwide and despite intensive 
research efforts, consensus agreement on management has proved difficult.  This could partly be 
attributed to the complexity of the disease, which has widely differing biological backgrounds.  
Understanding the molecular basis of malignancy will allow more rational surveillance, prevention and 
treatment in future. 
 
A family history of breast cancer has been a well-established risk factor for the disease for more than 
five decades (Gardner and Stephens 1950).  Many impressive pedigrees supporting the existence of 
these dominant highly penetrant breast and/or ovarian cancer genes have been published, but the first 
convincing localization of a breast cancer gene, BRCA1 (MIM #113705), was only achieved in 1990 by 
linkage analysis (Hall et al. 1990).  A second gene, BRCA2 (MIM #600185), was mapped in 1994 
(Wooster et al. 1994).  Although mutations in the BRCA1 and BRCA2 genes may explain the majority 
of familial breast cancer (refer to chapter two for a detailed review of the literature), familial breast 
cancer has been repeatedly shown to constitute only 5-10% of all breast cancer cases.   
 
 1
Stellenbosch University http://scholar.sun.ac.za
CHAPTER ONE           INTRODUCTION
___________________________________________________________________________________ 
 
Germline mutations in the BRCA1 and BRCA2 tumour suppressor genes markedly increase the risk of 
developing breast and ovarian cancer.  They are examples of Mendelian inheritance of susceptibility to 
a common, genetically complex, adult-on-set disease.  One defective copy of BRCA1 or BRCA2 in the 
germline may be enough to cause cancer predisposition, but the wild-type allele is often inactivated 
through loss of heterozygosity (LOH) with retention of the mutant allele (Smith et al. 1992).  The exact 
magnitude of this risk, that is, the penetrance of mutations in these genes, remains controversial.  The 
CHEK2 gene (MIM #604373), which is a cell cycle checkpoint kinase, has recently been shown 
(Meijers-Heijboer and The CHEK2-Breast Cancer Consortium 2002) to be a plausible candidate low-
penetrance breast cancer gene.  Various other breast cancer susceptibility loci have been identified, 
including putative BRCA3 loci; unfortunately none of these have been clearly elucidated.   
 
BRCA1 and BRCA2 are both relatively large genes and a few hundred mutations spanning the entire 
coding sequences of both have already been reported (Breast Cancer Information Core database 
http://research.nhgri.nih.gov/bic).  Mutation frequencies vary among different ethnic and 
geographically distinct populations.  Almost all studies performed to date have defined breast cancer 
risks and related genetic factors in women of European descent.  Few BRCA1 and BRCA2 studies have 
been done in any of the African populations or in the African American population.  Even less 
comprehensive molecular-genetic studies have been completed for the various South African 
populations.  To be able to implement predictive genetic testing for BRCA1 and BRCA2 mutations 
successfully in South Africa, the genes have to be characterised in South African breast cancer 
families.  The mutation spectrum has to be determined and possible founder mutations identified.  The 
molecular implications of new variants have to be elucidated in order to distinguish benign 
polymorphisms from pathogenic mutations. We are boldly moving into the age of genetics, by joining 
forces with patients, health care professionals, genetic counsellors and biotechnology companies, to 
define the settings in which genetic testing will become an indispensable tool used to improve clinical 
outcomes.  
 
Chapter two provides a detailed look at breast cancer as a disease, both clinically and molecularly.  The 
functions of the BRCA1, BRCA2 and the CHEK2 gene in the normal cell cycle are discussed as well as 
the role these genes play in malignant progression.  Available literature is presented to assess the 
relationship these genes have to hereditary breast cancer.  In chapter three the materials and methods 
used to conduct this study are presented.  Results are reported in chapter four, followed by a discussion 
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of the results in chapter five, which concludes this study with a short discussion of the relevance of this 
particular study for South African breast cancer patients. 
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2.  LITERATURE REVIEW 
 
2.1  BREAST CANCER INCIDENCE AND EPIDEMIOLOGY IN SOUTH AFRICA 
 
The source of information on cancer incidence and mortality in South Africa is the National Cancer 
Registry, which collects information from pathology laboratories on cancers histologically diagnosed 
(Vorobiof et al. 2001).  These statistics, which are reported on the CANSA website 
(www.cansa.org.za), are an underestimate of the true incidence of cancer, since not all individuals have 
their cancer clinically diagnosed.  In South Africa a total of 4789 new cases of female breast cancer 
were reported in 1997 (16.4% of all cancers reported).  Incidence rates vary enormously between South 
Africa’s ethnic groups, a trend that is at present not completely understood.  The lifetime risk (null to 
74 years) for women is one in 31 overall, but varies from one in 57 among African, one in 16 among 
Caucasian and Mixed Ancestry, to one in 13 among Asian women.  Previously, incidence was 
calculated separately for Caucasian and Mixed Ancestry women.  The lifetime risk was one in 13 
among Caucasian and one in 63 among women from Mixed Ancestry.  For Caucasian and Mixed 
Ancestry men the lifetime risk is one in 667.  Age standardised rates (expressed in new cases per 100 
000 people per year) for Caucasian South Africa women from 1993 to 1995 (70.2 per 100 000) was 
comparable to rates from developed countries, such as the United Kingdom (114 per 100 000) (UK 
National Statistics Online www.statistics.gov.uk) and the United States (135 per 100 0000) (Jemal et 
al. 2005).  In 1997 the combined age standardized rate for Caucasian and Mixed Ancestry women was 
55.49 per 100 000, but the average rate for all racial groups was only 29 women per 100 000 and 1.1 
men per 100 000.  
 
2.2  NORMAL STRUCTURE OF THE BREAST 
 
The breast is a collection of glands, fibrous connective tissue and adipose tissue that lies between the 
skin and the chest wall.  The glands are called lobules, and many lobules make up a lobe.  There are 
about 15 to 20 lobes in each breast.  Milk is transported to the nipple from the glands by way of tubes 
called the ducts.  A system of 15 to 20 ducts, converging at the nipple, branch out into the fatty mass of 
the breast and end in thousands of lobules (refer to Figure 2.1).  The lobules are small secretory units, 
called the terminal duct lobular units (TDLU) (Russo and Russo 2004).  The TDLU are highly folded 
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globular aggregates of tubules in a cellular stroma, which is composed of specialized and functionally 
active mesenchymal cells.  The stromal cells secrete, sequester or activate cytokines and growth factors 
and secrete matrix components, all of which influence growth and differentiation of the epithelial 
compartment.  Each tubule is lined by an inner layer of cuboidal epithelial cells surrounded by a layer 
of basal or myoepithelial cells, which are a network of specialized cells with both epithelial and 
mesenchymal characteristics.  The myoepithelial cells secrete the basement membrane of the secretory 
units and have an influence on development and function of the TDLU.  The TDLU can enlarge and 
unfold under hormonal stimulation (e.g. lactation) or in neoplasia, giving rise to larger diameter spaces.  
The breast epithelial and stromal cells are responsive to female hormones, particularly estrogen, 
progesterone and prolactin, and express the corresponding receptors.  Androgens cause atrophy of these 
cells (Reviewed in Stamp 2002). 
 
There are also blood vessels and lymph vessels in the breast.  Most of the lymph nodes that drain the 
breast are under the arm in what is called the axilla. 
 
  
i 
ii 
Figure 2.1  i)  A schematic profile of the breast:  A – ducts, B – lobules, C - dilated section of  a duct 
as at times of lactation, D – nipple, E – adipose tissue, F - pectoralis major muscle, G - chest wall and 
rib cage.  ii)  Enlargement of a duct:  A - normal duct cells, B - basement membrane, C - lumen.   
Reprinted with permission from BreastCancer.org (www.breastcancer.org) and MK Bryson. 
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2.3  TYPES OF BREAST CANCER 
 
Breast cancers may be biopsied for histological examination using a fine gauge needle to extract a cell 
sample (fine needle aspiration biopsy, FNAB) or by extracting a tissue core.  Alternatively a surgical 
biopsy is undertaken under anaesthesia, removing part of or the entire lesion.  Axillary lymph nodes are 
sampled to assess for the presence of metastasis.  The term non-invasive or in situ carcinoma is used 
when the cancer cells are confined to the ducts or lobules where it initially developed.  Invasive or 
infiltrating carcinoma means that the cancer cells have invaded surrounding adipose and connective 
tissues of the breast.  Stage 0 is used to describe non-invasive breast cancer, with stages I, II and IIIA 
describing invasive breast cancer according to the size of the tumour, with (stage II and IIIA) or 
without (stage I) the involvement of the lymph nodes.  Stage IIIB describes invasive breast cancer in 
which a tumour of any size has spread to the breast epidermis, the chest wall or to the internal 
mammary lymph nodes.  Stage IV is the most advanced form of breast cancer with definite metastasis 
to other organs (Harris 1991).  
 
Breast tumours include several histopathological subtypes.  Within many of these subtypes there exists 
a spectrum of appearances.  Tumours could be composed of relatively small, monotonous cells with a 
low rate of cell proliferation showing some features of normal breast tissue organization.  These types 
of tumours are associated with a relatively benign prognosis.  Conversely, tumours could be composed 
of pleomorphic cells with little evidence of normal tissue architecture and these cancers are associated 
with relatively poor outcome.  Pathologists use different grading systems to qualify and quantify the 
neoplasm.  The Van Nuys prognostic index uses lesion size, nuclear grade and the presence or absence 
of necrosis as scoring parameters (Silverstein et al. 1995).  Another grading system is the modified 
Bloom and Richardson system (Elston and Ellis 1991), which assesses the architecture by estimating a) 
the proportion of the tumour in which the epithelial cells organize themselves into tubular structures, b) 
the cytology by the size and regularity of the nucleus (pleomorphism), and c) the biological behaviour 
by the number of mitotic figures per unit area.   
 
A simplified discussion of the main histological subtypes follows.  Tumours could consist entirely of 
only one type, or could be a combination of any of these (Reviewed in Stamp 2002). 
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2.3.1  In situ carcinoma 
 
In situ carcinomas arise within the TDLU.  They may spread to adjacent TDLU, but usually do not 
bridge the basement membrane.  If the cells do acquire the ability to bridge the basement membrane, 
they become invasive.  In situ carcinomas can assume a variety of patterns, including cribriform 
(aggregates of epithelial cells arranged around well-defined lumina), micropapillary (peripherally 
organized projections of epithelial cells towards a common central lumen), solid (with few organized 
lumina, but rather wall-to-wall cell growth) and comedo (similar to the solid pattern but with areas of 
necrosis, which indicates that it is a fast growing tumour) (Jaffer and Bleiweiss 2002).  
 
Lobular carcinoma in situ (LCIS) develops inside the lobules and tends to have a monotonous 
appearance compared to a lot of structural variation seen in ductal carcinoma in situ (DCIS), which is 
confined to the ducts.  Compared to DCIS, LCIS cells tend to be of uniform size with round to oval 
nuclei, less pleomorphism and usually a lower mitotic index.  DCIS is the most common kind of non-
invasive breast cancer.  Atypical ductal hyperplasia (ADH) is a small lesion, usually involving part of 
the TDLU, where the proliferation does not display all of the features of DCIS.  Atypical lobular 
hyperplasia (ALH) refers to cells that are cytologically similar to those of LCIS, but less extensively 
involve the TDLU and small ducts.  ALH and LCIS are usually grouped together under the term 
“lobular neoplasia” (Simpson et al. 2003).    
  
2.3.2  Invasive carcinoma  
 
2.3.2.1  Invasive ductal carcinoma 
 
Invasive or infiltrating ductal carcinoma not otherwise specified (IDC NOS) are composed of epithelial 
cells arranged in groups which show varying degrees of organization into glandular and tubular 
elements.  These tumours do not have special features that are characteristic of the other types 
encountered, hence the designation “not otherwise specified” (NOS) (Fisher 1977).  Tumours initially 
begin in the ducts, but soon spread into the surrounding tissue.  This is the most common type of breast 
cancer and accounts for approximately 70% of all breast cancers (Rahman and Stratton 1998).  There 
are some variants of IDC which have a distinctive appearance.  Tubular carcinoma is composed of 
well-formed tubular structures whereas infiltrating cribriform carcinoma has tubular elements which 
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are complex and have small regular lumina distributed within them.  In mucinous carcinomas (also 
called colloid or gelatinous carcinoma), the bulk of the tumour is composed of gelatinous secreted 
mucin which contains dispersed aggregates of neoplastic cells (Fisher 1977).  Medullary carcinomas 
are well circumscribed and are composed of large syncytial aggregates of very pleomorphic tumour 
cells with an intervening stroma densely infiltrated by lymphocytes and plasma cells (Fisher 1977).  
Secretory carcinoma repeats the lactational phenotype and has large vacuolated cells lining spaces 
which contain the secrete.   
 
2.3.2.2  Invasive lobular carcinoma 
 
Invasive lobular carcinomas (ILC) originate in the lobules.  Like IDC NOS, ILC is poorly cohesive and 
do not form large, well-defined, glandular elements.  Cells tend to invade independently.  About 10% 
of all breast cancers are of this type (Cocquyt and Van Belle 2005).  There are a number of variant 
patterns, including the solid pattern, pleomorphic and signet ring variants (Weidner and Semple 
1992).  Better differentiated variants include the alveolar type, in which the cells form loose aggregates 
and the tubulo-alveolar type, where one will find poorly formed tubules. 
 
2.3.2.3  Inflammatory breast cancer 
 
Although this type of cancer is not common (about 1% of all breast cancers) it is an aggressive type of 
breast cancer that is considered stage IIIB.  Inflammatory carcinoma is in fact a distinct 
clinicopathological subset of IDC (Felix 1999).  The most distinguishing feature is the appearance of 
inflamed breasts with dimples and/or thick ridges caused by cells blocking lymph vessels in the breast 
epidermis.  This type of cancer could be mistaken for an infection. 
 
2.3.2.4  Paget’s disease of the nipple 
 
This is another rare form of breast cancer (also only occurring in 1% of all cases) which begins in the 
ducts and spreads to the skin of the nipple and areola.  This type of cancer may be associated with in 
situ or invasive carcinoma.  It could be caused by the spread of tumour cells from the ducts or lobules, 
but it may also be that the actual epithelial cells of the nipple spontaneously become cancerous.  
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Approximately 30-40% of women with Paget’s disease have metastasis at the time of surgery (Felix 
1999).   
 
2.3.2.5  Other rare variants of breast carcinoma 
 
A wide variety of uncommon differentiation patterns may be encountered in breast cancers.  They 
include extreme variants of morphology or metaplastic differentiation such as signet ring cell 
carcinoma, adenosquamous and squamous cell carcinoma, neuroendocrine carcinoma, apocrine 
carcinoma and clear cell carcinoma.  Metaplastic carcinomas can appear to undergo differentiation to 
distinct mesenchymal lineages, such as cartilage, osteoblasts or fibrosarcoma.  Myoepithelial tumours 
display characteristics of both epithelial and mesenchymal cells, even to the extent of fully 
differentiating into smooth muscle cells during involution of the lobules.  Another group of uncommon 
tumours which also seems to be composed of myoepithelial and epithelial components include tubular 
adenomyoepithelioma, clear cell adenomyoepithelioma, and adenomyoepithela with apocrine 
adenosis.  Fibroadenomas represent a common hormone-dependent overgrowth of the TDLU, which 
rarely undergo malignant progression (Fisher 1977).  Phyllodes tumours develop in the connective 
tissue and are stromal expansions which project into the epithelial compartment.  These are true 
neoplasms which do not respond to hormonal therapy. 
  
2.4  THE GENETICS OF BREAST CANCER 
 
Breast cancer has been subdivided into two broad types, early-onset and late-onset, a division that is 
based on an inflection in the age-specific incidence curve around the age of 50 years (Miki et al. 1994).  
Alternatively, the disease can be classified as pre-menopausal or post-menopausal.  The incidence in 
Western countries rises steeply with age until the age of about 50, and much more slowly thereafter.  
The conventional explanation for this is that breast mitotic activity is stimulated by estrogens and slows 
down at menopause (Easton 2000).  Hereditary breast cancer is characterized by early age at onset (an 
average of five to 15 years earlier than sporadic cases), bilaterality (or multifocal tumours), vertical 
transmission through both maternal and paternal lines and familial association with tumours of other 
organs, particularly the ovary and prostate gland.  Most breast cancers that are due to a genetic 
mutation occur before the age of 65.  A woman with a strong family history of breast cancer of early- 
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onset who is still unaffected at 65 years, has probably not inherited the genetic mutation (McPherson et 
al. 2000).  Familial breast cancer accounts for only a minority of all cases (5-10%).   
 
Heterozygous germline mutations in the BRCA1 tumour suppressor gene predispose one to early onset 
breast cancer as well as ovarian cancer.   BRCA2 mutation carriers are also predisposed to breast 
cancer, but generally have a later age of onset (Ford et al. 1998).  BRCA2 mutations are more strongly 
associated with male breast cancer than BRCA1 mutations.  It has been proposed that heterozygosity for 
BRCA mutations carry a phenotype that contributes to tumorigenic progression, instead of the loss of 
the wild type allele being stochastic.  Heterozygosity for a BRCA2 mutation has been shown to have a 
distinct phenotype, characterized by a reduced growth rate, increased cell death and heightened 
sensitivity to specific DNA damaging agents and reduced RAD51 (a eukaryotic homolog of bacterial 
RecA) focus formation after irradiation (Warren et al. 2003).  Thus in certain cell types, genome 
instability might be driven directly by heterozygosity for BRCA2 mutations and the same could be true 
for BRCA1 mutations.  Mice, heterozygous for Brca1 or Brca2 pathogenic mutations develop normally 
and do not appear to be more susceptible to mammary tumours than are mice with wild type Brca1 and 
Brca2, while similar to humans, homozygous pathogenic mutations are embryonically lethal (Ludwig 
et al. 1997). 
 
The role of the BRCA1 and BRCA2 genes in sporadic breast cancer remains unclear, since somatic 
mutations in either gene are uncommon (Gayther et al. 1998).  Decreased levels of the BRCA1 
transcript have, however, been observed in several sporadic breast tumours suggesting that loss of 
regulation and mutations in noncoding regions may be mechanisms by which BRCA1 plays a role in 
the development of sporadic tumours (Thompson et al. 1995).  Allele inactivation by promoter 
hypermethylation, which is an epigenetic effect, has been reported to occur at the BRCA1 locus in 
somatic breast cancer (Dobrovic and Simpfendorfer 1997), but not at the BRCA2 locus, even in those 
tumours with loss of heterozygosity (LOH) at this site (Collins et al. 1995; Collins et al.1997).  This 
observation suggests that the mechanism of transcriptional repression is unlikely to explain the absence 
of somatic BRCA1 and BRCA2 mutations in sporadic cancers.  Current pathologic, cytogenetic and 
gene expression data suggest that there are biological differences between BRCA1-related, BRCA2-
related, and sporadic cancers.  A clear understanding of these differences (and similarities) has not been 
reached yet.   
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Recent reports indicate that the proportion of breast cancer families attributable to the BRCA1 and 
BRCA2 genes may be smaller than initially thought (refer to paragraph 2.11.5 for a detailed discussion 
of the literature) and identification of additional breast cancer susceptibility genes is essential to be able 
to fully understand, prevent and treat the disease.  Other candidate loci and specifically the CHEK2 
gene are discussed in paragraph 2.13.  Other conditions associated with an autosomal dominant 
inheritance of breast cancer risk, but not BRCA1 or BRCA2 specifically, includes Li-Fraumeni 
syndrome (aberrant p53 expression), Cowden syndrome (most often due to mutant PTEN), Ataxia 
Telangiectasia (mutated copies of ATM) and Peutz-Jeghers syndrome (linked to STK11/LKB1). 
 
2.5  MALE BREAST CANCER 
 
Carcinoma of the male breast is a relatively rare disease that accounts for less than 1% of all cases of 
cancers in men and less than 1% of all diagnosed breast cancers (Sasco et al. 1993).  In contrast to the 
increasing incidence of breast cancer in women, the incidence of breast cancer in men has remained 
stable over the past four decades.  The median age at diagnosis spans ages 60-65 years, but the disease 
has been reported in males ranging from their mid-20s to their early 90s (Ravandi-Kashani and Hayes 
1998).  Incidence increases exponentially with age.   
 
Carcinoma of the male breast has many similarities to breast cancer in women, but the disease has 
different genetic and pathologic features.  Almost all of the histological subtypes of breast cancer that 
have been described in women have also been reported in men (Giordano et al. 2002).  Approximately 
90% of all breast tumours in men are invasive carcinomas.  Although lobular cancer is more common 
in women, the vast majority of breast cancers in men are invasive ductal cancers.  Carcinomas of the 
male breast have a higher rate of hormone receptor positivity (estrogen and progesterone) than do 
carcinoma of the female breast.  As in women, axillary lymph node status, tumour size, histological 
grade and hormone receptor status have been shown to be significant prognostic factors in men with 
breast cancer (Giordano et al. 2002) and clinical outcome for men with breast cancer is similar to that 
for women.  Bilateral disease is rare.   
 
Many of the risk factors for breast cancer in men involve abnormalities in estrogen and androgen 
balance, which indicate that breast cancer in men, as in women, may be hormonally driven (Giordano 
et al. 2002).  Other possible risk factors that relate to hormonal levels include obesity, which causes 
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increased peripheral aromatization of estrogens, and cirrhosis, which in turn results in a hyper 
estrogenic state. Other risk factors for breast cancer are testicular abnormalities, infertility, Klinefelter 
syndrome (47,XXY), benign breast conditions, radiation exposure, increasing age (Casagrande et al. 
1988; Thomas et al. 1992; Sasco et al. 1993). 
 
2.6  ENVIRONMENTAL FACTORS 
 
Environmental risk factors have been intensively studied by epidemiologists.  Nongenetic factors may 
significantly influence the penetrance of mutations.  Identifying these nongenetic or environmental 
influences on penetrance suggests new directions for studies of BRCA1- and BRCA2-associated 
carcinogenesis.   
 
One of the most important risk factors for breast cancer is age.  For women the median age of onset is 
between 40 and 50 years (Easton et al. 1994).  The incidence of breast cancer increases with age, 
doubling about every 10 years until menopause, when the rate of increase slows dramatically 
(McPherson et al. 2000).  Geographic distribution appears to play another important role.  The 
incidence and the mortality rate vary between different ethnically and geographically distinct 
populations by at least fourfold with the lowest incidence among Asians and the highest among North 
Americans, although the difference between Eastern and Western countries is diminishing.  Studies on 
people who migrated from Japan to Hawaii showed that the rates of breast cancer in the migrants 
assumed the rate in the host country within one or two generations, indicating that environmental 
factors are of just as great importance as genetic factors (McPherson et al. 2000).  Several studies have 
shown a birth cohort effect, whereby BRCA1 and BRCA2 mutation carriers born after 1930 or 1940 
have a higher lifetime risk than women born before this time period (Antoniou et al. 2003; King et al. 
2003).  
 
The predominance of data from epidemiologic studies indicates that, aside from a family history of 
breast cancer and age, most breast cancer risk factors are related to reproductive events (Clavel-
Chapelon and the E3N-EPIC Group 2002).  Early menarche and late age at menopause have been 
shown to be risk factors.  Nulliparity or late age at first birth (and also a late age at birth of a second 
child) increase the lifetime risk of breast cancer.  Breast feeding reduces the risk of breast cancer.  
Lifestyle choices relating to these reproductive factors also play a role, for example the use of oral 
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contraceptives and hormone replacement therapy (HRT) (Li et al. 2003).  Experimental data strongly 
suggest that estrogen, which can be linked to all above mentioned factors, have a role in the 
development and growth of breast tumours.  Although the exact mechanisms remain to be fully 
elucidated, the alkylation of cellular molecules and the generation of active radicals, together with the 
potential genotoxicity of estrogen and some of its metabolites (e.g., the catechol estrogens), have been 
implicated (reviewed in Clemons and Goss 2001).  Reactive oxygen species (ROS), generated in 
normal cellular respiration and during metabolism of xenobiotics, cause damage to membranes, 
mitochondria, and macromolecules including DNA and thus are plausible agents in the development of 
cancer.  Estradiol is metabolized to ROS through redox cycling of the catechol estrogens and the semi-
quinone radicals generated have been shown to result in DNA damage and upregulation of endogenous 
antioxidants in animal models (Cavalieri et al.2000).   
  
Many epidemiological studies have investigated the relationship between breast cancer and the 
consumption of alcohol and/or tobacco.  The published results from these studies have generally 
suggested that women who regularly consume alcohol may be at a slightly increased risk of the disease 
(an increase of 7.1% in the relative risk of breast cancer for each additional 10g per day alcohol), but 
the findings reported for tobacco are inconsistent (Collaborative Group on Hormonal Factors in Breast 
Cancer 2002).  There is also accumulating evidence that regular intakes of moderate amounts of 
alcohol affect sex hormone levels, therefore alcohol consumption can have an indirect relationship to 
breast cancer risk. 
 
Evidence is growing that low folate status may be a factor in the aetiology of several cancers, including 
breast cancer (Kim 1999).  There are two mechanisms by which folate deficiency could increase risk of 
malignancy: by causing DNA hypomethylation and proto-oncogene activation; and/or by inducing 
uracil misincorporation during DNA synthesis, leading to faulty DNA repair, DNA strand breakage and 
chromosome damage (Duthie 1999). 
 
For the most part breast cancer incidence suggests a lifestyle cause (McGrath 2003).  Most of the 
lifestyle choices in question either improve quality of life or has a role in the emotional wellbeing of 
woman.  This is especially true for breast cancer risk factors like oral contraceptive use, hormone 
replacement therapy, smoking and alcohol consumption.  None of these risk factors are going to vanish, 
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nor even importantly decrease on the grounds of possible attributable increases in breast cancer risk 
and will therefore remain an enduring problem for women wishing to avoid breast cancer. 
 
2.7  BREAST CANCER SCREENING AND PROGNOSIS  
 
Surveillance programs are essential, especially for women who have an increased risk of developing 
breast cancer, as the disease is progressive and earlier detection and timely treatment can alter its 
natural course.  Traditional surveillance guidelines for breast cancer would include monthly breast self-
examination, starting in early adulthood, and annual or semi-annual clinical breast examination and 
mammography beginning at age 25-35 years.  The limited sensitivity of mammography and an interest 
in methods of screening that do not involve ionizing radiation have led to evaluation of other screening 
techniques, including magnetic resonance imaging (MRI), breast ultrasound, breast ductal lavage, and 
digital mammography.  The development of these techniques may lead to further progress, especially in 
younger women whose breast density may prevent adequate screening by conventional mammography 
or in those at particularly high risk of developing breast cancer (Stoutjesdijk et al. 2001).  The 
availability of genetic testing to identify carriers of BRCA1 or BRCA2 mutations raises essential 
questions about optimal screening and preventive measures for breast cancer.   
 
The distinct pathologic features of BRCA1- and BRCA2-related tumours coupled with the relatively low 
frequency of somatic BRCA mutations suggest a specific pathogenetic basis, which could lead to 
differences in prognosis.  Most available data are, however, based on small numbers (<50 cases) and 
are probably confounded by different biases and lack of appropriate controls.  El-Tamer et al. (2004) 
found patients with BRCA1and BRCA2 mutations to have a similar outcome as non-mutation carriers, 
although BRCA mutation carriers had a higher incidence of bilateral disease.  There was no difference 
in five- or ten year breast cancer-specific survival between mutation and non-mutation carriers. 
 
2.8  TREATMENT 
 
There are two ways of treating breast cancer, with local therapies and with systemic therapies.  Local 
therapy targets the breast area and the lymph nodes involved though surgery and radiation.  With 
systemic therapy the whole body is treated through chemotherapy, hormone therapy or immune 
therapy.  A treatment plan usually involves a combination of these. 
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2.8.1  Surgery 
 
Breast conserving surgery (lumpectomy) involves removal of only the tumour and the marginal breast 
tissue.  In a total mastectomy all of the breast tissue is removed, while a modified radical mastectomy 
refers to removal of the breast as well as the lymph nodes.  During a radical mastectomy the underlying 
chest muscle will also be removed.  Bilateral prophylactic mastectomy has shown a reduction in risk 
for breast cancer in women with BRCA1 and BRCA2 mutations by 90% or more (Hartmann et al. 2001; 
Meijers-Heijboer et al. 2001; Rebbeck et al. 2004).   
 
2.8.2  Radiation therapy 
 
Radiation therapy could be administered by means of high levels of external x-rays directed towards 
the tumour to damage or destroy the cancer cells.  Radiation could also be performed through internal 
radiation which is administered by implanting a radioactive substance inside the body, close to the 
tumour.  This delivers very intense radiation to a small area of the body and limits the dose to affected 
tissue (Abramson Cancer Centre of the University of Pennsylvania www.oncolink.org). 
 
2.8.3  Chemotherapy 
 
Patients with high grade, hormone-receptor negative tumours with indications of lymphatic or vascular 
invasion are treated with chemotoxic agents, directed towards rapidly growing cells (Your guide to 
breast cancer treatment, developed by www.breastcancer.org).  More than one of these agents would be 
prescribed at a time in different combinations, e.g. CMF (combination of Cytoxan, Methotrexate and 5-
Fluorouracil) or AC±T (Adriamycin, Cytoxan and Taxol or Taxotene).   
 
2.8.4  Hormone therapy 
 
Hormone therapy has been the keystone of breast cancer treatment for more than 50 years (Duffy 
2005).  Hormone therapies include SERMs (selective estrogen receptor modulators), AIs (aromatase 
inhibitors), ERDs (estrogen receptor down-regulators) and ovarian ablation.  A prerequisite for 
hormone therapy is estrogen- and/or progesterone receptor positive tumours.  AIs (e.g. anastrozole, 
letrozole and exemestrane) reduce the amount of estrogen produced a women’s body after menopause.  
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ERDs (e.g. fulvestrant) block and destroy estrogen receptors.  Both AIs and ERDs are prescribed to 
menopausal women.  Ovarian ablation (available to pre-menopausal women), which lowers levels of 
circulating estrogen, is achieved by surgically removing the ovaries (oophorectomy), radiating the 
ovaries or with medication, which is only temporary (goserelin acetate is a luteinizing hormone-
releasing (LH) hormone agonists).  Ovarian ablation has been shown to produce a highly significant 
improvement in recurrence-free and in overall survival in premenopausal women diagnosed with breast 
cancer.  The benefits appear to be greater in women with estrogen receptor positive primary tumours 
(Early Breast Cancer Trialists’ Collaborative Group 1996).   
 
SERMs are prescribed to both pre- and post-menopausal women.  Of these, Tamoxifen is the most 
established adjuvant treatment (Goldhirch et al. 2001).  Tamoxifen functions as both an estrogen 
agonist and antagonist (Shang et al. 2000).  BRCA1 tumours are mostly estrogen-/progesterone receptor 
negative (Karp et al. 1997) and BRCA2 tumours more commonly positive for both receptors (Loman et 
al. 1998).  The lack of hormone receptor positivity in BRCA1 tumours suggests that treatment with 
tamoxifen, or other hormonal therapy, may be less effective in this patient population (Early Breast 
Cancer Trialists’ Collaborative Group 1998).  This drug is also described as a chemopreventive agent, 
as it decreases the incidence of invasive and non-invasive breast cancer (Fisher et al. 1998; Dumitrescu 
and Cotarla 2005).  It has also been suggested that Tamoxifen might reduce breast cancer risk through 
mechanisms other than receptor-mediated estrogen block (Narod et al. 2000). 
 
2.8.5  Immune therapy 
 
The HER-2 protein, which is also known as c-erbB-2 or neu, is a member of subclass 1 of the 
superfamily of receptor tyrosine kinases.  Over-expression of the HER-2 gene has been associated with 
increased mitogenesis, malignant transformation and invasion, increased cell motility and metastasis.  
Either gene amplification or increased production of HER-2 is generally found to correlate with 
adverse prognosis (Duffy 2005).  Herceptin (chemical name trastuzumab) is an antibody directed 
against the HER-2 protein.   
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2.9  THE BRCA GENES – BRCA1 AND BRCA2  
 
2.9.1  Cloning of the BRCA genes 
 
In 1990, a breast cancer susceptibility gene, BRCA1, was localized to chromosome 17q21 (Hall et al. 
1990).  A few years later the gene was positionally cloned using linkage analysis of families with 
multiple cases of breast and ovarian cancer (Miki et al. 1994).  Wooster et al. (1994) localized the 
second breast cancer susceptibility gene, BRCA2, to a 6cM interval on chromosome 13q12-13.  Their 
preliminary evidence suggested that mutated BRCA2 confers a high risk of breast cancer (similar to that 
of BRCA1 mutations) but, unlike BRCA1, does not confer a substantially elevated risk for ovarian 
cancer.  However, they only reported a partial sequence.  In the following two years the link between 
breast cancer and BRCA2 was confirmed in another study by Wooster et al. (1995) and also by 
Tavtigian et al. (1996), who both cloned the gene and determined the complete sequence of the BRCA2 
gene.   
 
2.9.2  Structure of the BRCA genes  
 
While BRCA1 certainly contains some general similarities to BRCA2, there are no significant 
homologies between them, or between BRCA1 or BRCA2 and any other characterised gene.  Given the 
differences in primary sequence, the genomic parallels between BRCA1 and BRCA2 are particularly 
striking.  Both genes are reasonably large, spanning approximately 70-80kb of genomic DNA, with 
coding sequences extremely rich in pyrimidines.  They both have extremely large central exons, 
constituting more than 60% of the respective proteins.  Comparison of the amino acid sequence of 
human BRCA1 and BRCA2 with mouse Brca1 and Brca2 indicates that the respective proteins share 
approximately 60% identity.  Figure 2.2 summarizes the most important binding domains for each 
protein.    
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P/CAF NLS
Figure 2.2  BRCA1 protein:  The zinc-binding RING finger domain is near the amino terminus, 
where many protein partners interact.  The NLS (nuclear localization signal), p53, RAD51, RNA 
polymerase II (with the help of RNA helicase A) are indicated as well as the serines phosphorylated by 
ATM in response to DNA damage (P).  BRCA2 protein:  The protein interacts with BRCA1, but a 
specific domain has not been identified.  The RAD51 interaction site is indicated.  The central portion 
containing the BRC repeats has been termed the ovarian cancer cluster region (OCCR).  The C-
terminus NLSs are indicated as well as the P/CAF binding domain at the N-terminus.  Adapted and 
reprinted with permission from the Nature Publishing Group (Nathanson et al. 2001). 
 
2.9.2.1  BRCA1  
 
The BRCA1 gene has 5589 nucleotides of coding sequence.  It encodes a 7.8kb transcript which 
produces a nuclear protein of 1863 amino acids (220 kD).  It is distributed over 24 exons, of which 22 
are coding.  Transcription start from one of two alternatively spliced first exons (exon 1a or 1b) (Xu et 
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al. 1995).  Translation starts in exon two and exon four is an intronic Alu element.  Insertion of exon 4 
introduces a premature stop codon, resulting in a truncated protein.  Exon 11 is the largest exon and 
comprises 60% of the coding sequence for the BRCA1 protein.  The functional domains suggestive of a 
role in DNA repair are clustered around exon 11, while motifs involved in transcriptional regulation 
appear to cluster mainly within the C-terminal BRCT (BRCA1 carboxyl-terminal) repeats (Hohenstein 
and Fodde 2003). 
 
The BRCA1 protein is normally located in the nucleus and contains phosphorylated residues (Chen 
1996).  Two recognizable protein motifs are found.  The amino terminus contains a RING finger 
domain and the C-terminus contains two BRCT repeat domains.  It also has two nuclear localizing 
signals (NLS), a central transcription activation domain which is able to bind DNA, and a RAD51 
binding domain (refer to Figure 2.2).  RING fingers are known to facilitate protein-protein or protein-
DNA interactions, whereas BRCT repeats only facilitate protein-protein interactions.  The BRCA1 
RING finger specifically interacts with BAP1 (BRCA1-associated protein) and also with BARD1 
(BRCA1-associated RING domain), another RING finger protein which was identified based on this 
interaction (Wu et al. 1996).  The BRCT repeats are each about 110 amino acids long and comprise 
amino acids 1653-1736 and 1760-1855.  The BRCT domains are usually involved in DNA repair, 
transcriptional co-activation and cell cycle regulation.  Williams et al. (2003) found that more than 
60% of clinically relevant BRCA1 mutations delete a portion of or all of the BRCT domains, which 
highlights the crucial role of the C-terminal.  The majority of BRCT missense alterations tested that 
target the three classes of BRCT folding determinants (BRCT fold, BRCA1 fold, and interface 
mutations), are destabilizing.  The BRCT domain of BRCA1 directly interacts with BACH1 (BRCA1-
associated carboxyl-terminal helicase) and with BRIP1 (BACH1-BRCA1-associated C-terminal 
helicase-1), both members of the DEAH helicase family.   
 
A crucial interaction which BRCA1 has is with RAD51, a key component in homologous 
recombination and double-strand break repair.  The BRCA2 protein also interacts with RAD51, and it 
is through this mutual association with which it interacts with BRCA1.  MYC, p53, RB and ZBRK1 all 
bind to a region of BRCA1 that includes the NLS.  ZBRK1 is zinc-finger protein that suppresses 
transcription through an interaction with another protein.  BRCA1 is required for this repression.  
SW1/SNF binding occurs between amino acids 260 and 553.  The DNA-binding domain encompasses 
amino acids 452-1 079.  It contributes to the DNA-repair-related functions of BRCA1, which are partly 
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mediated through proteins that make up the BRCA1-associated genome surveillance complex (BASC).  
This complex includes tumour suppressor and DNA damage repair proteins (MSH2, MSH6, MLH1, 
ATM, and BLM) and the RAD50-MRE11-NBS1 protein complex. BRCA1 binds the core RNA 
polymerase II as well as the RNA polymerase II haloenzyme via RNA helicase A (reviewed in 
Monteiro 2000).  This association reveals a function for BRCA1 in transcription. 
 
Jensen et al. (1996) discovered a perfect granin consensus in BRCA1 at amino acids 1214-1223.  Based 
on sequence homology, biochemical properties and cellular localization, BRCA1 is proposed to be a 
member of the granin family (Steeg 1996).  Granins are a family of acidic proteins that bind calcium 
and aggregate in its presence.  Granins are located in secretory granules and expressed in 
neuroendocrine tissues.  The breast and ovary are considered to be endocrine glands.  The expression of 
some granin family proteins is regulated by estrogen.  Intracellular, granins participate in the regulated 
secretory pathway.  BRCA1 could therefore encode one or more secreted peptides with autocrine or 
paracrine functions.  Other characteristics of BRCA1 such as estrogen regulation, glycosylation, heat 
stability and cAMP regulation are all consistent with the granin family, but are not specific for granins.   
  
A BRCA1 pseudogene, ψBRCA1, had been shown to lie ~30kb upstream of BRCA1 (Barker et al. 
1996).  The pseudogene is a duplication of a region containing BRCA1 exons 1a, 1b and exon two.  The 
first exons of the NBR2 (next to BRCA1 two) gene, located between BRCA1 and its pseudogene, are 
homologous to the first exons of the NBR1 gene (next to BRCA1 one), which lies head-to-head with 
ψBRCA1 (Xu et al. 1997).   
 
2.9.2.2  BRCA2 
 
The BRCA2 gene has an 11385bp transcript that codes for a nuclear protein of 3418 amino acids (384 
kD).  The BRCA2 gene is composed of 27 exons, of which 26 are coding.  As with BRCA1, translation 
starts in exon two and exon 11 comprises more than 60% of the coding sequence.  Like BRCA1, the 
protein is located in the nucleus and contains phosphorylated residues.  If BRCA1 is a granin or granin-
like protein, limited sequence similarity suggests that BRCA2 may also serve similar functions.   
BRCA2 has recently been identified as identical to the Fanconi anaemia gene (FANCD1) (Wagner et al. 
2004).   
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The structure of the BRCA2 gene is not as well characterised as the BRCA1 gene.  One important motif 
is the BRC repeats, which are conserved across mammals.  BRCA2 has eight BRC repeats consisting 
of 30-80 amino acids, of which four interact with RAD51 (Wong et al. 1997).  It has two nuclear-
localization signals (NLSs) located at the 3’ end of the genes, within the final 156 residues (Spain et al. 
1999).  The NLSs are essential for its cellular localization.  Mutations predicted to truncate BRCA2 5’ 
to the NLS would render it cytoplasmic and rule out any interaction with the RAD51 complex unless it 
is transported into the nucleus by alternative means.   
 
Crystallographic studies have revealed that the C-terminal region of BRCA2 contains DNA/DSS1-
binding domains (BRCA2DBD) (amino acids 2478-3185), which comprise a helix-turn-helix motif, 
OB1, OB2, OB3 (oligonucleotide/oligosaccharide-binding) and a Tower region (Yang et al. 2002).  
The function of the DSS1 protein has not been elucidated.  Single-stranded DNA (ssDNA) binding has 
been attributed to two of the three OB folds.  The Tower region has been implicated in the interaction 
with double-stranded DNA (dsDNA).  These domains implicate BRCA2 in ssDNA and dsDNA 
binding.  The C-terminal region of BRCA2 (~1000 residues) corresponds to the best-conserved portion 
of the protein (Warren et al. 2002).   
 
The BRCA2 N-terminus interacts with P/CAF (p300/CBP-associated factor) which has histone 
deacetylase activity.  Putative transcriptional activation domains are also located at the N-terminus of 
BRCA2 (Welcsh et al. 2000).   
 
2.9.3  Expression of the BRCA genes 
 
2.9.3.1  Tissue specificity of cancer predisposition 
  
The BRCA genes are ubiquitously expressed in most adult tissues and cell types.  Transcription is up-
regulated at the G1/S phase junction of the cell cycle, with expression being maintained at relatively 
high levels when cells progress through the S and G2/M phases (Wang et al. 1997).  Despite this 
ubiquitous expression, germline mutations in BRCA1 and BRCA2 predispose individuals to breast and 
ovarian tumours with only minor effects on the predisposition to cancer at other sites (refer to section 
2.9.5), indicating that gene expression does not account for the tissue-restricted phenotype of breast 
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(and ovarian) cancer.  Several hypotheses (discussed in Monteiro 2003) are entertained as to the tissue 
specificity of cancer predisposition associated with BRCA gene mutations.   
 
One possibility for tissue specific cancer predisposition is that in unaffected tissues there might be 
functional redundancy whereby other proteins perform the same function as the BRCA proteins, but in 
ovary and mammary gland these other proteins are not expressed at an adequate level.  Another 
suggestion is that BRCA1 and/or BRCA2 disruption may make breast cells more sensitive to the 
effects of local mutagens, such as estrogen metabolites.  Mammary gland tissues do have increased 
levels of carcinogenic estrogen metabolites that can adduct DNA.  Considered from the perspective that 
heterozygosity for BRCA mutations is sufficient to predispose to cancer, an alternative hypothesis is 
that the frequency with which loss of the second BRCA allele occurs may effectively be higher in 
certain tissues.  Breast tissue experience prolonged proliferative dormancy (when BRCA1 and BRCA2 
function may be dispensable for viability) alternating with periodic bursts of proliferation (during 
puberty and pregnancy).  It has been shown that expression is upregulated during puberty and 
pregnancy, when estrogen levels are dramatically increased (Welcsh and King 2001), which suggest 
that estrogen might stimulate expression of BRCA1 and/or BRCA2.  These periods of high proliferation 
may favour the accumulation of cells in which both BRCA alleles have been lost.  Unlike the cells of 
many rapidly proliferating epithelia, such as those of the intestine or of the uterine endometrium, 
progeny of this proliferative burst are retained within the breast epithelium.  Having a larger pool of 
mutant cells from which tumours could eventually evolve may be of particular significance in the light 
of the deleterious effects of homozygosity for BRCA1 and BRCA2 mutations.   
 
Elledge and Amon (2002) proposed a hypothesis to explain BRCA1 tissue-specificity by suggesting a 
delayed apoptotic response in the breast and ovary.  It is based on the idea that the loss of BRCA1 
function leads to apoptosis or severe proliferation defects in tissues other than breast and ovary, 
therefore preventing the accumulation of additional mutations required for tumour formation.  
Temporary suppression of lethality in breast and ovary cells lacking BRCA1 would allow sufficient 
time to accumulate additional mutations required for oncogenesis.  The balance between proliferation 
and apoptosis is tightly maintained in the mammary gland and cells undergo apoptosis after each 
estrogen cycle, suggesting that at least some cells are susceptible to apoptosis (Anderson 1999).  The 
apoptotic response may be controlled by tissue-specific factors.  Warren et al. (2002) propose that 
certain cell types, particularly those susceptible to tumorigenesis in human BRCA2 mutation carriers, 
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might be particularly sensitive to BRCA2 dosage leading to impaired fidelity of DNA repair.  The same 
could be true for BRCA1.  This gene-dosage effect is known as haploinsufficiency, whereby one 
defective allele would be enough to lead to tumorigenesis (Fodde and Smits 2002).   
 
Lastly, since their discovery, BRCA1 and BRCA2 have been implicated in a wide variety of functions 
(refer to section 2.9.4).  Thus, they could perform specific functions in certain tissues with the function 
performed in breast and ovarian tissues being the only one relevant for tumour suppression.  One 
possibility would be by modulating the activity of estrogen receptor α (ER-α).  It has been suggested 
that BRCA1 can mediate ligand-independent repression of the receptors for estrogen and progesterone.  
Analysis of BRCA1 tumours has, however, revealed that these tumours are mostly ER-α negative 
(Loman et al. 1998).  It remains unclear whether these tumours originate from ER-α negative cells or 
whether receptor expression is lost during tumour development.   
 
All the present hypotheses are valid, with no overwhelming evidence for or against any of them.  Many 
of the concepts underlying these various hypotheses are not mutually exclusive and tissue specificity is 
likely to be explained by a combination of several factors. 
 
2.9.3.2  Tumour pathology 
 
Various research groups (Lakhani and The Breast Cancer Linkage Consortium 1997; Lakhani et al. 
1998) have characterized the histopathological features of breast cancers in patients harbouring 
germline mutations in BRCA1 and BRCA2.  Their results show that the histological characteristics of 
breast cancers due to BRCA1 and, to a lesser extent BRCA2 mutations, differ from those of sporadic 
breast cancers, and that they even differ from each other.   
 
Breast cancer in patients with BRCA1 mutations are of higher grade and have higher mitotic counts, a 
greater degree of nuclear pleomorphism and less tubule formation than age-matched sporadic breast 
cancers unselected for family history.  BRCA1 carriers also have an excess of medullary and atypical 
medullary cancers.  However, multifactorial analysis demonstrated that many of the factors mentioned 
are associated with each other.  Tumours are more likely to be estrogen receptor-negative and 
progesterone receptor-negative (Verhoog et al. 1998; Lakhani et al. 2002).  Information regarding 
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BRCA2-related tumours is more limited.  These tumours are also of higher overall grade as a result of 
exhibiting less tubule formation, but are not significantly different from controls with respect to 
mitoses and pleomorphism.  Both the reduction in tubule formation and the presence of continuous 
pushing margins are significantly associated with BRCA2.  BRCA2 tumours are at least as likely to be 
hormone receptor-positive as control tumours of nonhereditary breast cancer (Lakhani et al. 2002).   
 
It is of major importance to define the morphological, immunohistochemical, and molecular features of 
the group of BRCA1 and BRCA2 tumours to improve genetic testing and also to gain further insight 
into the biological characteristics of these tumours.   
 
2.9.4  Functions of the BRCA proteins  
 
2.9.4.1  Introduction 
 
The biological basis of the cancer predisposition in BRCA1 and BRCA2 mutation carriers has not been 
clearly elucidated.  Although these genes are classic tumour suppressor genes in that the loss of both 
alleles has generally been believed to be required for the initiation of malignancy, information on 
which cellular pathways are affected by alterations in the BRCA genes is limited.  The observed 
distinction between BRCA1 versus BRCA2 deficient tumours emphasizes that cancer evolution 
proceeds down different routes in each group, consistent with the arguments that the BRCA proteins 
perform distinct functions in overlapping biological processes.   
 
Cancer susceptibility genes fall into either of two general classes (Kinzler and Vogelstein 1997):        
(1) Genes whose altered expression relieves normal controls on cell division, proliferation, cell death 
and lifespan have been termed “gatekeepers”.  Their alteration therefore results in the uncontrolled 
cellular proliferation that characterizes tumour cells.  (2) Those genes whose disruption causes genome 
instability, increasing the frequency of alterations in gatekeeper genes, work instead as “caretakers.”  
Genes in the caretaker class are involved in DNA metabolic processes and are responsible for 
maintaining the overall stability of the genome.  Collectively findings have established that the BRCA 
proteins mainly behave as caretakers, but they also display functions relating to gatekeepers.  BRCA1 
and BRCA2 have similar, but distinct functions in DNA damage sensing, DNA damage repair, 
checkpoint control and transcription, playing roles to contribute to the stability of the human genome.  
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BRCA1 is also involved in X-chromosome silencing (Ganasan et al. 2002).  Both BRCA1 and BRCA2 
are essential for cellular development since nullizygous BRCA1 or BRCA2 embryos die around the time 
of gastrulation (Ludwig et al. 1997).   
 
Most functions of the BRCA proteins have been discovered through the interactions they have with 
proteins of known function.  These functions are then confirmed by observing the response or 
behaviour of BRCA deficient cells.  Holt et al. (1996) provided the first direct evidence for a growth 
inhibitory role for BRCA1.  The authors did not only show that breast or ovarian cancer cell lines 
transfected with wild-type BRCA1 are less able to form tumours, but also that BRCA1 can inhibit the 
growth of established tumours.  BRCA1 could not inhibit growth of colon or lung cancer cell lines, nor 
could it inhibit normal fibroblasts, which provide a clear indication of the specificity of BRCA1 
mutations to breast and ovarian cancer, suggesting these cells have a distinct growth control pathway.  
Inhibition of BRCA1 expression does not lead to growth acceleration of only malignant cells, but also 
of normal breast epithelial cells (Thompson et al. 1995). 
 
The complicated network of events in which BRCA1 and BRCA2 are involved in as well as the various 
interactions these proteins have with other proteins are graphically presented in Figure 2.3.  A detailed 
discussion of these processes and interactions will follow.    
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Figure 2.3  The BRCA1 network.  Protein-protein interactions with BRCA1 are shown, as well as 
downstream events in the DNA damage signalling and repair pathway.  BRCA1’s relationship with 
BRCA2 and CHEK2 has also been indicated.  Reprinted with permission from the Nature Publishing 
Group (Narod and Foulkes 2004). 
 
2.9.4.2  DNA damage sensing 
 
BRCA1 is rapidly phosphorylated after DNA damage has occurred in dividing cells, suggesting that it 
may work downstream of the checkpoint mechanisms that sense and signal DNA damage or problems 
with DNA replication.  BRCA1 is phosphorylated by three kinases, including ATM (ataxia 
telangiectasia mutated), ATR (ataxia telangiectasia and RAD3 related) and CHEK2.  Phosphorylation 
of BRCA1 by each of these kinases is activated by distinct stimuli and is targeted to distinct clusters of 
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serine residues, suggesting that it will serve a distinct purpose in each instance.  The chemical nature of 
the initiating DNA lesion is an important influence, with differences apparent among ionizing radiation 
(which primarily induces DNA breakage), UV light (nucleotide lesions), or replication arrest induced 
by hydroxyurea (strand gaps).  ATM and CHEK2 phosphorylate BRCA1 after ionizing radiation (IR) 
(Cortez et al. 1999), whereas ATR is more specifically activated after UV treatment or replication 
arrest (Tibbetts et al. 2000).  BRCA1 could therefore be seen as a signal processor that coordinates 
DNA damage-sensing mechanisms with the appropriate biological response.  It is not known if BRCA2 
is a target of checkpoint kinases, but its behaviour changes when dividing cells undergo replication 
arrest or when there is a response to DNA damage (Chen et al. 1998). 
 
BRCA1 can exist as part of the BASC complex (Wang et al. 2000), indicating a role as a kind of 
platform for DNA surveillance complex building.  All members of this complex have roles in 
recognition of abnormal DNA structures or damaged DNA, suggesting that BASC may serve as a 
sensor for DNA damage.  
 
2.9.4.3  Checkpoint control 
 
BRCA1 is hyperphosphorylated during the G1 and S phases of the cell cycle and has been associated 
with the CDK2-cyclin complex, which controls the G1-S transition.  BRCA1, phosphorylated by 
Aurora-A, plays a role in G2 to M transition of the cell cycle (Ouchi et al. 2004).  BRCA1 also 
indirectly controls the G2/M checkpoint, by regulating the expression, phosphorylation and cellular 
localization of Cdc25C (cell cycle-promoting phosphatase) and Cdc2/cyclin B kinase proteins that are 
crucial for the G2/M transition (Yarden et al. 2002).  During the M phase BRCA1 is dephosphorylated.  
It is not known if BRCA2 is a target of S and G2 checkpoint kinases but, as mentioned before, aspects 
of its behaviour change during replication arrest and there is reason to believe that the changes can be 
brought about by phosphorylation.  Marmorstein and team (2001) discovered that the BRCA2 complex 
contains a DNA-binding protein called the BRCA2-associated factor (BRAF35).  The protein is mainly 
expressed during mitosis and the BRAF35-BRCA complex is associated with the early phases of 
mitotic cell cycle progression, when it is able to bind DNA crossover structures arising during 
recombination.  More work will be needed before it becomes clear whether or not BRCA2 is a 
regulator of cell cycle events, independent of its role in DNA repair.  It is possible that the second event 
in tumorigenesis might in fact involve the inactivation of a checkpoint gene, rather than loss of the 
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second BRCA1 or BRCA2 allele, which is in accordance with Knudson’s two hit hypothesis (Knudson 
1971). 
 
Although this needs further investigation, some of the protein-protein interactions of the BRCA 
proteins suggest their involvement in fixing stalled replication forks after an arrest or pause during 
normal cell growth.  Lomonosov et al. (2003) proposed that in BRCA2 deficiency the breakdown of 
replication forks triggers spontaneous DNA breakage, leading to mutability and cancer predisposition.   
 
2.9.4.4  Chromosomal instability through inappropriate DNA double-strand break (DSB) repair 
 
DNA double strand breaks (DSBs) are repaired through mainly three mechanisms.  Homologous 
recombination (HR) is the method of choice since it is regarded as being error-free.  Breaks are 
repaired in a RAD51 dependent manner through exchange between sister chromatids or between 
homologous chromosomes.  Both non-homologous end joining (NHEJ) and single-strand annealing 
(SSA) are RAD51 independent and error-prone mechanisms.  SSA is a type of HR between short 
stretches of single stranded DNA at staggered DSBs.  Repair is done by pairing versus strand exchange. 
 
The major role of BRCA2 in DSB repair is through control of the RAD51 recombinase, while BRCA1 
performs a distinct and more general function as a link between the sensing, signalling and effector 
components of the response to DNA damage (reviewed in Venkitaraman 2002).  BRCA2 binds directly 
with RAD51 (Sharan et al. 1997; Wong et al. 1997), a protein essential for DSB repair by HR 
(homologous recombination).  It has been shown that BRCA2 bound to DSS1 (BRCA2DBD) 
stimulates the RAD51-mediated strand pairing and exchange reaction in vitro (Yang et al. 2002).  It is 
predicted that the release of RAD51 from its sequestered, inactive state must specifically be triggered 
by DNA damage or replication arrest.  The direct role of BRCA2 in the control of RAD51 availability 
and activity may explain why both SSA and NHEJ are used in a BRCA2-deficient cell to repair site-
specific DSBs (Tutt et al. 2001).  BRCA1 also binds with RAD51 and forms another complex with 
RAD50, both of which are required for efficient HR, but far less is known about how BRCA1 may 
work in these reactions.  In BRCA1-deficient cells, however, SSA and HR appear to be decreased, and 
NHEJ predominates as the repair mechanism (Moynahan et al. 1999).  Therefore, chromosomal 
instability provoked by a BRCA deficiency is the result of incorrect routing of DSB processing down 
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inappropriate and therefore error-prone pathways, rather than the failure of repair per se (Narod and 
Foulkes 2004).   
 
Cytokinetic abnormalities have also been linked to hereditary cancer syndromes, characterized by 
chromosomal instability, and may help to explain why BRCA-deficient tumours are frequently 
aneuploid (Daniels et al. 2004).  BRCA1 has been implicated in the control of the assembly of the 
mitotic spindles and therefore also in the segregation of the chromosomes.  BRCA2 may regulate the 
fidelity of late stages in cytokinesis, but is not an essential component of the machinery for cell 
separation. 
 
2.9.4.5  Chromatin remodelling 
 
The process of chromatin remodelling facilitates DNA repair by allowing access to the site of damage 
for the repair machinery.  These sites are marked within minutes by the phosphorylation of a histone 
species, H2AX.  BRCA1 is an early migrant to sites of H2AX phosphorylation (Celeste 2002), which 
follows with several protein-protein interactions.  In a study by Bochar et al. (2000), researchers 
isolated the main BRCA1-containing protein complex from cells, and found that BRCA1 is a 
component of the multiprotein human chromatin remodelling complex SWI/SNF, mediating the ability 
of BRCA1 to function as a transcriptional coactivator.  BRCA1 also interacts with the 
MRE11/RAD50/Nbs1 protein complex (Zhong et al. 1999; Wang et al. 2000).  MRE11 encodes a 
nuclease, which opens double stranded DNA to form single-stranded DNA tracts. BRCA1 will in turn 
interact with other proteins that remodel chromatin, i.e. regulators of histone acetylation and 
deacetylation (Yarden and Brody 1999; Pao et al. 2000) and with DNA helicases such as BACH1 
(Cantor et al. 2001).  BRCA1 regulates cellular localization and recruitment of BACH1 to sites of 
repair.  These findings indicate involvement of chromatin-remodelling complexes in the pathways 
regulated by BRCA1.   
 
2.9.4.6  Transcription 
 
Apart from participating in protein complexes that have functions intrinsic to the sensing and signalling 
of different types of DNA lesions, BRCA1 also has upstream and downstream roles in the response.  It 
works as a sequence-specific transcriptional regulator of genes whose expression affects checkpoint 
 29
Stellenbosch University http://scholar.sun.ac.za
CHAPTER TWO                     LITERATURE REVIEW  
___________________________________________________________________________________ 
 
enforcement and other downstream biological responses.  BRCA1 can cause p53 mediated 
transcriptional activation of p21 cyclin dependent kinase after DNA damage.  P21 is a potent 
suppressor of growth at the G1/S checkpoint.  Inactivation of BRCA1 in embryos would lead to the 
accumulation of DNA damage and in response, p21, through p53, is induced.  This would reflect the 
activation of a DNA damage-dependent checkpoint, resulting in cell cycle delay, which could have 
catastrophic effects on a gastrulating embryo, leading to “death by checkpoint” (Scully & Livingston 
2000).  P53 and p21 nullizygosity delays the death of BRCA1-/- or BRCA2-/- embryos.  The same type of 
response can be seen in adult cells.  If loss of BRCA1 function were to occur in a pre-malignant cell 
wherein key checkpoints have already been inactivated, the aberrant DNA structures resulting from 
BRCA1 inactivation might be tolerated without cell cycle arrest, promoting neoplastic development.   
 
Another association of BRCA1, supporting its function as transcriptional regulator, is with the protein 
CtIP (function not known) (Wong et al. 1998; Yu et al. 1998).  BRCA1 has to release this protein to 
allow the transcription of DNA damage response genes, e.g. GADD45, which is upregulated if BRCA1 
is overexpressed.  The released CtIP will bind to CtBP, a transcriptional repressor.  BRCA1 also binds 
with ZBRK1 to form a nuclear protein complex, which modulates transcription of DNA damage-
inducible genes and acts as a repressor for Myc-mediated transcription activation (Zheng et al. 2000).  
This enables cell cycle arrest at G1/S.  ZBRK1 can repress GADD45 transcription in a BRCA1-
dependent manner (Yun and Lee 2003).  Moreover, BRCA1 interacts with the RNA polymerase II core 
enzyme, as well as with the RNA polymerase II haloenzyme through RNA helicase A (Anderson et al. 
1998).  BRCA1 deficiency would cause a blockage of the RNA polymerase II transcription machinery.  
Despite all these known interactions which BRCA1 has, there is no firm evidence that any of these 
interactions reflect general roles of BRCA proteins in the control of gene expression. 
 
Over-expression of the wild-type BRCA1 gene has been found to inhibit signalling by the ligand-
activated ER-α in various human breast cancer cell lines (Fan et al. 1999).  The amino-terminus of 
BRCA1 protein binds directly to the activation function (AF-2) domain of ER-α through an estrogen-
independent interaction, and the carboxyl-terminus binds to the DNA to repress the transcription of the 
receptor, and therefore its proliferative effect.  In addition, BRCA1 blocks the expression of two 
endogenous estrogen-regulated gene products, pS2 and cathepsin D (Fan et al. 2001). 
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BRCA2 associates with P/CAF, which is a transcriptional co-activator which has histone 
acetyltransferase activity (Fuks et al. 1998).  This interaction is proof for a transcription activation 
function of BRCA2.   
 
2.9.4.7  Ubiquitination 
 
Ubiquitination is the process in which proteins are tagged for degradation by the proteasome.  Like 
other RING proteins, the BARD1/BRCA1 complex functions as an E3 ubiquitin ligase with 
undetermined specificity (Ruffner et al. 2001; Kentsis et al. 2002).  BAP1 is an ubiquitin hydrolase that 
interacts with BRCA1 (Jensen et al. 1998) and can, in turn, remove ubiquitin.  Ubiquitination could be 
a way of regulating BRCA1 levels in the cell (Choudhury et al. 2004). 
 
2.9.5  Other cancers associated with the BRCA genes 
 
In addition to breast and ovarian cancer, individuals with BRCA1 or BRCA2 mutations also have an 
increased risk of other epithelial cancers, for which precise estimates are unavailable.  BRCA1 mutation 
carriers suffer increased risks of colon and prostate cancer, suggesting a lifetime risk of 6% for colon 
cancer in BRCA1 mutations carriers and 8% for prostate cancer (Ford et al. 1994; The Breast Cancer 
Linkage Consortium 1999).  Pancreatic cancer has shown a link with BRCA2 mutations (Schutte et al. 
1995) and is often observed in breast cancer families.  Cancers of the larynx, oesophagus, colon, 
stomach, gallbladder and bile duct, haematopoietic system, as well as malignant melanomas have to a 
lesser extent been observed in BRCA2 families (Easton et al. 1997; The Breast Cancer Linkage 
Consortium 1999).  The more general increase in cancer risk appears to contrast with BRCA1, where no 
excess risk has been observed except for prostate and colon cancer (Ford et al. 1994).  It should, 
however, be noted that some of the excess of stomach cancer incidence could be attributed to 
misclassification of ovarian cancer, and some of the cancers of the gallbladder and bile ducts might 
have been misclassified pancreatic cancers (The Breast Cancer Linkage Consortium 1999).   
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2.10  MUTATION ANALYSIS 
 
2.10.1  BRCA1 and BRCA2 mutation spectrum  
 
The isolation of the BRCA1 gene by Miki and colleagues in 1994 and the BRCA2 gene by Wooster and 
colleagues in 1995 has prompted a plethora of publications characterizing mutations and 
polymorphisms in various populations.  Several groups worldwide have characterized the spectrum of 
germline mutations throughout these genes.  The Breast Cancer Information Core (BIC) (Friend and 
The BIC Steering Committee 1995) is an open access online database hosted by the National Human 
Genome Research Institute (http://research.nhgri.nih.gov/projects/bic).  The database was established 
to catalogue the range and frequency of germline BRCA1 and later also BRCA2 mutations.  To date 
several hundred deleterious BRCA1 and BRCA2 mutations, polymorphisms and sequence variants with 
unclassified significance have been published or reported in the BIC database.  Mutations are nearly 
ubiquitously distributed over the coding region with no “hot spots” present (Couch et al. 1996a; Couch 
et al.1996b).  The search for mutations therefore requires extensive analysis of the entire coding 
sequence of both genes.   
 
While a small number of mutations have been found repeatedly in unrelated families, the vast majority 
have not been reported in more than a few families.  Mutations have been identified in various 
populations which could be traced back to a common ancestor (discussed in section 2.11.6).  Of the 
known BRCA1 and BRCA2 mutations, the majority are predicted to result in premature termination of 
translation, varying in length from 5% to 99% of the full length protein (Couch et al. 1996a; Couch et 
al. 1996b).  Collectively, mutations consist of small deletions (70%) and insertions (10%) that generate 
translational frameshift, single base substitutions that directly generate termination codons (10%) and 
splice site errors (5%) (Rahman and Stratton 1998).  Insertions and deletions are mostly only of one or 
two nucleotides.  Pathogenic mutations that cause amino acid substitutions account for a small 
proportion of BRCA1 and BRCA2 mutations (<5%).     
 
Almost all carriers of mutations in BRCA1 and BRCA2 are heterozygous and most BRCA1- and 
BRCA2-linked tumours have undergone LOH at these loci.  Nondisjunction with chromosome loss or 
with duplication, interstitial and terminal deletion, gene conversion, mitotic recombination between 
homologous chromosomes and translocations are all mechanisms by which a cell might undergo LOH 
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(Monteiro 2003).  An exception is a woman who was found to be homozygous for BRCA1 2800delAA, 
which results in an in-frame stop codon at nucleotide 2820 (Boyd et al. 1995).  This allele is expected 
to encode a 900 amino acid protein.  The individual developed breast cancer at age 32, but was 
developmentally normal.  This case is intriguing because it suggests that BRCA1 may not be essential 
for normal development and it contrasts with results obtained from complete Brca1 nullizygous mice, 
which die in utero (Hakem et al. 1996; Ludwig et al. 1997).  A double BRCA1 heterozygote, BRCA2 
heterozygote has also been reported.  This individual was developmentally normal but developed breast 
cancer at age 48 and ovarian cancer at age 50 (Ramus et al. 1997).   
 
2.10.2  Chromosomal rearrangements:  Large deletions and duplications 
 
The genomic sequence of BRCA1 contains a relatively high percentage of Alu repeat elements (41.5% 
or one per 0.65kb) (Smith et al. 1996), compared to the average repeat element content of the human 
genome (30.4%).  These repetitive elements have been suggested to facilitate intragenic recombination 
leading to exon deletions or duplications in BRCA1 (Puget et al. 1999a).  The genomic sequence of 
BRCA2 harbours approximately half as many Alu-repeats as does BRCA1, but still these elements occur 
on average every 1.5kb.  Large genomic deletions in BRCA1 are infrequent, accounting for only 5-10% 
of all genomic mutations, and these mutations are probably even less common in BRCA2 (Puget et al. 
1999a).  Even though large gene rearrangements are rare, any attempt to provide a comprehensive 
mutation screening strategy for BRCA1 and BRCA2 should include a method for the identification of 
this type of mutation, which would be missed by conventional PCR-based mutation detection methods 
(Robinson et al. 2000).  These alternative methods would include Southern blotting or long-range PCR, 
or as Robinson et al. (2000) suggest, a semiquantitative PCR-based fluorescent assay.   
 
Petrij-Bosch et al. (1997) identified three large BRCA1 Alu-mediated deletions in Dutch cancer patients 
accounting for 36% of all pathogenic mutations identified in this population (discussed in the section 
on founder mutations 2.11.6).  It has also been demonstrated that BRCA1 genomic deletions account for 
more than a third of the pathogenic BRCA1 mutations in Italian breast cancer families (Montagna et al. 
2003).  Researchers have discovered deletions which removed BRCA1’s non-coding exons 1a and 1b 
(promoter region) as well as exon two which contains the transcription start site (Swensen et al. 1997; 
Brown et al. 2002; Puget et al. 2002).  This deleted area is then replaced with the pseudogene which is 
a duplication of exons 1a, 1b and exon two.  Various other large deletions encompassing one or more 
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exons have been reported (Puget et al. 1997; Puget et al. 1999a; Unger et al. 2000; Tancredi et al. 
2004; Ward et al. 2005).  It has been suggested that large BRCA1 deletions represent 8-12% of disease 
causing mutations in American families (Puget et al. 1999a; Unger et al. 2000). 
 
Another type of BRCA1 rearrangement has been detected in breast cancer families.  Puget et al. 
(1999b) identified a large duplication, involving exon 13 and 6kb of intronic sequence.  They 
demonstrated that a founder effect is likely, but that the mutation is relatively old and will therefore be 
found in families around the world (also see section on founder mutations 2.11.6).  The exon 13 
duplication have been shown to be present in 11% of breast cancer patients residing in the UK 
(Robinson et al. 2000). 
 
Only a few large genomic rearrangements in BRCA2 have been published thus far.  One of these 
involves the insertion of an Alu-element into exon 22 which resulted in alternative splicing and exon 
skipping (Miki et al. 1996).  Another pertains to a 5kb genomic deletion encompassing exon three, but 
it is unclear whether the deletion is caused by Alu-recombination (Nordling et al. 1998).  More recently 
Tournier et al. (2004) identified three large BRCA2 rearrangements in male breast cancer families, i.e. a 
deletion of exons 12 and 13, a duplication of exons one and two and a complete deletion of BRCA2.  
Five novel rearrangements have been identified in breast cancer patients from Australia and New 
Zealand (Woodward et al. 2005), with BRCA1 arrangements identified in 2.2% of cases and BRCA2 in 
2%.    
 
2.10.3  Mutations affecting BRCA1 and BRCA2 expression 
 
It has been estimated that mutations that affect expression, splicing or stability of the transcript may 
account for 15-20% of all BRCA1 and BRCA2 mutations (Szabo and King 1995).  The promoter region 
of BRCA1 has been screened in only a few published studies and even less data is available on the 
promoter region of BRCA2.  However, to date, results indicate that mutations in regulatory regions of 
the BRCA1 and BRCA2 genes are rarely expected to be the basis of genetic predisposition to breast and 
ovarian cancer (Brown et al. 2002). 
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2.10.4  Polymorphisms and unclassified variants 
 
The presence of multiple polymorphisms suggests that the development of DNA based screening tests 
will be technically challenging.  False-positive results may occur because of the difficulty in 
distinguishing between benign polymorphisms and pathological mutations.   
 
Three basic methods are available to determine the clinical significance of these mutations (Shattuck-
Eidens et al. 1997): (1) family studies to determine whether the mutation segregates with breast cancer 
in family members; (2) allele frequency analysis to determine whether the allele has a higher frequency 
in cancer patients than in the general population; and (3) protein function assays to measure the effect 
of the mutation on the protein. 
 
2.10.5  Variation in risk related to specific mutations 
 
From the viewpoint of genetic counselling, it is important to determine whether different mutations are 
associated with variable risk.  Diez et al. (1997) reported an identical twin pair with a family history of 
breast and ovarian cancer.  A BRCA1 pathogenic mutation, causing a severely truncated protein, was 
identified.  One sister developed breast cancer when she was 32 and ovarian cancer when she was 39 
years old.  At the time of the study they were 49 years old.  Her sister remained healthy.  Both had 
similar reproductive histories and both had a similar lifestyle.  This is just one example of the variable 
penetrance of BRCA1 mutations against an identical genetic and similar environmental background.   
 
Although some research studies have suggested differences in cancer risk associated with different 
BRCA1 mutations, no definitive data is available yet.  However, it is worth noting that the ratio of 
ovarian cancers to breast cancers has been reported to be higher in families with truncating mutations 
toward the 5’ end of the BRCA1 coding sequence than in families with mutations close to the 3’ end 
(Gayther et al. 1995).  The junction between these two areas is best characterized as a sharp 
demarcation point (rather than a gradual transition region) located between codons 1435-1443.  
Thompson et al. (2002a) found that a division of BRCA1 into three regions, of roughly equal size, with 
different risks associated with mutations in each region, improve the fit.  The ovarian-breast cancer 
ratio was similar for the 3’ and 5’ regions, but significantly higher in the centre.  Although the 
biological mechanism underlying the genotype-phenotype correlation is not known, this observation 
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adds weight to the hypothesis that BRCA1 proteins truncated midway through the RAD51-binding 
domain have bound incompletely and behaves differently from truncated proteins that have either 
bound correctly or not at all.  Overall, the balance of evidence remains in favour of the heterogeneity of 
risk for different BRCA1 mutations.   
 
Analysis of BRCA2 mutation data has provided evidence that the risks of breast and ovarian cancer are 
related to the position of the mutation: truncating mutations in families with the highest risk of ovarian 
cancer relative to breast cancer are clustered in a region in the middle of exon 11, bounded by 
nucleotides 3035 and 6629 (Gayther et al. 1997). This region was coined the “ovarian cancer cluster 
region” or the OCCR.  Thompson and Easton (2001) found that the risk of breast cancer for mutations 
inside the OCCR was lower than that for other BRCA2 mutations (52.3% risk outside versus 33% risk 
within for breast cancer and 11% outside versus 20% within for ovarian cancer).  The distinct 
phenotype associated with OCCR mutations relative to other BRCA2 mutations appears to be 
predominantly a reduced risk of breast cancer rather than an increased risk of ovarian cancer.  It is 
interesting that most of the families with more than one case of male breast cancer had mutations 
outside the OCCR.  Conversely, male carriers of BRCA2 mutations that lie outside the OCCR have 
been proposed to have an increased risk of developing prostate cancer (Thompson and Easton 2001).  
The observation that at least six of the RAD51-binding motifs, the BRC repeats, lie within the 
boundaries of the OCCR defined in this study suggests that they may play a role in the variation in 
cancer risk observed.  Risch et al. (2001) found that apart from ovarian and prostate cancer, colorectal, 
stomach and pancreatic cancer occurred only when mutations were in the OCCR. 
  
2.11  BRCA1 AND BRCA2 PENETRANCE 
 
2.11.1  Autosomal dominant inheritance of breast cancer predisposition 
 
More than a decade before the cloning of the BRCA genes, segregation analysis of families selected for 
high risk suggested that an autosomal dominant gene influenced risk of premenopausal breast and 
ovarian cancer, another gene (with different penetrance) influenced postmenopausal breast cancer, and 
a third (combined with environmental and/or polygenic effects) influenced childhood tumours and 
early-onset breast cancer (Go et al. 1983).  The first complex segregation analysis of a population-
based series of families indicated that an autosomal dominant allele with high penetrance could fully 
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explain clustering of breast cancer in families, but that genetic susceptibility was present in only 4% of 
the families (Newman et al. 1988).  The majority of studies hereafter, prior and after the cloning of the 
BRCA1 and BRCA2 genes, confirmed these result (refer to Table 2.1).  The proportion of breast cancer 
cases attributable to inherited susceptibility is much higher for early-onset breast cancer (Claus et al. 
1991; Claus et al.1996). 
 
Table 2.1  Summary of the literature addressing inherited susceptibility to breast cancer. 
Percentage of Breast Cancer Attributable to Inherited Susceptibility 
Newman et al. 
(1988) 
Claus et al. 
(1991) 
 
Colditz et al. 
(1993) 
Claus et al. 
(1996) 
Struewing et al. 
(1996) 
Szabo and King 
(1997) 
4% 2.5% 2.5% 7% 10% 6-10% 
 
2.11.2  Lifetime risk of developing breast cancer 
 
Risk can be presented in more than one way, e.g. odds ratios, lifetime risk, annual risk per 100 000 
women, risk at a certain age or risk for a specific time period (Sauven 2004).  The lifetime risk of 
developing breast cancer is usually defined as the risk up to the age of 70 years.  Age-specific 
penetrance refers to the likelihood that breast cancer will develop in a carrier of a predisposing 
mutation by a certain age.  For adult onset diseases, penetrance is usually quoted in conjunction with 
age and gender components.   
 
It was initially proposed that female BRCA1 mutation carriers have a lifetime risk of either breast or 
ovarian cancer of close to 100% (Ford et al. 1994).  With only one breast cancer susceptibility gene 
identified at the time, the observed patterns of breast and ovarian cancer risks were presumed to be 
explained by two different BRCA1-susceptibility alleles, one conferring a lifetime breast cancer risk of 
91% and the other conferring a lifetime risk of 70%.  The second susceptibility “allele” Ford et al. 
(1994) referred to was most likely BRCA2.   
 
An individual’s risk to develop breast cancer can be stratified for different age groups.  Estimates for 
BRCA1 and BRCA2 mutation carriers at age 50 and age 70 years (also referred to as lifetime risk) are 
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compared in Table 2.2.  These results indicate that the lifetime breast cancer risk in BRCA2 mutation 
carriers is comparable to that for BRCA1.  Antoniou et al. (2003) did a meta-analysis that combined 
data from 22 studies in which patients from the US, UK, Australia and Europe were unselected for a 
breast cancer family history.  The average cumulative risk was 65% by age 70 years in BRCA1 
mutation carriers and 45% in BRCA2 mutation carriers.  The average risk of breast cancer (and also 
ovarian cancer) is therefore higher in BRCA1 mutation carriers than in BRCA2 mutation carriers, as can 
be deduced from Table 2.2.  Relative risks of breast cancer declined significantly with age for BRCA1 
mutation carriers, but not for BRCA2 mutation carriers.       
 
In men, BRCA1 does not appear to be associated with a significantly increased risk for breast cancer, 
although mutations in this gene have been described in affected men (Struewing et al. 1995).  The most 
likely interpretation of these findings is that BRCA1 mutations do confer an increased risk of male 
breast cancer, but that the risk is lower than the risk conferred by BRCA2.  The association between 
BRCA1 and male breast cancer is thus not clear.  The absolute risk of male breast cancer is still small, 
and many families where the risk of breast cancer is attributable to BRCA2 will be characterized by 
female breast cancer only (Wooster et al. 1994).  Data suggest therefore that BRCA1 and BRCA2 
mutations do not show the same high penetrance values in male carriers as it does in female carriers.  
BRCA2 mutations are responsible for between 8% and 14% of the observed breast cancer risk in male 
patients (Couch et al. 1996a; Friedman et al. 1997; Basham et al. 2002).  
 
The penetrance of BRCA mutations is still a matter of intense research more than 10 years after the 
cloning of these genes.  There is still controversy regarding which estimates of penetrance should be 
used to counsel women with BRCA1 and BRCA2 mutations, as different studies continue to generate 
different figures.   
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Table 2.2  Cumulative lifetime risk for BRCA1 and BRCA2 mutation carriers to develop breast cancer. 
Study Population BRCA1  BRCA2  
  50 yrs 70 yrs  50 yrs  70 yrs  
Female Breast Cancer      
Claus et al. (1991) 
 
US  92%   
Easton et al. (1993) 
 
UK, US, Europe 59% 82%   
Ford et al. (1994) North America, Western Europe 73% 87%   
Easton et al. (1997) 
 
Ireland   60% 80% 
Schubert et al. (1997) 
 
US with European ancestry   32% 67% 
Marroni et al. (2004) Italian 27% 39% 26% 44% 
      
Male Breast Cancer      
Easton et al. (1997) 
 
Ireland    6.3% 
Thompson and Easton (2001) 
 
Western Europe, US, Canada    2.8% 
 
2.11.3  Contralateral breast cancer        
 
Ascertainment of bilaterality is biased in very high-risk families in that some women will choose 
bilateral mastectomy following their first diagnosis of breast cancer (Friedman et al. 1994).  The 
contralateral rate immediately following the first primary is also likely to be inflated by increased 
surveillance (Peto and Mack 2000).  It is important to note that contralateral breast cancer could in fact 
be misdiagnosed recurrences or metastasis to the contralateral breast rather than new independent 
primary lesions.   
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In the largest published study of contralateral breast cancer incidence (Harvey and Brinton 1985) it was 
found that the rate of bilateral breast cancer was 1% per year in young patients within five years of 
their initial breast cancer, but subsequent incidence was independent of age at initial diagnosis and 
remained almost constant at approximately 0.7% per year for more than 20 years.  This constant rate 
stands in contrast to the rate of breast cancer in the general population, which increases sharply up to 
age 50 and more slowly from ages 50 to 80.  For women who did not have an oophorectomy or any 
chemotherapy, the 10 year risk of contralateral cancer have been estimated to be 43.4% for BRCA1 
mutation carriers and 34.6% for BRCA2 mutation carriers (Metcalfe et al. 2004).   
 
It is likely, that if a particular allele indeed plays a predisposing role in breast cancer development, it 
would evidently be overrepresented in bilateral cases (Van’t Veer et al. 2002).  Bilateral tumours share 
the genetic background of the host, a history of exposure to external hazards and probably some 
essential features of the metabolic environment (Imyanitiv and Hanson 2002).   
 
2.11.4  Family and twin studies 
 
The risk of breast cancer is approximately doubled among women whose mothers had breast cancer 
diagnosed before the age of 40 years or who have a sister with breast cancer (relative risk of 2.1), and 
remains elevated even for those whose mothers were diagnosed with breast cancer at the age of 70 
years or older (relative risk of 1.5) (Colditz et al.1993).  The risk in 1st degree relatives is ~0.3-0.4% 
per year.  Loman et al. (2003) found that breast cancer risk in first degree relatives of early-onset breast 
cancer cases are elevated, irrespective of the BRCA1 and BRCA2 mutation status, but the cumulative 
risk by age 50 years is likely to be higher in first degree relatives of BRCA1 and BRCA2 mutation 
carriers compared with first degree relatives of carriers of unidentified breast cancer susceptibility 
genes.   
 
The annual risk for monozygotic (MZ) twins is 1.31% per year and 0.5% per year for dizygotic (DZ) 
twins (Peto and Mack 2000).  The value for MZ twins would mean ~0.7% increase for each breast, 
which is similar to the value for contralateral breast cancer.  The annual incidence in risk for MZ twins 
remains relatively constant throughout life (Peto and Mack 2000).  Hamilton and Mack (2003) did a 
case-control study in MZ and DZ twin pairs.  They investigated the role of ovarian hormones in breast 
cancer risk.  Their findings suggest that the risk of breast cancer for genetically susceptible women is 
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determined not by cumulative exposure to ovarian hormones but rather by unusual sensitivity to 
pubertal hormones (earlier exposure or exposure to high levels).  These results could explain the 
constant age-specific pattern of risk in twins, which is inconsistent with causation by cumulative 
exposure to hormones.   
 
Comparisons of the concordance of cancer between MZ and DZ pairs of twins provide information on 
whether the familial pattern is due to hereditary or environmental influences.  One research group has 
found the genetic determinant to be 27%, the shared environmental effect 6% and the non-shared 
environmental factors accounting for the remaining 67% (Lichtenstein et al. 2000).  The high incidence 
among MZ twins of breast cancer cases as well as the fact that this finding is more pronounced in 
younger cohorts (Ahlbom et al. 1997, Lichtenstein 2000), serves to verify the heritability of this 
disease.  The similarity of the observed high and constant age-specific rate to that in the contralateral 
breast of breast cancer cases provides additional evidence that bilateral disease is largely attributable to 
the genome rather than the environment.   
 
The most plausible high-risk genotype consists of multiple co-existing susceptibility alleles acting 
through heightened susceptibility to hormones, and/or defective tumour suppression (Mack et al. 
2002).  Combinations of synergistic genes could presumably provide a purely genetic explanation of 
the much higher rate of risk in patients’ MZ twins than in their sisters of all other ages, but both genetic 
predisposition and environmental factors (perhaps in utero) may have a major role in conferring 
susceptibility to breast cancer. 
 
2.11.5  BRCA1 and BRCA2 mutation carrier frequencies in breast cancer families  
 
From the maximum-likelihood Mendelian model, Newman’s group (Newman et al. 1988) determined 
the frequency of the breast cancer susceptibility allele to be 0.0006 (about one in 1500) in the general 
population.  After the identification of the BRCA1 and BRCA2 genes, it was determined that the 
frequency of cancer-predisposing mutations in the Caucasian population is between one in 500 and one 
in 1500 (Ford et al. 1995; Couch et al. 1996a; Couch et al. 1996b; Whittemore et al. 1997; Peto et al. 
1999).  Szabo and King (1997) compared risk estimates for BRCA1 and BRCA2 mutations from various 
studies.  In all populations the frequency of BRCA1 mutations was 1.5 to two-fold higher than the 
frequency of BRCA2 mutations.   
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Initially, the BRCA genes appeared to be responsible for disease in 45% of families with multiple cases 
of breast cancer only, and in up to 90% of families with both breast and ovarian cancer (Easton et al. 
1994).  It has been shown that the frequencies are in fact much lower.  Important variables, which 
would influence these estimations, are the number of affected individuals in a family for both breast 
and ovarian cancer, age at diagnosis and the presence or not of male breast cancer cases.  Families in 
which breast cancer has occurred and in which at least one male has been affected have been reported 
to have a 60-76% chance of carrying BRCA2 mutations (Ford et al. 1998).   
 
Experimental results on the different contributions of BRCA1 and BRCA2 mutations to the breast 
cancer phenotype vary greatly.  This is mainly a consequence of the selection criteria used to include 
patients in a particular study.  In order to compare data, studies were divided into groups according to 
these criteria (Table 2.3).  For this purpose, high-risk breast cancer families are considered to have 
three or more first or second degree relative with breast and/or ovarian cancer, early-onset breast cancer 
(<35 years at diagnosis), bilateral disease and male breast cancer.  Moderate risk breast cancer families 
have one or two first or second degree relatives with breast and/or ovarian cancer or individuals with 
three or more distant relatives (third or fourth degree) with breast and/or ovarian cancer.  The 
population-based studies did not take family history or age of onset of the disease into account. 
 
Only a few published studies have concentrated explicitly on male breast cancer.  Although BRCA1 
mutations have been identified in male breast cancer patients, BRCA2 mutations are mainly responsible 
for the increased risk.  Germline BRCA2 mutations have been identified in men diagnosed with breast 
cancer regardless of a family history of the disease (Couch et al. 1996a).   
 
 
 
 
 
 
 
 
 
 42
Stellenbosch University http://scholar.sun.ac.za
CHAPTER TWO                     LITERATURE REVIEW  
___________________________________________________________________________________ 
 
Table 2.3  BRCA1 and BRCA2 mutation carrier frequencies in breast cancer patients from high- and 
moderate-risk breast cancer families and in patients unselected for a family history of breast cancer. 
Study Population Method Carrier Frequencies 
High-risk   BRCA1 BRCA2 
Easton et al. 1993 UK Linkage analysis 39%  
Castilla et al. 1994 US SSCP 16%  
Schubert et al. 1997 European PTT, SSCP  27% 
Håkansson et al. 1997 Scandinavian PTT, SSCP 22.6% 11.3% 
Vehmanen et al. 1997 Finish PTT, SSCP/HA  8% 
Wagner et al. 1999 Central European dHPLC 9% 8% 
Ford et al. 1998 UK Linkage analysis, 
incorporating mutation 
data 
52% 32% 
Claes et al. 2004 Belgian PTT, HA, DGGE, MPLA 14% 9.2% 
Moderate-risk   BRCA1 BRCA2 
Inoue et al. 1995 Japanese SSCP 10%  
Krainer et a. 1997 US PTT, ASO  2.7% 
Couch et al. 1997 UK CSGE 16%  
Greenman et al. 1998 UK SSCP, FCCM 19%  
Malone et al. 1998 US SSCP 6.7%  
Peto et al. 1999 UK CSGE 4.9% 2.3% 
Ozdag et al. 2000 Turkish HA 4% 4% 
Ottini et al. 2000 Italians PTT, SSCP 3.7% 4.4% 
Armakolas et al. 2002 Greek SSCP  17.9% 
Kataki et al. 2005 Greek PTT, SSCP 6.8% 9.2% 
Population-based   BRCA1 BRCA2 
Langston et al. 1996 US SSCP, ASO 7.5%  
Newman et al. 1998 US PTT, SSCP, ASO 3.3%  
Risch et al. 2001 Canadian, European, UK PTT, DGGE 7.5% 4% 
UK – United Kingdom; US – United States; SSCP – single-strand conformation polymorphism; PTT – protein truncation 
test; HA – heteroduplex analysis; dHPLC –denaturing high performance liquid chromatography; DGGE – denaturing 
gradient gel electrophoresis; MPLA – multiplex ligation-dependent probe amplification; ASO – allele specific 
oligonucleotides; CSGE – conformation sensitive gradient electrophoresis; FCCM – fluorescent chemical cleavage of 
mismatch. 
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Eeles (1999) constructed a table with combined data from various studies.  According to this analysis, 
the chance of finding a BRCA1 or BRCA2 mutation is less than 10% in all single cases of breast or 
ovarian cancer, ~10% if it is diagnosed before the age of 35 years and between 10% and 30% if there 
are two breast cancer cases in the family diagnosed before the age of 50 years.  The odds are raised to 
50% if three breast cancer cases diagnosed before the age of 50 years are present.  They proposed that 
the chance of detecting a mutation is in fact lower because at least 15% of mutations are regulatory, i.e. 
not in the coding region of the gene which is the area tested, and the genetic screening methods are 
approximately 80% sensitive.   
 
2.11.6  Founder mutations    
 
A likely reason for the preponderance of a disease in a specific population is a founder gene mutation 
effect.  This occurs when a population is either established by a small number of people or when a 
population bottleneck occurs that reduces the population to a small number.  When the population 
expands, the mutation in a founder becomes prevalent (Neuhausen 2000).  A population or ethnic 
group refers to individuals having a common national or cultural tradition, referring to origin of birth or 
descent (as defined by the Oxford Complete Wordfinder 1996).  Identification of a genetic mutation in 
seemingly non-related individuals from the same population does not necessarily indicate a founder 
mutation, but merely suggest a common ancestor (i.e. an ancient mutation).  Various founder and 
ancient BRCA1 and BRCA2 mutations have been identified.  
 
The Ashkenazi Jews are a genetically homogeneous population in which three mutations (185delAG 
and 5382insC in BRCA1 and 6174delT in BRCA2) account for almost all BRCA mutations, with a 
population frequency of 2% (Struewing et al. 1997).  Approximately 30% of breast cancer diagnosed 
under 40 years of age and 10% of those with breast cancer diagnosed after the age of 40 years are 
caused by these mutations (Abeliovich et al. 1997).  In Dutch women three large deletions in BRCA1 
account for 36% of all breast cancer cases (Petrij-Bosch et al. 1997).  One of the deletions encompasses 
exon 13 and another exon 22.  The third deletion comprises exons 13 to 16 (approximately 14kb).  In 
the Netherlands another founder mutation in BRCA1, 2804delAA, has been identified (Peelen et al. 
1997).  The BRCA2 mutation 999delTCAAA accounts for up to 40% of male breast cancer patients in 
the Icelandic population (Thorlacius et al. 1997).  Puget et al. (1999b) reported a 6kb duplication of 
exon 13 which creates a frameshift in the coding sequence.  The BRCA1 Exon 13 Duplication 
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Screening Group (2000) speculates that this duplication is most likely a founder mutation distributed 
mainly in English-speaking countries or in countries with historical links to Britain.  The BRCA1 
943ins10 mutation, a 10bp tandem duplication in exon 11, was originally identified in the African 
American population, but could be traced back to the Ivory Coast of West Africa and is possibly more 
than 200 years old (Mefford et al. 1999).  Other populations for which founder mutations have been 
described include the Finns, Germans, Norwegians, Russians, Swedish and French-Canadians 
(reviewed in Neuhausen 2000). 
 
Reeves et al. (2004) screened BRCA1 in South African breast and/or ovarian cancer families (at least 
three affected family members with breast cancer ≤ 55 years and ovarian cancer ≤ 60 years of age) of 
predominantly European descent.  Only 20% of their families (15% if Ashkenazi Jewish families are 
excluded) had pathogenic mutations within the coding region of BRCA1, which agrees with figures for 
moderate- to high-risk families from other populations (refer to table 2.3).  These mutations included 
six different frameshift (185delAG; 448insA; 1127insA; 1493delC; 4957insC; 5382insC), and two 
distinct nonsense mutations (E881X; S451X).  Four of these mutations have not been described 
previously (S451X; 1493delC; E881X; 4957insC).  The E881X mutation was identified in 6% of the 
study population.  Haplotype analysis confirmed that these patients shared a common ancestor.  These 
results show that the majority of Afrikaner mutations either arose independently in this country or are 
rare in the various countries of origin.   
 
 2.11.7  African and African American populations     
 
The epidemiology of breast cancer among women of sub-Saharan Africa appears to be similar to that of 
African-American women as both groups have relatively low incidence rates, higher mortality rates, 
increased prevalence of early-onset disease and advanced stage tumours.  It has been postulated that the 
lower postmenopausal breast cancer incidence rates observed for African populations are a 
consequence of demographics, especially population age and overall life expectancy (Fregene and 
Newman 2005).  Breast cancer case ascertainment may also be lower among older African women.  
The reproductive patterns within African populations, which include multiparity, initiation of 
childbearing at younger ages, and prolonged lactation, could contribute towards a lower incidence rate.  
The available information on the epidemiology of breast cancer in African American women and the 
contributing genetic factors are summarized in a review from Newman (2005).  It is apparent from this 
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review, that the influences of parity, socioeconomic status, screening rates, and hereditary factors on 
the ethnicity-related breast cancer risk deserve further study. 
 
Few BRCA1 and BRCA2 studies have been done in any of the African populations or in the African- 
American population.  Almost all studies performed to date have defined breast cancer risks and related 
genetic factors in Caucasian women of European descent.  Earlier studies suggested that inherited 
BRCA1 and BRCA2 mutations might be less common in breast cancer patients of African American 
ancestry than in other populations (Newman et al. 1998).  Gao et al. (2000) selected African American 
families according to a minimum eligibility criterion of two cases of breast and/or ovarian cancer 
among first-degree relatives.  They reported BRCA1 mutations in 21.4% and BRCA2 mutations in 
12.5% of families, which is consistent with mutation frequencies in other populations (refer to table 
2.3).  It has been proposed that African Americans have a unique mutation spectrum (Olapade et al. 
2003).   
 
2.11.8  Models for predicting risk 
 
Various probability models have been developed to estimate the likelihood that an individual or family 
has a mutation in the BRCA1 or BRCA2 genes.  Four priori probability models (Couch et al. 1997; 
Shattuck-Eidens et al. 1997; Frank et al. 1998) and BRCAPRO, a computer program that implements a 
statistical model (Parmigiani et al. 1998), are most often referred to.  Each has unique attributes 
determined by the methods, sample size, and population used to create the model.  Two other models 
for predicting breast cancer risk, the Gail (Gail et al. 1989) and the Claus model (Claus et al. 1994), are 
also widely used in research studies and clinical counselling.  The Gail model is a well validated model 
but, although it includes epidemiological factors, it does not adequately weigh familial risk factors.  
The tables published by Claus are also well validated and in a simple pedigree, give a good estimate of 
risk.  However, these tables do not take unaffected relatives into account and in a large family will 
therefore overestimate the risk in these circumstances, neither do they include paternal relatives or 
cases of ovarian cancer, both of which may increase risk.  Recently, Evans et al. (2004) published a 
new scoring system to calculate the risk of identifying a BRCA1 or BRCA2 mutation.  Their system 
assigns scores depending upon the type of cancer and age at diagnosis, such that a total score of 10 is 
equivalent to a 10% chance of identifying a mutation.   
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All models have limitations, and the risk estimates derived from the models may differ for an 
individual patient.  They do, however, represent the best methods currently available for individual risk 
assessment.   
 
2.11.9  Predictive testing 
 
Genetic screening or genetic susceptibility testing are terms widely used and understood in medical 
practice for the assessment of genetic risk.  It is essential for clinicians to be able to select high-risk 
patients, since so few cases are hereditary.  Although computer models and written guidelines exist for 
predicting the chance of finding a mutation (see previous section on models for predicting risk), none 
of these include all the information that an experienced clinician will use to make a judgment about 
genetic testing (Eccles 2003).  Risk perception is a complex issue and is not directly related to the 
absolute level of risk.  Women with a family history of breast cancer often over-estimate their personal 
risk for cancer and may view themselves as candidates for genetic testing even when the likelihood of 
an informative test result is low (Burke et al. 2000).  A threshold for mutation analysis has been put at a 
10% (US) and at a 20% (UK) likelihood of identifying a mutation (Sauven 2004).   
 
Although clinical evaluation of the BRCA1 and BRCA2 genes has been available since 1996, there has 
been no clear consensus on the specific personal and family history features that should prompt 
consideration of hereditary cancer risk assessment (Frank et al. 2002).  Candidates for genetic testing 
according to Sauven (2004) are: 
• single cases of breast cancer at <40 years of age if Ashkenazi Jewish 
• two breast cancer cases <40 or three <50 years of age 
• four cases of breast cancer at <60 years of age 
• > four cases of breast cancer at any age 
• ovarian and breast cancer in a family (breast cancer <50 years of age if only one ovarian and  
one breast cancer case) 
• female breast cancer at <60 years of age and male breast cancer at any age 
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For predictive or diagnostic testing, it is essential to be able to correctly interpret an observed sequence 
variant to establish the causal role of the variation in the pathogenesis of the disease.  Since both BRCA 
genes have a great number of heterogeneous sequence variations, this is a major challenge.  Extensive 
biological assays and/or family studies have to be done to elucidate whether observed variants have a 
consequence for the protein function.  This is particularly true for sequence changes that have not been 
reported previously.  If experimental evidence is not available, the pathological significance of a 
variation has to rely on plausible considerations.  All other variants must be considered as 
“unclassified” until functional evidence is available. 
 
Predictive testing should only be offered to individuals when accompanied by pre- and post-testing 
counselling with a qualified genetic counsellor.  Because of the heterogeneity of BRCA1 and BRCA2 
mutations, laboratory testing for all possible mutations is challenging.  False-positive results may occur 
as a result of missense mutations that are not associated with an increased risk for breast cancer.  False-
negative results may also occur because not all mutations are known.  Emphasis should be laid on the 
fact that a positive result does not indicate if or when breast cancer will develop, but only documents an 
increased risk of developing the disease (Mosconi and Leccese 2004).  Genetic counselling provides an 
opportunity to convey the limitations of genetic testing for women at risk, including the high likelihood 
of a non-informative test result.   
 
Several approaches, such as intense or more frequent surveillance programs, lifestyle changes, 
chemoprevention and prophylactic surgery have been demonstrated to provide a clinical benefit for 
women who test positive for a BRCA1 or BRCA2 mutation or for their relatives (Eeles 1999).  
Decisions regarding these options must be individualised and psychological support must be offered 
during the period of decision and follow-up.  As regards the reasons for not wanting to be tested, Bruno 
et al. (2004) found in their study that most women could only provide an emotional reply, declaring 
that there were no specific reasons justifying their reluctance.  Reliability of modern medicine and 
concerns regarding legal and social implications seem to be of secondary importance in determining the 
reluctance of women to be tested (Bruno et al. 2004).  Education should focus on scientific fact, but it 
should encompass psychological, social and ethical aspects.   
 
The evidence as to whether genetic testing has an adverse effect on psychological functioning is varied, 
with some studies reporting no significant effects on general distress and other studies revealing 
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psychological difficulties specific to genetic test results (reviewed in Halbert 2004).  Negative test 
results are generally associated with a decrease in depressive symptoms, decreases in anxiety and 
decreases in cancer-specific distress for individuals who consider themselves to be at an increased risk 
for developing breast cancer with regards to a family history of the disease.   
 
2.11.9.1  Ethical issues 
 
Genetic testing for breast cancer susceptibility raises ethical and social concerns related to the adequacy 
of informed consent, the availability and quality of pre- and post-test counselling, and the avoidance of 
genetic discrimination.  It is essential to offer pre-test counselling, both to evaluate the individual’s 
capacity for autonomous decision-making and to provide a realistic view of the risks and benefits, the 
efficacy and alternatives, the seriousness and potential treatment of disorders, as well as the social and 
ethical implications involved.  It is important to explain that the results of DNA testing have 
implications not only for the patients, but also for their biological kin.  The disclosure of genetic test 
results can have psychological and economic ramifications not only for the person screened, but also 
for her (or his) relatives (Durfy et al. 1998).  Some individuals screened may experience anxiety or 
other adverse psychological effects or disrupted personal relationships (Coughlin et al. 1999), again 
emphasizing the importance of genetic counselling.  Genetic knowledge may either increase the sense 
of control on a woman’s life or it may paralyze the decision-making process by shedding a dim light on 
the woman’s future (Surbone 2004).   
 
Other ethical and social issues concern the cost of and access to genetic tests for BRCA1 and BRCA2 
mutations, especially among women who are socioeconomically disadvantaged or uninsured.  While 
newly identified, high-risk individuals may be more motivated to undergo genetic testing, payment for 
genetic counselling and testing may be an important factor in testing decisions.   
 
Finally, an important issue is whether minors should be tested for mutations in BRCA1 and BRCA2, as 
it is an adult onset disease, which is treatable.  For the same reasons and for important consequences 
with respect to abortion and eugenics, prenatal DNA testing for BRCA1 or BRCA2 is also 
contraindicated (Di Pietro et al. 2004).   
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2.12  OTHER CANDIDATE BREAST CANCER SUSCEPTIBILITY GENES  
 
It has been shown that a number of families with large numbers of early onset breast cancer cases are 
not linked to BRCA1 or BRCA2 mutations.  Even if the likelihood of missed mutations and other biases 
are taken into account, most of the familial risk of breast cancer appears to be due to genes other than 
BRCA1 and BRCA2.  After analysis of three-generation population-based families with breast cancer, 
Cui et al. (2001) concluded that there appears to be residual dominantly inherited risk for breast cancer 
in addition to those risks derived form mutations in BRCA1 and BRCA2, even when additional 
recessive or polygenic effects are allowed for.  This suggests that there is still substantial dominantly 
inherited risk not explained by BRCA1 and BRCA2.  Support for a major autosomal recessive 
component to breast cancer susceptibility also exists (Kaufman et al. 2003).   
 
2.12.1  The putative BRCA3 locus 
 
Several candidate regions for a third high penetrance breast cancer gene have been proposed.  
Suggested regions include chromosome 13q21 (Kainu et al. 2000) and chromosome 8p12-22 (Seitz et 
al. 1997a; Seitz et al.1997b), but both have been strongly refuted by analysis of data from independent 
families (Rahman et al. 2000; Thompson et al. 2002b).  More recently the NuMA region on 
chromosome 11q13 has been implicated (Kammerer et al. 2005).  NuMA is a cell cycle-regulator 
protein essential for normal mitosis.  Another candidate locus which familial breast cancer has been 
linked to is chromosome 19q13.2.  The ICAM adhesion molecules have been mapped to this area.  
Further investigation is needed to confirm these associations.     
 
2.12.2  BRCA1 and BRCA2 modifier genes 
 
Modifier loci of BRCA1 are under investigation, including a possible modifier locus on chromosome 5q 
(Nathanson et al. 2002) and the HRAS1 variable number of tandem repeat (VNTR) locus (Phelan et al. 
1996; Tamimi et al. 2003).  Recently a novel gene product, EMSY, has been described (Hughes-Davies 
et al. 2003) which suppresses the transcriptional activity of BRCA2.  Overexpression of EMSY may 
mimic the effects of BRCA2 inactivation.   
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2.12.3  Low penetrance breast cancer genes 
 
Apart from BRCA1 and BRCA2, all other susceptibility alleles, identified to date, are predicted to be 
rare in the population, with mutations in these genes accounting for a very small fraction of heritable 
susceptibility for breast cancer (Nathanson et al. 2001).  Candidate genes from many cellular pathways 
have been investigated, including hormone metabolism, carcinogen detoxification, DNA-damage 
response and immune surveillance.  It is unlikely that the final list of breast-cancer susceptibility alleles 
will be neatly divided into high- and low-penetrance.  If mutations in several genes acting in concert 
account for small subsets of the BRCA1- and BRCA2-negative families, identifying such genes by 
linkage analyses and positional cloning will be difficult.  Associations are constantly confirmed and 
refuted.  Some of the candidate genes, which have been the most extensively studied and have shown 
positive association, will be mentioned in the following paragraphs.    
 
Enzymes involved in the metabolism of environmental carcinogens, like the cytochrome P450 proteins, 
the N-acetyltransferases (NAT1 and NAT2) and the glutathione-S-transferases (GSTM1 and GSTT1) 
have been investigated for polymorphism that may lead to individual differences in susceptibility to 
breast cancer.  The relationship between specific gene polymorphisms and environmental factors has 
therefore also been explored.  Examples of these include possible interactions between NAT1, NAT2, 
GSTM1 and GSTT1 and diet, alcohol consumption and smoking.  These genes are polymorphically 
expressed in a variety of tissues.  Another association which has been reported is between 
methylenetetrahydrofolate reductase (MTHFR) and folate intake, other dietary factors and alcohol 
(Sharp et al. 2002; Le Marchand et al. 2004).  The MTHFR protein is involved in folate metabolism, 
DNA biosynthesis, methylation and genomic integrity in actively dividing cells.  Distinct combinations 
of the X-ray repair cross-complementation group (XRCC1, XRCC2 and XRCC3) polymorphisms appear 
to be associated with either an increased breast cancer risk or the possibility of developing an adverse 
radiotherapy response seen in some breast cancer patients (Moullan et al. 2003).   
 
The role of endogenous and exogenous estrogens in breast tumorigenesis has been discussed in section 
2.6.  Some of the cytochrome genes, which have been implicated in breast cancer risk, include 
CYP1A1, CYP1B1, CYP17 and CYP19, all of which are involved in the synthesis and metabolism of 
estrogen (reviewed in Kristensen and Børresen-Dale.2000).  Catechol-O-methyltransferase (COMT) is 
another protein involved in this pathway, regulating the oxidizing of estrogens to catechol estrogen and 
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estrogen quinines, which have been implicated in breast cancer.  Sequence variations in the 
progesterone receptor (PR), estrogen receptor (ER) and androgen receptor (AR) genes have also been 
associated with an increased risk for developing breast cancer. 
  
Some of the more recent breast cancer associations which have been reported in the literature include 
Aurora-A/STK15/BRAK, which is implicated in the regulation of centrosome duplication thereby 
regulating mitosis (Lo et al. 2005), and the vitamin D receptor (VDR) (Lowe et al. 2005).  The CHEK2 
gene, which is a cell cycle checkpoint kinase, has been shown (Meijers-Heijboer and The CHEK2-
Breast Cancer Consortium 2002) to be a plausible candidate low-penetrance breast cancer gene and 
will be discussed in section 2.12.4.         
 
2.12.4  CHEK2  
 
2.12.4.1  Gene and protein structure  
 
Cell-cycle-checkpoint kinase two (CHEK2 [MIM #604373] also known as CHK2), mapped to 22q12.1, 
is a 1731bp cDNA homologue of the yeast G2-checkpoint kinases CDS1 (Schizosaccharomyces 
pombe) and RAD53 (Saccharomyces cerevisiae) (Matsuoka et al. 1998).  The gene, which has 15 
exons, encodes a 60kD translation product of 543 amino acids.  This nuclear protein is a member of the 
Cds1 subfamily of serine/threonine protein kinases.  Two transcript variants encoding different 
isoforms have been identified for this gene, as well as variants utilizing alternative polyadenylation 
signals.  Blasina et al. (1999) and Chaturvedi et al. (1999) independently identified CHEK2.  The gene 
has a single kinase domain (residues 226-486) and a fork head-associated domain (residues 115-175) 
(Matsuoka et al. 1998), which is involved in protein-phosphoprotein interactions.  These interactions 
are essential for transmitting DNA damage signals to CHEK2.  Any alteration of the  association of 
CHEK2 with upstream signalling proteins could lead to the failure of CHEK2 activation following 
DNA damage.  In addition, the FHA (fork head associated) domain mediates transmitting signals from 
CHEK2 to downstream effectors such as p53, BRCA1 and Cdc25C.   
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2.12.4.2  Pseudogenes 
 
A number of regions of the genome exhibit a high homology to the 3’ terminal exons of CHEK2, 
possibly pseudogenes, making mutational analysis problematic.  This phenomenon was first reported 
by Sodha et al. (2000; 2002a), who did a database search which revealed homologous loci on 
chromosomes seven, 10, 15, 16, 22 and X.  Together these loci encompass exons 10 through 14 of the 
gene and share 95-98% homology.  Further mapping studies (Bell et al. 2000) showed additional 3’ 
gene fragments on chromosomes two, 13 and Y.   
 
2.12.4.3  Functions of the CHEK2 protein 
 
Cell cycle checkpoints are biochemical pathways that ensure the orderly and timely progression and 
completion of critical events such as DNA replication and chromosome segregation.  Activation of 
checkpoints in the G1 and G2 phases in response to DNA damage, in the S-phase upon inhibition of 
DNA replication, or in mitosis after disruption of the spindle, leads to cell cycle arrest.  Such delays 
provide time for repair processes or, in case of severe damage, for the activation of programmed cell 
death.  Defects in the checkpoint regulatory network result in increased sensitivity to damaging agents 
and to the genomic instability that is often observed in cancer.  CHEK2 is involved both in DNA 
replication and in DNA damage checkpoints.   
 
CHEK2 is required for blocking the cell cycle in response to DNA damage and other stresses.  
Phosphorylation and therefore activation of CHEK2 occurs when cells are treated with hydroxyurea, in 
response to ultraviolet radiation and also through phosphorylation by the ATM protein in response to 
ionizing-radiation.  In return it phosphorylates and inactivates Cdc25C which ultimately results in G2 
arrest and prevention of the initiation of mitosis.  It also phosphorylates p53, BRCA1 and other proteins 
(see Figure 2.4). CHEK1 has a similar function to CHEK2.  It phosphorylates Cdc25C at the same site 
as CHEK2.     
 
By phosphorylating p53, the protein is stabilized and its accumulation leads to cell cycle arrest in the 
G1 phase and ultimately ending in apoptosis.  Cells lacking CHEK2 fail to accumulate p53 when 
necessary.  Disruption of p53 is a frequent event in cancer.  Tominaga et al. (1999) propose the 
existence of a counter-regulatory mechanism; when cells lose functional p53 and thus G1 checkpoint 
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control, CHEK2 plays a pivotal role in the DNA damage checkpoint during the G2 phase of the cell 
cycle.  CHEK2 phosphorylates p53 at multiple DNA-damage inducible sites and reciprocally is down-
regulated by p53 (Chehab et al. 2000).  CHEK2 inactivation is therefore partially equivalent to p53 
inactivation, in that CHEK2 deficiency facilitates the development, survival and proliferation of 
BRCA1-deficient T cells at the expense of genomic integrity (McPherson et al. 2004).  
Phosphorylation of BRCA1 is required for the release of BRCA1 from CHEK2, which is important for 
the ability of BRCA1 to restore survival after DNA damage (Lee et al. 2000).  CHEK2 is also capable 
of phosphorylating Cdc25A, leading to activation of an S-phase checkpoint.  Defects in the ionising 
radiation-induced S-phase checkpoint cause “radio resistant DNA synthesis”, a phenomenon that has 
been identified in cancer-prone patients suffering from ataxia-telangiectasia.  CHEK2 is therefore a 
tumour-suppression gene.   
 
 
Figure 2.4  Outline of the involvement of CHEK2 in response to DNA damage.  Reprinted with 
permission form Elsevier, The Lancet (Bradbury  2002). 
 
2.12.4.4  CHEK2 expression 
 
Northern blot analysis done by Matsuoka et al. (1998) revealed wide expression of low amounts of 
CHEK2 with larger amounts in human testis, spleen, colon and peripheral blood leukocytes.  Lukas et 
al. (2001) also addressed the issues of expression and regulation of CHEK2 in relation to various cell 
cycle phases and in proliferating versus differentiated cells and tissues in their study.  Their findings 
indicated that CHEK2 is a long-lived, predominantly nuclear protein that is constitutively expressed at 
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low levels but can become activated to increased levels of expression upon DNA damage in all phases 
of the cell cycle as well as in non-proliferation and terminally differentiated cells.  Furthermore, their 
results indicate that the highest degree of homogenous expression of CHEK2 is in the cancer-prone, 
continuously renewing epithelial cell populations exposed to environmental carcinogens, such as the 
epidermis, the epithelia of the alimentary canal and also in tissues of the breast and endocrine glands, 
regardless of the proliferation status.  CHEK2 is also localized in postmitotic neurons.  However, there 
is a lack of CHEK2 expression in a few terminally differentiated, static cell populations such as adult 
skeletal muscle and cartilage.  These findings correspond to the predominance of sarcomas, breast 
cancer, brain tumours, leukaemia and tumours of the adrenal cortex in Li-Fraumeni Syndrome in which 
CHEK2 mutations are also implicated.   
 
2.12.4.5  CHEK2 as a candidate gene for breast cancer and the 1100delC variant 
 
CHEK2 was first linked to cancer susceptibility in 1999 (Bell et al. 1999), when patients with Li-
Fraumeni syndrome were found to have germline CHEK2 mutations.  The syndrome is characterized 
by familial clustering of specific cancers, including breast cancer.  Three CHEK2 mutations were 
found, one of which was the 1100delC variant in exon 10, a frame shift mutation leading to a premature 
stop at codon 381.  Exons 10 to 12 encode part of the kinase domain of the expressed protein, which 
makes the CHEK2*1100delC a true disease-causing mutation with the loss of kinase activity (Wu et al. 
2001). 
 
Meijers-Heijboer and The CHEK2-Breast Cancer Consortium (2002) analysed the CHEK2 gene and 
found the CHEK2*1100delC variant at a frequency of 1.1% in healthy individuals and 5.1% in 
individuals with breast cancer derived from families that did not carry mutations in BRCA1 or BRCA2, 
including 13.5% of individuals from families with male breast cancer.  They estimated that the 
CHEK2*1100delC variant results in an approximately two-fold increase of breast cancer risk in women 
and a 10 fold increase risk in men.  Walsh et al. (2002) evaluated the relative risk the 
CHEK2*1100delC variant confers in a population based breast cancer study.  The variant accounted for 
2% of high-risk BRCA1 and BRCA2 mutation negative families from North America.  A lower 
frequency (0.45%) was observed among women of Jewish ancestry.  This study also included African 
American breast cancer cases, but the 1100delC allele was not found in any of these individuals.  
Another research group (Vahteristo et al. 2002), reported a frequency of 1.4% among controls, 1.5% 
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among patients of Finnish ancestry with no family history of breast cancer and a frequency of up to 
6.2% among patients with one affected first degree relative.   
 
The CHEK2*1100delC variant have only been detected in patients who tested negative for BRCA1 and 
BRCA2 mutations (Meijers-Heijboer and The CHEK2-Breast Cancer Consortium 2002; Vahteristo et 
al. 2002; Walsh et al. 2002).  Therefore, the variant does not confer an increased cancer risk in carriers 
of BRCA1 or BRCA2 mutations.  It has been suggested that the biologic mechanisms underlying the 
increased risk of breast cancer in CHEK2 mutation carriers are already overturned in carriers of BRCA1 
or BRCA2 mutations, which is consistent with participation of the encoded proteins in the same 
pathway (Meijers-Heijboer and The CHEK2-Breast Cancer Consortium 2002). 
 
2.12.4.6  Other CHEK2 variants and breast cancer 
 
Various groups screened the entire coding sequence of CHEK2 in breast cancer patients, still 
identifying only the CHEK2*1100delC mutation.  The Ingvarsson group (Ingvarsson et al. 2002) used 
microsatellite markers to analyse LOH at chromosome region 22q, where the CHEK2 gene is located, 
and screened breast and other tumours for mutations.  They found that CHEK2 inactivation did not play 
a major role in cancer growth.  One of the variants identified, Thr59Lys, could be a low-penetrance 
allele with respect to breast cancer.  In another study three variants, Arg180His, Arg117Gly and 
Arg137Gln, together with 1100delC, were found to account for 7% of familial breast cancer cases 
(Sodha et al. 2002b).  Kuschel et al. (2003) determined that two common polymorphisms in the gene, 
IVS1+38insA and Ala1013Gly, are not associated with breast cancer, but evidence has been found that 
the Ile157Thr variant may be associated with breast cancer risk (Kilpivaara et al. 2004).  Recently, in a 
population based case-control study among North American women, three CHEK2 variants (1100delC, 
Arg145Trp and Ile157Thr) have been analysed (Freidrichsen et al. 2004).  No statistically significant 
association was observed between any of the CHEK2 variants and breast cancer risk.  Recently an 
ancient CHEK2 allele has been identified in the Ashkenazi Jewish population (Shaag et al. 2005).  This 
variant, Ser428Phe, which falls within the kinase domain of the protein, was detected at a frequency of 
2.88% among breast cancer patients with a family history of breast cancer and at a frequency of 1.37% 
among controls.  This would constitute a ~2 fold increased risk, similar to the risk conferred by the 
1100delC variant (Meijers-Heijboer and The CHEK2-Breast Cancer Consortium 2002; Vahteristo et al. 
2002).   
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Published data suggest that the CHEK2 coding sequence is highly conserved and that variants are rare, 
cryptic or specific to certain populations.  The low prevalence and penetrance of CHEK2 mutations, 
together with no or an uncertain elevation in risk for other CHEK2 mutations, suggest a limited 
relevance for CHEK2 mutations in familial breast cancer (Allinen et al. 2001; Schutte et al. 2003; 
Dufault et al. 2004). 
    
2.12.4.7  CHEK2  and other cancers 
 
Unlike most BRCA1 and BRCA2 mutations, the CHEK2*1100delC variant does not seem to be 
associated with ovarian cancer (Vahteristo et al. 2002). Other CHEK2 mutations have been identified 
in lung cancer (Matsuoka et al. 2001) and in patients with osteosarcoma and ovarian cancer (Miller et 
al. 2002).  Mutations are, however, not common in these cancers.  Meijers-Heijboer et al. (2003) linked 
the 1100delC mutation to 18% of families with hereditary breast and colorectal cancer (HBCC).  This 
mutation was, however, not the major predisposing factor but appeared to act in synergy with other 
susceptibility genes.  Dong et al. (2003) identified a range of CHEK2 mutations in prostate cancer 
cases.  Sixteen of these mutations were not present in their control group, suggesting a possible 
pathological effect of CHEK2 mutations in prostate cancer development. 
 
2.13  MUTATION DETECTION TECHNIQUES 
 
Numerous techniques have been developed for the detection of single base substitutions and small 
deletions or insertions.  These include direct DNA sequencing (DS), single-strand conformation 
polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), denaturing high-
performance liquid chromatography (dHPLC) and heteroduplex analysis (HA).  Most germline 
mutations (>80%) found in BRCA1 and BRCA2 result in premature truncated proteins (Friend and 
Breast Cancer Information Core Steering Committee 1995; Shattuck-Eidens et al.1995; Couch et al. 
1996a; Couch et al. 1996b).  The protein truncation test (PTT) is therefore often used, especially for the 
larger exons (exon 11 of BRCA1 and exon 10 and 11 of BRCA2).  It is important to note that no single 
technique currently available can guarantee the identification of all cancer-predisposing mutations in 
the BRCA1 and BRCA2 genes.   
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Alternative methods are used for detecting large rearrangements, which would not be detected with 
conventional PCR-based screening techniques.  These would include RFLP analysis, Southern blot 
analysis, or modified PCR-based analyses, e.g. long PCR and real-time PCR.   
 
2.13.1  Single-strand conformation polymorphism / heteroduplex analysis (SSCP/HA) 
 
SSCP analysis and HA are PCR-based mutation scanning technologies.  During electrophoresis, single-
stranded DNA folds into a three-dimensional shape according to its primary sequence (Orita et al. 
1989).  The electrophoretic mobility of separation then becomes a function of the shape of the folded, 
single-stranded molecule.  The principle of HA, similar to SSCP, depends on the conformation of 
duplex DNA in a native gel, which consists of complementary strands or strands that have one or more 
base pair mismatches.  Mismatched DNA duplexes (heteroduplexes) have an altered electrophoretic 
mobility relative to the homoduplexes (Nataraj et al. 1999).  A number of factors can influence 
sensitivity in an unpredictable way, such as electrophoretic conditions; including temperature of the gel 
during electrophoresis, gel composition and the dimensions of the gel.  The fragment length and the 
location of the sequence variation along the DNA fragment should also be considered (Nataraj et al. 
1999).  The addition of glycerol has been empirically shown to enhance mobility shifts, but the reason 
for this effect has remained unexplained (Hayashi 1999).  Kukita et al. (1997) proposed that this effect 
was due to the lowering of the pH of the electrophoresis buffer as a result of the reaction of glycerol 
and borate. 
 
The simplicity and efficiency of SSCP, as well as its cost-effectiveness (Sevilla et al. 2002) makes this 
mutation-detection method appealing for rapid analysis of large patient groups.  Sensitivity is, however, 
a major cause for concern when using SSCP as a screening method for novel mutations.  Analysis of 
genes other than BRCA1 or BRCA2 suggested that only 80% of single base pair substitutions (a higher 
proportion of small insertions and deletions) can be detected by this technique when performed 
correctly (Vidal-Puig and Moller 1994; Jordanova et al. 1997).   
 
When utilizing SSCP screening of a gene as large as BRCA1 or BRCA2, no one set of conditions or 
even one method may be optimal for all of the exons.  Rather, a variety of different methods and 
conditions should be studied for each set of amplimers under analysis.  One standard protocol or even a 
single method cannot adequately screen large genes.  A few mutations, likely single base pair changes 
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that tend to produce more subtle gel pattern perturbations, will be missed even in an optimal setting.  
Detection power is increased when combining the SSCP technique with the HA technique (Kotze et al. 
1995). 
 
2.13.2  Melt-point analysis by microplate-array diagonal-gel electrophoresis (melt-MADGE) 
 
Melt-MADGE was invented by Day in 1994 (Day and Humphries 1994).  It is a PCR-based screening 
method implementing temporal-thermal-ramp electrophoresis analysing duplex melting.  The melt-
MADGE system uses the same principle as DDGE or TGGE (thermal gradient gel electrophoresis), but 
exchanges the dimension of the gradient so that it is a thermal ramp in time rather than a gradient in 
space.  The PCR products for analysis are loaded on a homogeneous gel and the temperature of the 
entire gel is raised during the course of electrophoresis.  It is theoretically 100% sensitive to point and 
frameshift variations and is backed by a precise mathematical model that predicts the electrophoretic 
behaviour and resolution of alleles along a temperature gradient (Day et al. 1998).  This technique 
allows high-throughput cost-effective screening of large genes. 
   
2.13.3  Direct DNA sequencing (DS) 
 
DS has been proclaimed to be the gold standard for mutation detection (Dianzani et al. 1993), although 
not necessarily 100% accurate as unequal amplification of alleles in heterozygous samples have been 
reported (Van der Heiden et al. 2004).   Most other screening techniques, such as SSCP and HA, still 
require DNA sequencing of detected variants to be able to identify the exact nucleotide change.  The 
most serious disadvantage of direct DNA sequencing is the high-cost involved (Sevilla et al. 2002).   
 
In automated DNA sequencing dideoxynucleotides (ddNTPs), labelled with different fluorochromes, 
are used.  The labels are incorporated into the ddNTPs and this is used to carry out chain termination.  
Alternatively the primers can be labelled with fluorochromes, which mean the same primers cannot be 
used for the initial PCR amplification and the sequencing reaction.  The four chain-terminated products 
are run on the same track of a denaturing electrophoresis gel.  Capillary electrophoresis utilizes liquid 
polymers in thin capillary tubes.  Each product, with their base-specific dye, is excited by a laser and 
the dye then emits light at its characteristic wavelength.  A diffraction grating separates the emission, 
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which are detected by a charge-coupled device (CCD) and the sequence is interpreted by a computer 
(Molecular biology and basic techniques 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60
Stellenbosch University http://scholar.sun.ac.za
CHAPTER TWO                     LITERATURE REVIEW  
___________________________________________________________________________________ 
 
 61
2.14  OBJECTIVES OF THIS STUDY 
 
The BRCA1 and BRCA2 genes have been intensively studied since they were cloned in the mid 1990’s.  
Although allele frequencies of polymorphisms in the BRCA genes have been determined and the 
mutation spectrum identified in various populations across the world, in only one other published study 
(Reeves et al. 2004) BRCA1 was screened for mutations in South African populations.  The breast 
cancer patients were mostly Caucasians of European descent. In this study we include patients of 
Mixed Ancestry (consisting of Koi San, Malay, African and European Caucasian ancestry (Nurse et al. 
1985)), also referred to as the Coloured population.  Since BRCA1 and BRCA2 are relatively large and 
also polymorphic genes, more comprehensive studies are needed in all our population groups in order 
to investigate the implementation of predictive genetic testing for South African families.   
 
The specific aims of this study: 
 
1. Determine the BRCA1 and BRCA2 mutation spectrum and prevalence in two populations, 
Caucasian and Mixed Ancestry, from the Western Cape Province of South Africa.  
2. Evaluate the relevance of mutations in these genes in individuals with a moderate breast cancer 
family history.   
3. Determine the frequency of the CHEK2*1100delC in South African breast cancer patients with a 
family history (populations described in (1)) and without a family history of breast cancer 
(Caucasian, Mixed Ancestry, Indian and African patients with sporadic breast cancer). 
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3.  MATERIALS AND METHODS 
 
3.1  PATIENTS 
 
In this study we investigated 101 unrelated patients (98 women and 3 men), presenting with 
incident invasive breast cancer.  Patients were from four South African population groups (Mixed 
Ancestry n=65, Caucasian n=30, African n=3, Indian n=1 and unknown ethnicity n=2), all accrued 
from the Tygerberg Academic Hospital in the Western Cape.  Participants gave informed consent to 
the use of their DNA for studying the genetic basis of their breast cancer (refer to Appendix A for 
an example of the informed consent form the patients signed).  Each patient also completed a 
questionnaire (available in both English and Afrikaans: Appendix B) which included information 
pertaining to known environmental modifiers of cancer risk, for example a history of smoking, 
alcohol consumption and hormonal contraceptive use and/or hormone replacement therapy (HRT).  
Reproductive history was also ascertained for the patients.  The study was approved by the Ethics 
Review Committee of the Faculty of Health Sciences, University of Stellenbosch (2001/C062) and 
the Medical Research Council of South Africa (2004/07/29).   
 
Patients were divided into two groups according to their family history of cancer. The first group 
(n=48) is considered to have a modest increased risk for familial breast cancer and was therefore 
screened for both the CHEK2*1100delC variant as well as the entire coding sequences of the 
BRCA1 and BRCA2 genes.  These patients have previously been screened for the Ashkenazi Jewish 
founder mutations (BRCA1 185delAG and 5382insC and BRCA2 6174delT) and the BRCA1 
Afrikaner founder mutation (E881X) in another study by C Scholtz and MJ Kotze.  The familial 
group included individuals from the Caucasian (n=19) and Mixed Ancestry (n=29) population 
groups.  Only one case of bilateral breast cancer was observed in this group (first cancer at 69 years 
of age in right breast, second cancer at 77 years of age in left breast and bilateral breast cancer at the 
age of 83 years).  The age distribution of this group is summarized in Table 3.1.  Fifty-six percent of 
the patients were diagnosed between the ages of 50 and 70 years.  Table 3.2 contains the family 
history of cancer in these patients.  An excess of stomach, oesophageal, colon, pancreatic and 
prostate cancer was noted in the families of this patient group.  Only two patients reported family 
members with ovarian cancer.   
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Table 3.1  Age of onset distribution for the familial breast cancer patient group. 
Population Age Distribution 
 31-40 
years 
41-50 
years 
51-60 
years 
61-70 
years 
71-80 
years 
81+ 
years 
Total 
Mixed Ancestry  8 5 8 5 2 1 29 
Caucasian  0 1 8 6 4 0 19 
Total 8 6 16 11 6 1 48 
 
 
Table 3.2  Family history of cancer for the familial breast cancer group.  Patients have been divided  
into two groups according to age of onset of breast cancer. 
Family history of 1st and 2nd degree relatives  
 
Proband 
BC 
only 
BC and/or 
stomach 
cancer 
BC and/or 
oesophageal 
cancer 
BC and/or 
ovarian  
cancer 
BC and/or 
colon  
cancer 
BC and/or 
pancreatic  
cancer 
BC and/or 
prostate  
cancer 
Other 
cancers 
Breast cancer   
≤50 years 
2 3 2 0 0 0 1 6 
Breast cancer   
>50 years 
15 3 1 2 3 3 2 5 
Total  17 6 3 2 3 3 3 11 
BC - breast cancer 
 
The second group (n=53: Mixed Ancestry n=36, Caucasian n=11, African n=3, Indian n=1 and 
unknown ethnicity n=2) is regarded as sporadic cases and was therefore only screened for the 
CHEK2*1100delC variant.  The sporadic group included only one male patient of Mixed Ancestry.  
Of these patients, 44 (83%) reported not to have a family history of any type of cancer.  Four 
patients (0.08%) reported one family member previously diagnosed with breast cancer.  The age 
distribution of this group is summarized in Table 3.3.  Fifty-three percent of the patients were 
diagnosed between the ages of 50 and 70 years.  Although the prevalence of the mutation has been 
reported to be greater in women with a family history of breast cancer (Meijers-Heijboer et al. 
2002; Vahteristo et al. 2002), an increased breast cancer risk has also been shown to be evident in 
women unselected for a family history (The CHEK2 Breast Cancer Case-Control Consortium 
2004).       
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Table 3.3  Age of onset distribution for the sporadic breast cancer patient group. 
Population Age Distribution 
 31-40 
years 
41-50 
years 
51-60 
years 
61-70 
years 
71-80 
years 
Total 
Mixed Ancestry 3 8 12 6 7 36 
Caucasian 1 0 4 3 3 11 
African 0 1 1 0 1 3 
Indian 0 0 1 0 0 1 
Ethnicity unknown 0 1 1 0 0 2 
Total 4 10 19 9 11 53 
 
 
3.2  METHODS 
 
3.2.1  DNA extraction  
 
Genomic DNA was extracted from whole venous blood according to an adapted salting out 
procedure (Miller et al. 1988).   
 
Blood was collected in 5ml EDTA (vacutainer) tubes.  These tubes were emptied into 40ml Greiner 
tubes (Greiner Labortechnik) and cold lysis buffer (0.155M NH4Cl; 0.01M KHCO3; 0.0001M 
EDTA; pH7.4) was added to a final volume of 40ml.  The mixture was kept on ice for 30 minutes 
and inverted every 5 minutes.  A 45 minutes centrifugation step at 350rcf (relative centrifugal force) 
at 4°C followed.  Subsequently the supernatant was discarded and the pellet washed with 20ml PBS 
(phosphate buffered saline) (0.027M KCl; 0.137M NaCl; 0.008M Na2HPO4; 0.0015M KH2PO4).  
This solution was centrifuged for 30 minutes at 350rcf at 4°C, after which the supernatant was 
discarded and the pellet resuspended in 3ml nucleic lysis buffer (0.01M Tris-HCl; 0.4M NaCl; 
0.002M EDTA; pH8.2), 60μl 10mg/ml proteinase K and 300μl 10% (w/v) SDS.  After an overnight 
incubation period at 55°C, 2ml of a saturated NaCl solution was added and the tube shaken 
vigorously for 1 minute.  The tube was then centrifuged for 30 minutes at 1000rcf at 21°C.  
Subsequently the supernatant was transferred to a new Greiner tube, leaving the foam and pellet 
behind.  The supernatant was shaken for another 15 seconds and centrifuged for 15 minutes at 
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500rcf at 21°C.  The supernatant was transferred to a third Greiner tube.  Two volumes of cold 
100% (v/v) ethanol were added to precipitate the DNA.  The gDNA spindle which formed was 
transferred with a sterile plastic inoculation needle to a clean 1.5ml Eppendorf tube containing 1ml 
70% (v/v) ethanol.  The tube was centrifuged at 17500rcf for 10 minutes at 4°C.  The ethanol was 
poured off and the pellet left at room temperature to dry.  Depending on the size of the pellet, 100-
500μl SABAX water was added to resuspend the DNA.  To ensure a homogenous solution, samples 
were stored for at least 24 hours at 4°C before being subjected to analysis. 
 
3.2.2  DNA quantification     
 
DNA concentration and purity were determined using the NanoDrop® ND-100 Spectrophotometer 
v3.0.1 (NanoDrop Technologies Inc, DE, USA) or with gel electrophoresis, using lambda DNA as 
standards.  Dilutions were made where possible to obtain a final concentration of not less than 
30ng/μl.  
 
3.2.3  Polymerase chain reaction (PCR) primer design 
 
3.2.3.1  BRCA1  
 
Several of the BRCA1 exons have been screened previously in the study population (Appendix C, 
Scholtz et al. 2003).  These include exons 2, 3, 5, 6, 7, 8, 9, 10, 12, 13, 14, 16 and exon 20.  The 
primer design and screening protocol for these fragments will not be discussed.  Primers were 
designed to screen the remaining coding exons of the BRCA1 gene (exons 11, 15, 17, 18, 19, 21, 22, 
23 and exon 24) using the GenBank reference sequences U14680.  The analysis excluded exons 1 
and 4, since exon 1 is non-coding and exon 4 is only a splicing variant.  Because of its size, exon 11 
was screened using 14 overlapping primer sets, including one set designed to screen for the E881X 
mutation.  Primers were placed ≥40 nucleotides away from the 5’ splice boundary of each exon, and 
≥15 nucleotides away from the 3’ splice boundary in order to ensure thorough screening of all 
splice sites.  By keeping the fragments relatively small, the sensitivity of the screening technique, 
namely SSCP/HA, was maximised.  The final list of primer sequences appear in Table 3.4.   
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3.2.3.2  BRCA2  
 
Primers were designed to screen the 26 coding exons of the BRCA2 gene, using the GenBank 
reference sequence U43746 and the on-line primer design software, Primer3 (available at 
www.http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi).  The same criteria were used as 
for the design of the BRCA1 primers.  Exon 11 of BRCA2 is even larger than that of BRCA1 (~5kb 
versus ~3kb).  It was therefore considered to be more cost-effective and less time consuming to 
screen exon 11 by means of direct DNA sequencing.  The exon was amplified in 7 fragments and 
sequenced in both directions.  Exon 10 is also relatively large and had to be divided into 5 
fragments to allow for SSCP/HA.  Both exons 10 and 11 primers were designed to allow ample 
overlap within the exons.  Primer sequences are listed in Table 3.5.   
 
3.2.3.3  CHEK2 
 
A number of regions of the human genome exhibit a high homology to exons 10 to 14 of CHEK2, 
making mutational analysis problematic (Sodha et al. 2000).  The CHEK2*1100delC falls within 
exon 10.  The primer set which was used for the detection of this variant could discriminate 
between the functional gene (GenBank AL131197) and homologous copies of the fragment  in the 
pseudogenes (forward primer 5’GCA AGT TCA ACA TTA TTC CCT TTT 3’; reverse primer 
5’ATC ACC TCC TAC CAG TCT GTG C 3’) (Sodha et al. 2002a).  Amplification yielded a 245bp 
amplicon, suitable for single strand conformation polymorphism and heteroduplex analysis 
(SSCP/HA).   
 
 3.2.4  Polymerase chain reaction (PCR) amplification 
 
PCR was carried out in 25μl volumes containing ~30ng of genomic DNA, 1X NH4 PCR buffer 
(supplied with the DNA polymerase), 0.1mM each of dATP, dGTP, dTTP and dCTP (Promega 
Corporation, Madison, WI, USA), 1.5mM MgCl2 and 0.5U Taq polymerase (BIOTAQTM DNA 
polymerase, Bioline Ltd., London, England).  The PCR conditions were individually optimized by 
varying the primer concentrations, which are listed in Tables 3.4 and 3.5 for BRCA1 and BRCA2 
respectively.   
 
Three PCR cycling regimes were used for amplifying BRCA1 and BRCA2 fragments.  The first 
program (Program A) comprised an initial denaturation step at 94° for 5 minutes, 35-40 cycles 
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consisting of denaturation at 94°C for 30 seconds, annealing (see Tables 3.4 and 3.5 for 
temperatures) for 45 seconds and extension at 72°C for 30 seconds with a final extension period at 
72°C for 5 minutes.  The second program (Program B) comprised an initial denaturation step at 
95°C for 5 minutes, 35 cycles consisting of denaturation at 95°C for 1 minute and annealing (see 
Tables 3.4 and 3.5 for temperatures) for 2 minutes.  A terminal 10 minute extension at 72°C 
completed the amplification.  The third program is a two-step cycling regime (Program C). The 
regime comprised an initial denaturation step at 95°C for 2 minutes, 40 cycles with a 95°C 
denaturation and a 72°C elongation step (both for 30 seconds), for which the first 10 cycles the 
annealing temperature was higher than the annealing temperature for the last 30 cycles (for 45 
seconds in both instances).  The program was completed with a final elongation step at 72°C for 2 
minutes.  Various PCR cycling regimes were tested to amplify exon 10 of the CHEK2 gene, 
including Program A and Program C at different annealing temperatures.  Another regime (Program 
D) was tested.  This is a touch-down program with the denaturation and extension similar to 
program C.  During the first cycle the annealing temperature is between 60°C and 65°C, decreasing 
by 0.5°C after each cycle, for 10 cycles.  This is followed with 30 cycles at the annealing 
temperature of the last touch-down cycle.  The PCR thermocyclers used were the Perkin Elmer 
GeneAmp PCR System, models 9700 and 2700 (Perkin Elmer Applied Biosystems, Warrington 
WA, Great Britain).    
 
Three of the BRCA2 exons were amplified by means of a nested-PCR.  Exon 15 was amplified 
using the forward primer for exon 14B and the reverse primer for exon 15 (10pmol/μl of each 
primer; Program B; 66°C annealing temperature).  Exon 20 was amplified using the forward primer 
for exon 19 and the reverse primer for exon 20 (5pmol/μl of each primer; Program B; 55°C 
annealing temperature).  Exon 22 was amplified using the forward primer for exon 22 and the 
reverse primer for exon 23 (5pmol/μl of each primer; Program B; 60°C annealing temperature).  
One microlitre of the amplification product was subsequently used as the template for the nested 
reaction in each instance.  The conditions for these reactions can be found in Table 3.5.        
 
The intensity and size of the PCR products were determined on a 1.5% agarose gel with 1X TBE 
running buffer (stock 5X TBE:  0.089M Tris; 0.089M boric acid; 0.002M EDTA), with ethidium 
bromide incorporated in the gel at a concentration of 0.5μg/ml.  A 100bp DNA molecular marker 
(Promega Corporation, Madison, WI, USA) was loaded alongside the amplicons.  Electrophoresis 
was performed at 120V for at least 40 minutes.  The fragments were visualised with UV light and 
captured using the MultiGenius Image Capture System (Syngene, Cambridge, England). 
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 Table 3.4  Primer sequences and conditions for amplifying and analysing the various BRCA1 fragments.  Primer sequences are cited in the 5’→3’ 
direction.   
 
Exon  Forward Primer Reverse Primer Primer 
Concentration 
(pmol/reaction) 
PCR 
Program 
Annealing 
Temp 
Amplicon 
Size (bp) 
Mutation 
Detection 
11A TAGCCAGTTGGTTGATTTCC CCCATCTGTTATGTTGGCTC 15 C 60/55°C 394 SSCP/HA 
11B CCATGTGGCACAAATACTCA TGATTCAGACTCCCCATCAT 15 C 60/55°C 399 SSCP/HA 
11C GAAACTGCCATGCTCAGAGA ATTTATTTGTGAGGGGACGC 15 C 60/55°C 437 SSCP/HA 
11D AGGAGCATTTGTTACTGAGC TTTAATTCGAGTTCCATATTGC 15 A 60°C 348 SSCP/HA 
11E TTCAAAACGAAAGCTGAACC TTGGAAGGCTAGGATTGACA 15 C 60/55°C 445 SSCP/HA 
11F GGTAAAGAACCTGCAACTGG TCAAATGCTGCACACTGACT 15 C 65/60°C 416 SSCP/HA 
11G GAAAGGGTTTTGCAAACTGA TTCCTCTTCTGCATTTCCTG 15 C 60/55°C 381 SSCP/HA 
11H TGAACTTGATGCTCAGTATTTGC AGTCCAGTTTCGTTGCCTCT 15 B 60°C 345 SSCP/HA 
11I TAAGCCAGTTGATAATGCCA TTTTGGCCCTCTGTTTCTAC 15 C 65/60°C 430 SSCP/HA 
11J ACTAATGAAGTGGGCTCCAG TAACCCTGAGCCAAATGTGTAT 15 A 66°C 455 SSCP/HA 
11K TTCCTGGAAGTAATTGTAAGCA TAACCCTGAGCCAAATGTGTAT 15 B 60°C 313 SSCP/HA 
11L GACATTAAGGAAAGTTCTGCTG TTTGCCAATATTACCTGGTTAC 15 A 60/55°C 329 SSCP/HA 
11M TGTCTAAGAACACAGAGGAG GGGGCAAACACAAAAACCTG 15 A 60°C 374 SSCP/HA 
E881X GTCGGGAAACAAGCATAGAAAT TGATATTAACTGTCTGTACAGG 30 C 62/55°C 258 SSCP/HA 
15 TTGCCAGTCATTTCTGATCT GTGTTTGTTCCAATACAGCAG  15 C 60/55°C 347 SSCP/HA 
17 GTGCAGGATTGCTACATAGG CAAAGTGCTGCGATTACAGG 15 B 60°C 290 SSCP/HA 
18 AGTGGTGTTTTCAGCCTCTG CTCAGACTCAGCATCAGCAA 15 C 63/60°C 342 SSCP/HA 
19 TTAAAGGGCTGTGGCTTTAG AAGGAAAGTGGTGCATTGAT 15 C 63/60°C 279 SSCP/HA 
21 CAGGTGGTGAACAGAAGAAA ACATTTCAGCAATCTGAGGA 15 C 65/60°C 298 SSCP/HA 
22 CATCCGGAGAGTGTAGGGTA CATCCATAGGGACTGACAGG 15 C 65/60°C 240 SSCP/HA 
23 CCCTGTCTCAAAAACAAACA CAAGCACCAGGTAATGAGTG 15 C 60/55°C 234 SSCP/HA 
24 TGGAGTCGATTGATTAGAGC AGCCAGGACAGTAGAAGGAC 15 C 65/60°C 311 SSCP/HA 
 
Temp – temperature; SSCP/HA – single-strand conformation polymorphism / heteroduplex analysis 
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 Table 3.5  Primer sequences and conditions for amplifying and analysing the various BRCA2 fragments.  Primer sequences are cited in the 5’→3’ 
direction. 
Exon  Forward Primer Reverse Primer Primer 
Concentration 
(pmol/reaction
)
PCR 
Program 
Annealing 
Temp 
Amplicon 
Size (bp) 
Mutation 
Detection 
2 TTCCCATCCTCACAGTAAGC GTACTGGGTTTTTAGCAAGC 30 B 66°C 334  SSCP/HA 
3 TCTTTAACTGTTCTGGGTCAC GTTTGTAGTTCTCCCCAGTC 15 B 60°C 360  SSCP/HA 
4 CTCCCTATACATTCTCATTCC TCTTCTACCAGGCTCTTAGC 15 B 60°C 345  SSCP/HA 
5&6 CAACAATTTATATGAATGAGAATC CAAAGGTATAACGCTATTGTC 15 B 60°C 352  SSCP/HA 
7 AGCATTCTGCCTCATACAGG ACAATTATCAACCTCATCTGC 15 B 60°C 291  SSCP/HA 
8 CACTGTGTTGATTGACCTTTC AAGGCATTCCAAAATTGTTAGC 15 B 60°C 279  SSCP/HA 
9 TGAAATCACCAAAAGTGAAACC GGTGACAGAGCAAGACTCC 15 B 60°C 300  SSCP/HA 
10A TTTCTATGAGAAAGGTTGTGAG TGAGTATTTTTCTTTCACTTGG 10 B 60°C 348  SSCP/HA 
10B TCATTATGTTTTTCTAAATGTAGA TCTGAAATATTTTGGTCACATG 10 B 55°C 350  SSCP/HA 
10C GTCTTTGGCCTGTGAATGG ATATAGACTTTTTGATACCCTG 10 B 60°C 350  SSCP/HA 
10D GTAAATAAGAGAGATGAAGAGC TTAAACCTGCATTCTTCAAAGC 10 B 60°C 346  SSCP/HA 
10E CTGTTTGCTCACAGAAGGAG AAAAACACAGAAGGAATCGTCA 10 B 60°C 349  SSCP/HA 
11A ACTGTGCCCAAACACTACC CTTCAGAGTCTGGATTGACAG 10 B 66°C 829  DS 
11B GTTGAGCTGTTGCCACCTG CAAACTGACTTCCTGATTCTTC 10 B 63°C 886  DS 
11C CATTTACAGAGTAGTGTAGTTG CTGATCAGTAAATAGCAAGTCC 10 B 60°C 873  DS 
11D CAAGAGAAATACTGAAAATGAAG TCTGCATTTCTTTACACTTTGG 10 B 58°C 848  DS 
11E TTTTGATGAAAAAGAGCAAGG AATTATTACTATTAGATATGGAC 10 B 56°C 875  DS 
11F CTAGTTTTTCCAAAGTAATATCC GTGTAAGGAACTTTCTAAAATGG 10 B 60°C 869  DS 
11G TCACAAGAGAAGAAAATACTGC CACTCTTAATTGTTAGCATACC 10 B 63°C 860  DS 
12 CATTTAAAGAGTCAATACTTTAGCT GCACAGTGGCTCATGTCTGTA 10 B 60°C 329 SSCP/HA 
13 GAGCATCTGTTACATTCACTG AAACGAGACTTTTCTCATACTG 15 B 60°C 253  SSCP/HA 
14A TGTAGCAAATGAGGGTCTGC TTTGGTTGGTCTGCCTGTAG 15 B 66°C 296  SSCP/HA 
14B AAGCAATTTAGCAGTTTCAGG ACGGAAATATCTAACTGAAAGG 15 B 60°C 375  SSCP/HA 
 
Temp – temperature; DS – direct sequencing; SSCP/HA – single-strand conformation polymorphism / heteroduplex analysis 
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Table 3.5  Continues from previous page. 
 
Exon  Forward Primer Reverse Primer Primer 
Concentration 
(pmol/reaction) 
PCR 
Program 
Annealing 
Temp 
Amplicon 
Size (bp) 
Mutation 
Detection 
15* CAAAGTGCTGGGATTACAGG ACACTCTGTCATAAAAGCCATC 10 B 66°C 325  SSCP/HA 
16 AATTTTTGGTAAATTCAGTTTGG GAGAAGAAAGAGGGATGAGG 10 B 55°C 354  SSCP/HA 
17 GATCTTGAACAATGTAGTTTTTG CAGAAACCTTAACCATACTGC 15 B 60°C 331  SSCP/HA 
18A TTCTCAGTTATTCAGTGACTTG TTCAATAATGGCCACTTTTTGG 15 B 60°C 268  SSCP/HA 
18B ATGGAAAGGGATGACACAGC GAATTTAACTGAATCAATGACTG 15 B 60°C 358  SSCP/HA 
19 GCAGTTCTAGAAGAATGAAAAC CAAGAGACCGAAACTCCATC 15 B 60°C 339  SSCP/HA 
20* ATTACAGATGTGAGCCACTG GTTAAATTCAAAGTCTCAAGAC 10 B 66°C 309  SSCP/HA 
21 TCTTTAAATCTCCCTTCTTTGG GCCAGAGAGTCTAAAACAGC 30 B 60°C 297  SSCP/HA 
22* GTTGTATTTGTCCTGTTTAAAGC TTAATAAAACTGATAAAAACAAAGC 10 B 60°C 331  SSCP/HA 
23 AAGCAAAATCCACTACTAATGC GAGATTCCATAAACTAACAAGC 15 B 60°C 349  SSCP/HA 
24 AACAACTACCGGTACAAACC CAAATTTGCCAACTGGTAGC 15 B 60°C 343  SSCP/HA 
25 ATATTAGAGTTTCCTTTCTTGC GACTGTCAAAATAGAAAAATACC 15 B 60°C 384  SSCP/HA 
26 ACAATTGGTATCACATTTAGGG GATGGCCTCCATATATACTTC 15 B 60°C 338  SSCP/HA 
27A AGGGGAGGGAGACTGTGTG AATGGGACTAACAGGTGGAG 15 B 60°C 331  SSCP/HA 
27B ATTGATGACCAAAAGAACTGC TGTTGAACCAGACAAAAGAGC 30 B 60°C 297  SSCP/HA 
27C AATTCTCCTCAGATGACTCC AACTGGAAAGGTTAAGCGTCA 15 B 60°C 354  SSCP/HA 
Temp – temperature; DS – direct sequencing; SSCP/HA – single-strand conformation polymorphism / heteroduplex analysis 
 
* Exons amplified by means of a nested-PCR.  See text for PCR conditions for the first amplification on gDNA.   
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3.2.5  Single strand conformation polymorphism and heteroduplex analysis (SSCP/HA) 
 
SSCP/HA was used for detecting the CHEK2*1100delC variant and to screen BRCA1 and BRCA2 
(excluding exon 11) for known and novel variants.   
 
Denaturing loading buffer (95% (v/v) formamide, 10mM EDTA pH8.0, 0.05% (w/v) xylene 
cyanole and 0.05% (w/v) bromophenol blue) were added to the amplified DNA fragments in a 1:1 
ratio.  The samples were than denatured for 10 minutes at 95°C, cooled rapidly to 4°C and kept on 
ice until it could be loaded onto the gel.  This was done to allow single-strand conformations and 
homo- and heteroduplexes to form. Of the sample and buffer solution 10-20μl (depending on the 
PCR product yield after amplification) were loaded on a 12% (w/v) polyacrylamide gel (99 
acrylamide : 1 bisacrylamide, 1% cross linking) supplemented with 7.5% (w/v) urea.  The 
dimensions of the gel system (Duel Slab Gel Unit, C.B.S. Scientific Co., Del Mar, CA, USA) used 
were 165mm (width) x 370mm (height) x 0.75mm (depth).  The mixture for one 50ml gel consisted 
of 15ml of 40% (w/v) polyacrylamide stock, 15 ml of 5X TBE, 20 ml dH20, 800μl of 10% (w/v) 
ammonium persulphate (APS) and 80μl of TEMED.  1.5X TBE was used as the running buffer. 
Electrophoresis was performed at 4°C for 14-20 hours (depending on the fragment size) at 350V.  
The banding patterns were subsequently visualized by either ethidium bromide staining or by silver 
staining. 
 
All fragments were analysed according to the protocol described above, except for exon 9 of 
BRCA2.  In an attempt to improve the resolution of the SSCP banding pattern for this fragment, 
different gel matrices were tested.  This included a 10% (w/v) polyacrylamide gel (99 acrylamide : 
1 bisacrylamide, 1% cross linking) supplemented with 0.05% glycerol, for which a 0.5X TBE 
running buffer was used and electrophoresis took place at room temperature at 200V.  The other gel 
matrix tested was a 20% (w/v) polyacrylamide gel (99 acrylamide : 1 bisacrylamide, 1% cross 
linking) without glycerol or urea and 0.5X TBE as the running buffer.  Electrophoresis was 
performed at 4°C at 200V for at least 20 hours. 
 
One of the exon 11 fragments (11J) of the BRCA1 gene is relatively large, 455bp, which could 
compromise the sensitivity of the screening method.  The fragment was therefore digested with a 
restriction enzyme in order to reduce the size of the amplicon.  MvaI (Roche Diagnostics 
Corporation, Indianapolis, IN, USA) was used which cuts the fragment only once, in a 1:2 ration, 
yielding a 146bp and a 309bp product.   
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In addition to the system described above, the CHEK2 fragment was also analysed on a Mighty 
Small (Hoefer Pharmacia Biotech Inc, California, USA) system.  The dimensions of the gel used 
were 100mm (width) x 105mm (height) x 0.75mm (depth).   A 10% as well as a 15% (w/v) 
polyacrylamide gel (99 acrylamide : 1 bisacrylamide, 1% cross linking) were tested.  
Electrophoresis was done in the presence of 1.5X TBE and 1X TBE running buffer respectively, at 
room temperature at 200V for 2 hours.  
 
3.2.6  Silver staining 
 
Gels were loosened from the glass plates and subjected to a 10 minute incubation period in fixing 
solution (10% (v/v) ethanol, 0.5% (v/v) acetic acid) after which each gel was rinsed for 
approximately 1 minute in dH2O.  Another 10 minute incubation period with staining solution 
(0.1% (w/v) silver nitrate) followed.  After staining, the gels were briefly rinsed with dH2O.  Finally 
the gels were developed with developing solution (1.5% (w/v) NaOH and 0.155% (v/v) 
formaldehyde which was only added when staining commenced).  The last step continued until 
clear bands could be seen.  Developing ended after the gels were rinsed with dH2O and sealed 
between transparencies.  All incubation steps were performed on a belly-dancer (Stoball Life 
Sciences Inc, NC, USA) set at low speed.  
 
3.2.7  Melt-point analysis by microplate-array diagonal-gel electrophoresis (melt-MADGE) 
 
In addition to SSCP/HA, exon 11 of the BRCA1 gene was screened with melt-MADGE by 
microplate-array diagonal-gel electrophoresis) by INM Day. This allowed comparison of the 
sensitivity of the two techniques.  Samples with reported variations were subsequently sequenced 
(refer to next section).  
 
3.2.8  Sequence analysis 
 
All the samples were subjected to SSCP/HA analysis for the BRCA1 exons and BRCA2 exons (with 
the exception of exon 11).  Only when aberrant mobility was detected on the SSCP/HA gels, the 
samples which showed variation were analysed by DNA sequence analysis.  The samples were re-
amplified and purified with the Qiaquick PCR purification kit (Qiagen, GmbH, Hilden, Germany) 
or with the GFX PCR DNA and gel band purification kit (Amersham Biosciences Corporation, 
Buckinghamshire, England) according to manufacturers’ instructions.  The concentrations of the 
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amplification products were subsequently determined with either the NanoDrop® ND-100 
Spectrophotometer v3.0.1 (NanoDrop Technologies Inc, DE, USA) or with gel electrophoresis 
using lambda DNA as concentration standards.  Samples were then diluted to a final concentration 
of 3.3ng/μl.  Five samples were randomly chosen for DNA sequencing of the CHEK2 fragment in 
order to confirm amplification of the correct sequence.  These samples were prepared for 
sequencing according to the protocol described above.  BRCA2 exon 11 fragments were amplified 
and the concentrations determined using gel electrophoresis and lambda concentration standards.  
Samples were diluted to a final concentration of 6.6ng/μl and subsequently purified with ExoSAP-
IT (Amersham Biosciences Corporation, Ohio, USA).   
 
The PCR products of the samples were sequenced bidirectional (5’ to 3’ and 3’ to 5’), using an ABI 
PRISM di-deoxy Terminator Cycle Sequencing kit v3.1 and the ABI Prism 3100 Genetic Analyzer 
(Perkin Elmer, Applied Biosystems, Warrington WA, Great Britain) according to manufacturers’ 
instructions.  Electropherograms of each amplicon were analyzed by proprietary sequence analysis 
software followed by visual inspection and confirmation, assisted by sequence alignments with the 
wild-type reference sequence for each gene.  Sequence alignments were done using the BioEdit 
Sequence Alignment Editor v6.0.7 (Hall 1999).     
 
BRCA1 and BRCA2 amino acid conservation between species were determined for the detected 
unclassified variants which did cause an amino acid change in the peptide.  Alignments were done 
using the canine (Canis familiaris) homolog with GenBank accession NM001013416 for BRCA1 
and NM001006653 for BRCA2.  GenBank accession NM009764 was used for the murine (Mus 
musculus) BRCA1 homolog and NM009765 for the BRCA2 homolog.  Analyses were done using 
the BioEdit Sequence Alignment Editor v6.0.7 (Hall 1999).       
 
The presence of unclassified BRCA1 and BRCA2 variants were established in ethnically-matched 
control samples.  Genotyping was only done for novel variants which caused non-conservative 
amino acid changes or inframe deletions or insertions.  The control samples comprised 50 random 
individuals of the appropriate South African population group.   
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3.2.9  Nucleotide numbering 
 
3.2.9.1  BRCA1 and BRCA2 
 
In the interest of consistency, nucleotides were numbered according to the Breast Cancer 
Information Core (BIC) mutation database (http://research.nhgri.nih.gov/bic/) (Szabo et al. 2000).  
The BIC database has adopted most of the nomenclature system recommendations from Den 
Dunnen and Antonarakis (2001) for designation of mutations in the BRCA1 and BRCA2 genes as 
derived from the cDNA GenBank reference sequences U14680 and U43746, respectively.  One 
significant departure from these recommendations is that the cDNA number system used by the BIC 
designates the first nucleotide of the GenBank entry as nucleotide #1.  For BRCA1, this entry 
includes 119 bases of 5’ untranslated sequence with protein translation starting at nucleotide #120.  
The reference BRCA2 sequence contains a 5’ untranslated region of 228 nucleotides.  Although the 
untranslated segments must be taken into account when calculating the nucleotide numbers, it 
should not be included when converting from the cDNA position to the codon number (codon one 
being the first ATG after the transcription start site). 
 
3.2.9.2  CHEK2  
 
The CHEK2 gene sequence is numbered according to Den Dunnen and Antonarakis (2001) with 
GenBank accession AL131197 used as the wild type sequence. 
 
3.2.10  Statistical analysis  
 
Allele and genotype frequencies were only calculated for variants which appeared to be relatively 
common in the study population of breast cancer patients.  Hardy-Weinberg equilibrium (HWE) 
was tested for one detected BRCA2 variant for which possible in utero selection has been reported 
(Healey et al. 2000) (refer to section 5.2.2.1 for a detailed discussion).  This was done using 
Fisher’s exact test.  This test statistic is more appropriate to use for smaller sample sizes than chi-
square analysis (Elston and Forthofer 1977).  The computer software Tools for Population Genetic 
Analysis, TFPGA (Miller and Mark 1997) was used to calculate the test statistic and P values.   
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4.  RESULTS  
 
The BRCA1 and BRCA2 variants detected in the two South African breast cancer populations will be 
presented in this chapter.  The outcome of the CHEK2*1100delC screening will also be addressed.  
Results reported in this chapter have been presented at several national conferences (Appendix C) and 
will be submitted for publication shortly. 
 
4.1  THE BRCA1 GENE 
 
The study population was previously screened for the BRCA1 Ashkenazi Jewish founder mutations 
185delAG and 5382insC and the Afrikaner founder mutation (E881X) (see Appendix C, Scholtz et al. 
2003).  The 185delAG and the 5382insC mutations were not detected in the study population.  The 
E881X mutation was identified in one individual (refer to Table 4.1).   
 
4.1.1  Polymerase chain reaction (PCR) amplification 
 
The coding exons of the BRCA1 gene were amplified in 22 fragments, excluding the exons (2, 3, 5, 6, 
7, 8, 9, 10, 12, 13, 14, 16 and) that have been screened previously as part of another study (Appendix 
C, Scholtz et al. 2003).  The 22 fragments include the 14 fragments which comprise exon 11, of which 
one has been designed to specifically screen for the E881X mutation.  A second primer set had to be 
designed for exon 11D since the first pair could not be optimized.  A second forward primer was 
designed for exon 17 for the same reason.  All amplicons were resolved on a 1.5% agarose gel to 
confirm successful amplification before SSCP/HA was conducted.  A representative example of an 
agarose gel showing the overlapping fragments of exon 11 are presented in Figure 4.1.  Fragment sizes 
can be derived from the 100bp DNA molecular marker loaded in the first lane.  PCR amplification and 
band size verification were done for all the other fragments and compared with the fragment length 
calculated from the reference sequence in order to confirm amplification of the correct fragment.  A 
negative control (i.e. without template DNA) was always included to exclude possible PCR 
contamination.   
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Figure 4.1  BRCA1 exon 11 fragments amplified by PCR.  The two 1.5% agarose gels were resolved 
for 1 hour at 100V in 1X TBE buffer and stained with 0.5μg/μl EtBr.  The photographs were taken after 
exposure to UV light.  100bp molecular markers are loaded in the first lanes (M) of each gel, with the 
500bp band indicated.  Lanes A1 to M2 represent the different fragments for exon 11, with the negative 
control loaded in the third lane of each fragment (A3 to M3).     
 
Exon 11 fragments were screened with SSCP/HA, a screening method which does not require high 
PCR product concentrations.  The staining method used (silver staining and ethidium bromide staining) 
can also be adapted to increase band visibility on polyacrylamide gels.  Lower concentrations of PCR 
 M    A1  A2   A3     B1    B2    B3   C1   C2    C3    D1   D2   D3    E1    E2    E3   F1   F2     F3    G1  G2    G3 
  M      H1   H2   H3       I1     I2     I3       J1      J2      J3      K1   K2    K3      L1    L2     L3      M1   M2   M3 
ex11A ex11B ex11C ex11D ex11E ex11F ex11G
            ex11H             ex11I              ex11J             ex11K               ex11L           ex11M 
500bp 
500bp 
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products, for examples exon 11D in Figure 4.1, would therefore not hamper the screening process.  
Primer dimers were still present for some of the fragments (for example exon 11J and 11M) after 
extensive attempts at optimization of the PCR reactions.  Since SSCP/HA was employed, the short 
dimer fragments (~20bp) did not interfere with the banding patterns of the fragments on the 
polyacrylamide gels, as it moved from the gel into the running buffer after a period of 16 hours.   
Neither the low concentrations of PCR amplification products or the presence of primer dimers were a 
concern for DNA sequencing of the variant bands.  The fragments are relatively small (<450bp), 
requiring only 3.3ng/sequencing reaction.  All PCR products were purified with either the Qiaquick 
PCR purification kit or the GFX PCR DNA purification kit before sequencing (refer to section 3.2.8).  
Both of these commercial products separate the amplified products from primer dimers.   
 
4.1.2  Single strand conformation polymorphism / heteroduplex analysis (SSCP/HA) 
 
Only one SSCP gel electrophoresis system was used to screen the BRCA1 gene for sequence variations.  
All fragments were resolved on a 12% (w/v) polyacrylamide gel supplemented with 7.5% (w/v) urea.  
This system allowed for clear banding patterns which could unambiguously be identified.  All 
fragments were electrophoresed overnight (minimum 16 hours) except for exon 11B which was 
electrophoresed for only 4 hours to improve the resolution.  Exon 11J was digested with the restriction 
enzyme MvaI, yielding a 146bp and a 309bp product.  Although faint, banding patterns for both 
fragments could be distinguished on the SSCP/HA gel.  No variants were detected.  The original large 
fragment was also subjected to SSCP/HA analysis to confirm the results.      
 
SSCP/HA gels from four of the exon 11 fragments with variant migration patterns are shown in Figures 
4.2 to 4.5.  Exon 11 fragments overlapped.  Some of the variants could therefore be detected with more 
than one primer set (e.g. P871L in the fragments amplified with the E881X primer set and with the 
exon 11G primer set.  See Figures 4.2 and 4.3).  The variants have been characterized by subsequent 
sequencing of these samples.  Single base substitutions were mostly observed with SSCP analysis.  
Small deletions manifested with HA (e.g. Figure 4.5).  Relatively few of the detected variants changed 
the conformation of both the single-stranded DNA and the heteroduplexes (Figure 4.4 shows one of 
these exceptions).  
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1    2    3    4    5    6   7    8  
 He  Ho  He  He  Ho  Ho  Ho  Ho WT He  Ho  Ho WT  He 
 1    2    3    4     5    6    7     8    9   10   11  12  13  14 
Figure 4.2  BRCA1 exon 11G fragment. 
SSCP/HA polyacrylamide gel stained 
with EtBr.  Individuals with both the 
L771L and the P871L variant can be seen 
in lanes 1-3 and lanes 5-7.  Individuals 
with only the P871L variant appear in 
lanes 4 and 8.          
Figure 4.3  BRCA1 exon 11 fragment using the 
E881X primers for PCR amplification.  SSCP/HA 
polyacrylamide gel stained with AgNO3.  
Heterozygous (He) and homozygous (Ho) individuals 
for the P871L variant are indicated, as well as the 
individuals with the wild-type sequence (WT). 
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    1      2       3      4      5 
   1      2      3      4     5     6     7      8      9     10 
Figure 4.4  BRCA1 exon 11K fragment. 
SSCP/HA polyacrylamide gel stained 
with EtBr.  An individual with the 
S1140G variant has been marked (lane 
3). 
Figure 4.5  BRCA1 exon 11C fragment. SSCP/HA 
polyacrylamide gel stained with EtBr.  An individual 
with the 1623delTTAAA allele has been marked (lane 
8). 
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4.1.3  Melt-point analysis by microplate-array diagonal-gel electrophoresis (Melt-MADGE)    
 
Melt-MADGE analysis was done for exon 11 by INM Day.  The fragments which have been reported 
to show variant migration were subsequently sequenced.  Results have been included in Table 4.1.  
Three variants in BRCA1 exon 11 (D693N, S694S and L771L) were detected with both Melt-MADGE 
analysis and SSCP/HA.  The three other exon 11 variants detected with Melt-MADGE (T703T, N723D 
and T1349M) could not be detected with SSCP/HA.  The nine remaining exon 11 variants were only 
detected with SSCP/HA. 
  
4.1.4  DNA sequencing 
 
Samples showing SSCP/HA variants were re-amplified and electrophoresed on an agarose gel before 
DNA sequencing was performed.  This was done to ensure amplification and also to assist in 
calculating the concentration in order to obtain the best possible sequencing results. 
 
The chromatographic tracings were visually inspected to exclude missed heterozygotes due to unequal 
amplification of the two alleles, after which multiple alignments were performed using the ClustalW 
program (version 1.4) in the BioEdit Sequence Alignment Editor software (Hall 1999).  A total of 25 
variants were detected (21 in this study) (Table 4.1).  Four of the variants (5451+88T>C, 5526-76delT, 
5585T>C, 5587-55C>G) could not be detected with SSCP/HA, but were identified after DNA sequencing 
of random samples to confirm amplification of the wild-type sequence.  These variants were in return 
detected in all of the samples sequenced and it was established that these changes are either in the 
intronic regions or did not cause amino acid changes (indicated in Table 4.1).  The high cost of direct 
sequencing of all the patients was therefore not justified.  It is thus not possible to determine allele 
frequencies.  Only one of these variants, 5451+88T>C, was also present in the homozygous form.   
 
Most of the detected variants have been described in the BIC database (Breast Cancer Information Core 
http://research.nhgri.nih.gov/projects/bic), either as disease-causing mutations (M), benign 
polymorphisms (P) or unclassified variants (UV).   Five of the variants detected in this study have not 
been described elsewhere and will be regarded as novel variants.  Two of these, G677G and H1822H 
do not cause an amino acid change.  The remaining three (5451+88T>C, 5526-76delT and 5587-
55C>G) falls within intronic regions.  The exon 11 variants identified in a previous study (Appendix C,  
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Table 4.1  Summary of BRCA1 variants detected in the study population. 
Detection Method Exon/ 
Intron 
Nucleotide number &  
base change 
Amino acid 
change 
Mutation 
Effect*  
Number of 
Samples 
SSCP/HA 8 622A>C K168T** Not in 
database 
1 
SSCP/HA 11 1623_1627delTTAAA STOP503** M 1 
SSCP/HA 11 2150A>G G677G Not in 
database 
1 
Melt-MADGE & 
SSCP/HA 
11 2196G>A D693N P 2 
Melt-MADGE & 
SSCP/HA 
11 2201C>T S694S P 4 
Melt-MADGE 11 2228A>G T703T UV 1 
Melt-MADGE 11 2286A>G N723D UV 1 
Melt-MADGE & 
SSCP/HA 
11 2430T>C L771L P Refer to Table 
4.3 for allele 
frequencies 
SSCP/HA 11 2731C>T P871L P Refer to Table 
4.3 for allele 
frequencies  
SSCP/HA 11 2760G>T E881X** Not in 
database 
1 
SSCP/HA 11 2933A>G P938P P 1 
SSCP/HA 11 3232A>G E1038G P 3 
SSCP/HA 11 3238G>A S1040N UV 1 
SSCP/HA 11 3537A>G S1140G UV 1 
SSCP/HA 11 3667A>G K1183G P 5 
Melt-MADGE 11 4165C>T T1349M UV 1 
SSCP/HA 18 5271+66G>A (IVS18+G>A) Non-coding P 4 
SSCP/HA 18 5271+85delT (IVS18+85delT) Non-coding UV 1 
SSCP/HA 20 5313delC STOP1764** Not in 
database 
1 
DS 21 5451+88T>C (IVS21+88T>C) Non-coding Not in 
database 
All samples 
sequenced  
(n= 8) 
SSCP/HA 22 5525+8T>C (IVS22+8T>C) Non-coding P 2 
DS 22 5526-76delT (IVS23-76delT) Non-coding Not in 
database 
All samples 
sequenced  
(n= 5) 
DS 23 5585T>C H1822H Not in 
database 
All samples  
sequenced  
(n= 5) 
DS 23 5587-55C>G Non-coding Not in 
database 
All samples  
sequenced  
(n= 5) 
SSCP/HA 24 3’UTR36C>G Non-coding UV 5 
P = polymorphism, UV = unclassified variant, M = disease causing mutation 
 
*Classification of variants according to the BIC database (last accessed 2005/08).   
**Variants identified in previous study (Appendix C, Scholtz et al. 2003). 
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Scholtz et al. 2003) were independently confirmed during this study.  The sequencing chromatogram 
for mutation 1623delTTAAA is shown in Figure 4.6.  All variants were verified by bi-directional 
sequencing. 
 
 
 
Figure 4.6  Results obtained from the automated sequencing in the sense (5’→3’) direction of the 
BRCA1 exon 11C fragment of a heterozygous individual containing the 1623delTTAAA mutation. 
 
The human BRCA1 protein shows 56% sequence identity to the mouse (Mus musculus) Brca1 protein 
and 74% identity to the dog (Canis familiaris) Brca1 protein.  Amino acid conservation in these 
mammals were established at selected positions.  This was done for the unclassified variants which will 
result in an amino acid change.  The various residues at the selected positions are listed in Table 4.2.  
The only residue conserved between all three species, is asparagine, which is changed by the N723D 
variant to aspartic acid.   
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Table 4.2  Amino acids identified in the wild-type sequence of the BRCA1 protein for three 
mammalian species.  The amino acids in question are indicated and forty flanking residues are 
included.  Amino acids conserved across all species have been shaded. 
Variant Organism    Amino acid sequence 
K168T* 
 
 
Human 
Mouse 
Dog      
N723D 
 
 
Human 
Mouse 
Dog 
      
S1040N 
 
 
Human 
Mouse 
Dog 
     
T1349M 
 
 
Human 
Mouse 
Dog 
     
*Variant identified in previous study (Appendix C, Scholtz et al. 2003). 
 
4.1.5  Statistical analysis 
 
The majority of the reported variants was only detected in five samples or less and was therefore 
regarded as rare.  However, two variants, L771L and P871L were observed at a high frequency.  
Genotype frequencies for the L771L and the P871L variants have been calculated and are shown in 
Table 4.3. 
 
Table 4.3  Genotype frequencies for the L771L and P871L variants in the study population. 
Polymorphism Genotype Population 
  Caucasian  
n=19 (%) 
Mixed Ancestry 
n=29 (%) 
Total 
n=48 (%) 
L771L TT 7 (36.8%) 16 (55.2%) 23 (47.9%) 
 TC  9 (47.4%) 12 (41.4%) 21 (43.8%) 
 CC 3 (15.8%) 1 (3.4%) 4 (8.3%) 
P871L CC 7 (36.8%) 0 (0.0%) 7 (14.6%) 
 CT 9 (47.4%) 13 (44.8%) 22 (45.8%) 
 TT 3 (15.8%) 16 (55.2%) 19 (39.6%) 
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Fifty random controls of the Mixed Ancestry population were genotyped for the novel variant K168T 
(identified in a previous study by Scholtz et al. 2003 (Appendix C)).  Genomic DNA was amplified 
with BRCA1 exon 8 primers (forward 5’-AGCTGACTGATG-3’ and reverse 5’-AAATTCACTTCC-
3’), PCR Program A (refer to section 3.2.4) at an annealing temperature of 55°C.  The resulting 
amplicons of 338bp were analysed together with the positive control for the variant with SSCP/HA 
(refer to section 3.2.5).  None of the control individuals are carriers of the threonine allele.             
 
4.2  THE BRCA2 GENE 
 
The study population was screened for the BRCA2 Ashkenazi Jewish founder mutation 6174delT 
before this study commenced by CL Scholtz and MJ Kotze (unpublished data).  The mutation was not 
detected. 
 
4.2.1  Polymerase chain reaction (PCR) amplification 
 
The coding exons of the BRCA2 gene were amplified in 39 fragments, including the five overlapping 
fragments for exon 10 and the seven overlapping fragments for exon 11.  A nested PCR was performed 
for exons 15, 20 and 22, as amplification of the individual exons yielded either non-specific products or 
no amplification at all.  Adjacent exons were amplified together with the exon in question in an initial 
reaction.  The product was used as template for a second reaction (refer to Table 3.5).   
 
As for BRCA1, all amplicons were resolved on an agarose gel to verify amplification of the correct 
fragment before further analysis either by SSCP/HA or direct DNA sequencing.  Figure 4.7 and Figure 
4.8 show examples of such gels, with exon 10 and exon 11 fragments respectively.  As can be seen in 
these figures, fragment sizes were ~350bp for exon 10 fragments and ~850p for exon 11 fragments.  
All PCR reactions were successfully optimized.  No primer dimers were visible on the agarose gels. 
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Figure 4.7  BRCA2 exon 10 fragments.  A 1.5% agarose gel, resolved for 1 hour at 100V in 1XTBE 
buffer and stained with 0.5μg/μl EtBr.  The photograph was taken after exposure to ultra- violet light.  
A 100bp molecular marker is loaded in the first lane (M), with the 500bp band indicated.  Lanes A1 to 
E2 represent the different fragments for exon 10, with the negative control loaded in the third lane of 
each fragment (A3 to E3).     
 
        
 
Figure 4.8  BRCA2 exon 11 fragments.  A 1.5% agarose gel, resolved for 1 hour at 100V in 1XTBE 
buffer and stained with 0.5μg/μl EtBr.  The photograph was taken after exposure to ultra violet light.  A 
100bp molecular marker is loaded in the first lane (M), with the 500bp band indicated.  Lanes A1 to G2 
represent the different fragments for exon 11, with the negative control loaded in the third lane of each 
fragment (A2 to G3).     
 
          M        A1    A2    A3        B1    B2    B3          C1    C2     C3       D1      D2     D3         E1      E2      E3       
          ex10A                      ex10B                      ex10C                      ex10D                     ex10E     
 
500 bp 
 
            ex11A                ex11B               ex11C              ex11D                ex11E              ex11F               ex11G
500bp 
M    A1  A2  A3      B1   B2   B3      C1   C2   C3     D1   D2   D3    E1    E2   E3      F1    F2    F3    G1    G2   G3 
Stellenbosch University http://scholar.sun.ac.za
CHAPTER FOUR              RESULTS 
___________________________________________________________________________________ 
 
 86
A few of the BRCA2 exon 11 fragments were not analysed for some of the patients.  This was due to 
poor quality of the PCR amplification products after repeated attempts were made of obtaining suitable 
template for DNA sequencing.  Due to insufficient amounts of DNA samples for these individuals, any 
further efforts had to be abandoned.  This included one patient for each of exons 11A, 11C and 11D for 
whom no results are available, as well as ten patients for exon 11E which was only sequenced in the 
sense direction, still allowing for sequence analysis.   
 
4.2.2  Single strand conformation polymorphism / heteroduplex analysis (SSCP/HA) 
 
As for BRCA1, only one SSCP gel electrophoresis system was used to screen the BRCA2 gene for 
sequence variations.  All fragments except exon 9 were resolved on a 12% (w/v) polyacrylamide gel 
supplemented with 7.5% (w/v) urea at 4°C.  Exon 9 fragments showed improved resolution on a 20% 
(w/v) polyacrylamide gel without glycerol or urea, electrophoresed at room temperature.  
Representative gels are shown in Figures 4.9, 4.10 and 4.11.  The banding pattern for the N372H 
variant is shown in Figure 4.11.  Band intensities were not considered as PCR products were not 
diluted to have similar concentrations before being subjected to electrophoresis.  Band intensities on 
the printed polyacrylamide gel images may therefore vary, e.g. lanes 5 and 11 in Fig 4.10.  Analyses 
were performed on enlarged images on a standard computer monitor in order to enable compensation 
for differences in band intensities. 
 
Stellenbosch University http://scholar.sun.ac.za
CHAPTER FOUR              RESULTS 
___________________________________________________________________________________ 
 
 87
 
 
Figure 4.9  BRCA2 exon 16.  SSCP/HA gel polyacrylamide gel stained with AgNO3.  No variants were 
detected in this fragment for any of the patients. 
 
 
 
 
 
 
 
 
 
 
     1     2     3     4     5     6     7     8      9   10   11   12   13   14    15   16   17   18
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    1     2     3    4     5     6    7     8    9    10  11  
Figure 4.10  BRCA2 exon 12.  SSCP/HA 
polyacrylamide gel stained with AgNO3.  
No variants were detected in this fragment 
for any of the patients.   
Figure 4.11  BRCA2 exon 10B.  SSCP/HA 
polyacrylamide gel stained with EtBr.  
Individuals heterozygous for the N372H variant 
can be seen in lanes 2, 3, 6 and 7.  All other lanes 
contain wild-type sequences. 
 1    2    3    4    5    6    7    8    9   10  11  12  13  14  
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4.2.3  DNA sequencing 
 
Samples showing SSCP/HA variants were re-amplified and electrophoresed on an agarose gel before 
direct DNA sequencing.  Exon 11 fragments were directly sequenced.  The chromatographic tracing 
were visually inspected before multiple alignments were performed using the ClustalW program 
(version 1.4) in the BioEdit Sequence Alignment Editor (Hall 1999).  A total of 29 variants were 
detected (Table 4.4).     
 
The BIC database was searched for the detected variants and classified according to reports submitted 
to this database.  Most of the detected variants have been described in the BIC database, either as 
disease-causing mutations, benign polymorphisms or unclassified variants.  Nine of the detected 
variants have not been described elsewhere and will be referred to as novel variants.  Four of these are 
non-coding variants (5’UTR199T>G, 5’UTR212G>A, 549-26C>T, 7236-27A>T).  Two variants 
(L775L, D3341D) do not cause an amino acid change.  One of the novel variants does cause an amino 
acid change (N2447D) and one variant is a 2 base pair insertion (6677insTA) (see Figure 4.12 for the 
sequencing results).  The ninth unreported variant, N1600del, is an inframe three base pair deletion, 
removing asparagine from the peptide.  One previously reported mutation has been identified in three 
patients, 8162delG (Figure 4.14).  All the variants that were encountered will be discussed in detail in 
Chapter 5.  The chromatogram for two alleles of the N372H variant is shown in Figure 4.13.  Since this 
variant can be detected with SSCP/HA, only a few selected samples have been sequenced to serve as 
controls for determining the genotype of the remaining samples.   
 
 
Figure 4.12  Results obtained from the automated sequencing in the sense (5’→3’) direction of the 
BRCA2 exon 11G fragment of a heterozygous individual containing the 6677insTA mutation. 
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Table 4.4  Summary of BRCA2 variants detected in the study population. 
Detection 
Method 
Exon/ 
Intron 
Nucleotide number &  
base change 
Amino acid 
change 
Mutation 
Effect* 
Number of 
Samples 
SSCP/HA 2 5’UTR199T>G  Non-coding Not in database 1 
SSCP/HA 2 5’UTR212G>A Non-coding Not in database 3 
SSCP/HA 3 549-26C>T (IVS4-26C>T) Non-coding Not in database 2 
SSCP/HA 10 1093A>C N289H P 2 
SSCP/HA 10 1342C>A N372H P Refer to Table 
4.4 for allele 
frequencies 
DS 11 2457T>C H743H P 1 
DS 11 2511T>A L775L Not in database 1 
DS 11 3111G>A Q961Q P 1 
DS 11 3199A>G N991D P 1 
DS 11 3624A>G K1132K P Refer to Table 
4.4 for allele 
frequencies  
DS 11 3673A>G M1149V UV 1 
DS 11 4035T>C V1269V P Refer to Table 
4.4 for allele 
frequencies 
DS 11 4086_4088delAAA K1285del UV 1 
DS 11 4296G>A L1356L P 1 
DS 11 4791G>A L1521L P 2 
DS 11 5026_5028delAAT N1600del Not in database 1 
DS 11 5642A>G N1805S P 2 
DS 11 5972C>T T1915M P 1 
DS 11 6640G>T V2138F P 2 
DS 11 6677_6678insTA or 
6675_6676dupTA 
STOP2167 Not in database 2 
DS 11 6741C>G V2171V P 2 
SSCP/HA 13 7236-27A>T (IVS14-27A>T) Non-coding Not in database 3 
SSCP/HA 14 7470A>G S2414S P 3 
SSCP/HA 14 7567A>G N2447D Not in database 1 
SSCP/HA 16 8035-15T>C (IVS17-15T>C) Non-coding P 2 
SSCP/HA 17 8162delG** Stop2647 M 3 
SSCP/HA 25 9486-17T>C (IVS26-17T>C) Non-coding P 1 
SSCP/HA 27 10251C>T D3341D Not in database 5 
SSCP/HA 27 10462A>G I3412V UV 1 
P = polymorphism, UV = unclassified variant, M = disease causing mutation 
 
*Classification of variants according to the BIC database (last accessed 2005/07).   
**Mutation detected in the two male patients from the study group. 
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   i 
       
   ii 
         
   iii 
         
 
Figure 4.13  Results obtained from the automated sequencing in the antisense (3’→5’) direction of the 
BRCA2 exon 10B fragment showing the N372H variant for i) individual homozygous for the G allele 
(His), ii) heterozygous individual and iii) individual homozygous for the T allele (Asn).   
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Figure 4.14  Results obtained from the automated sequencing in the antisense (3’→5’) direction of the 
BRCA2 exon 17 fragment of a heterozygous individual containing the 8162delG mutation. 
 
The human BRCA2 protein shows 57% sequence identity to the mouse (Mus musculus) Brca1 protein 
and 69% identity to the dog (Canis familiaris) Brca1 protein.  Amino acid conservation these mammals 
were established at selected positions.  This was done for the unclassified variants which will result in 
an amino acid change or an inframe deletion or insertion.  The various residues at the selected positions 
are listed in Table 4.5.  The amino acid is only conserved between all three species for one of the 
selected variants, K1285del, a deletion of lysine. 
 
Table 4.5  Amino acids identified in the wild-type sequence of the BRCA2 protein for three 
mammalian species.  The amino acids in question are indicated and forty flanking residues are 
included.  Amino acids conserved across all species have been shaded. 
Variant Organism Amino acid sequence 
M1149V 
 
 
Human 
Mouse 
Dog 
 
K1285del 
 
 
Human 
Mouse 
Dog 
  
N1600del 
 
 
Human 
Mouse 
Dog 
  
N2447D 
 
 
Human 
Mouse 
Dog 
  
I3412V Human 
Mouse 
Dog 
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4.2.4   Statistical analysis 
 
Three variants were observed at an elevated frequency in the sample population.  The genotype 
frequencies for the N372H, K1132K and V1269V variants have been calculated and are shown in 
Table 4.6.  Hardy-Weinberg equilibrium (HWE) for one variant, N372H, was tested for using Fisher’s 
exact test.  The computer software Tools for Population Genetic Analysis, TFPGA (Miller and Mark 
1997) was used to calculate the test statistic and P values.  Both the Caucasian (P=0.3177) and the 
Mixed Ancestry population (P=0.3899) demonstrated Hardy-Weinberg equilibrium at a 95% 
significance level.  When calculating probability values for the total study population, including and 
excluding the male breast cancer patients, Hardy-Weinberg equilibrium was still demonstrated 
(P=0.1013 and P=0.1723 respectively).   
 
Table 4.6  Genotype frequencies for the N372H, K1132K and  the V1269V variants in the study  
population. 
Polymorphism Genotype Population 
  Caucasian  
n=19 
(%) 
Mixed Ancestry  
n=29 
(%) 
Total 
n=48 
(%) 
N372H AA 6 (31.6%) 14 (48.3%) 20 (41.7%) 
 AC 12 (63.2%) 14 (48.3%) 26 (54.2%) 
 CC 1 (5.3%) 1 (3.4%) 2 (4.2%) 
K1132K AA 6(31.6%) 21(72.4%) 27(56.3%) 
 AG 13(68.4%) 8(27.6%) 21(43.8%) 
 GG 0(0.0%) 0(0.0%) 0(0.0%) 
V1269V TT 13(68.6%) 22(44.8%) 35(72.9%) 
 TC 6(31.6%) 6(20.7%) 12(25.0%) 
 CC 0(0.0%) 1(3.4%) 1(2.1%) 
 
Fifty random controls of the Mixed Ancestry population were genotyped for the novel variant 
K1600del.  Genomic DNA was amplified with BRCA2 exon 11E primers (refer to section 3.2.4) where 
after the resulting amplicons of 875bp were analysed together with the positive control for the variant 
CHAPTER FOUR              RESULTS 
___________________________________________________________________________________ 
 
 94
with SSCP/HA (refer to section 3.2.5).  Despite the size of the fragment, the three base pair deletion 
could be distinguished from the wild-type allele.  The deletion was not detected in any of the control 
samples.             
 
4.3  THE CHEK2*1100delC VARIANT 
 
4.3.1  Polymerase chain reaction (PCR) amplification 
 
Exon 10 of the CHEK2 gene was amplified, yielding a 245bp fragment.  Figure 4.15 shows an agarose 
gel photo of amplification products for some of the samples.  A 100bp DNA molecular marker was 
always included as well as a negative control (i.e. without template DNA).  Primer dimers were not a 
concern as it does not influence the results when using SSCP/HA as a screening method.  As discussed 
in previous chapters, the CHEK2 gene has various homologous sequences spread across the genome.  
One of these pseudogenes, located on chromosome 15, is the exact same length as exon 10.  It was 
therefore not possible to distinguish between the two fragments on an agarose gel, but only after 
electrophoresis of the SSCA/HA polyacrylamide gel.  Figure 4.16 shows the various products obtained 
with different PCR annealing temperatures.  The PCR was optimized according to these results.  
Amplification was optimal using Program C, with 10 cycles at 65°C annealing and 30 cycles at 60°C 
annealing.  At these annealing temperatures, difficulties were experienced when attempting to amplify 
some of the samples, as is apparent from lane four in Figure 4.16.  This was resolved by increasing the 
gDNA concentrations.   
           
 
 
 
 
 
   M                1        2       3      4 
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Figure 4.15  A 1% agarose gel, resolved for 1 hour at 100V in 1XTBE buffer and stained with 0.5μg/μl 
EtBr.  The photograph was taken after exposure to ultra violet light.  A 100bp molecular marker is 
loaded in the first lane (M).  Lanes 1 to 3 represent the exon 10 fragment of the CHEK2 gene, with the 
negative control loaded in lane 4.     
    
4.3.2  Single strand conformation polymorphism / heteroduplex analysis (SSCP/HA) 
 
Two different SSCP/HA gel systems were used to test the CHEK2 fragment for the presence of the 
1100delC mutation.  The first system tested was the Mighty Small gel (10% and 15% (w/v) 
polyacrylamide gel).  The other system tested had different gel dimensions and composition (12% 
(w/v) polyacrylamide gel containing 7.5% (w/v) urea).  The second system allowed for electrophoresis 
to be performed for a longer period of time, improving separation of the bands.  Neither of the gel 
systems used showed any variation in the banding pattern.  A positive control sample was not available.  
As a deletion would be expected to cause a conformational change in the DNA which will alter the 
motility of the fragment, it can be concluded that the 1100delC allele (nor any other exon 10 variation) 
is not present in the breast cancer population sampled.     
 
245 bp amplicon 
CHAPTER FOUR              RESULTS 
___________________________________________________________________________________ 
 
 96
 
 
Figure 4.16  Electrophoresis performed on a Mighty Small polyacrylamide gel to determine which 
program was optimal for PCR amplification.  Lane 1 and 2: touch-down PCR program D (65→60°C); 
lane 3 and 4: two-step PCR program C (65/60°C); lane 5 and 6: touch-down PCR program D 
(64→59°C); lane 7 and 8: two-step PCR program C (64/60°).  Lane 3 is indicative of a single 
amplification product, all other lanes represent non-specific amplification of homologous sequences.  
Amplification was unsuccessful of the sample loaded in lane 4. 
  
4.3.3  DNA sequencing 
 
Five samples were subjected to direct DNA sequencing to confirm amplification of the CHEK2 gene 
and not any of the homologous sequences.  The discrepancies between the gene and the pseudogene are 
marked in Figure 4.17.  Sequencing results clearly show amplification of the correct fragment.  The 
DNA sequencing data supported the SSCP/HA results, which do not suggest the presence of the 
CHEK2*1100delC mutation in the study population.   
 
 
 
 
Hetero- / Homoduplexes 
SSCP banding pattern 
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                          C>T                  T>G                     C>T 
 
Figure 4.17  Results obtained from the automated sequencing in the sense (5’→3’) direction of the 
CHEK2 exon 10 fragment with.  The bases discriminating the exon 10 fragment on chromosome 22 
from the pseudogene on chromosome 15 are indicated. 
 
4.4  Summary of results 
 
In this study, 5 899bp (4139bp coding and 1760bp non-coding) of gDNA have been screened for the 
BRCA1 gene in 48 individuals.  SSCP/HA was performed for the coding and adjacent non-coding 
regions (intron-exon boundaries) in 22 fragments.  A total of 22 variants have been detected (plus three 
variants from the previous study by C Scholtz and MJ Kotze).  Fifteen of these variants have been 
detected in coding regions.  The ratio of coding to non-coding areas screened is 2.35:1, and the ratio of 
variants detected in the coding to non-coding areas is 2.14:1.  Coding areas therefore appear to be as 
polymorphic as non-coding areas.   
 
For the BRCA2 gene, 14 799bp (10257bp coding and 4542bp non-coding) of gDNA have been 
screened in 48 individuals.  SSCP/HA was performed in 32 fragments of coding regions and splice 
sites.  Direct DNA sequencing was done for 7 fragments (exon 11).  A total of 29 variants have been 
detected.  Twenty-three of these were in the coding regions.  The ratio of coding to non-coding areas 
screened is 2.26:1, and the ratio of variants detected in the coding areas in relation to variants detected 
in the non-coding areas is 3.83:1.  This suggests that the coding areas are more polymorphic than the 
non-coding areas.  It should, however, be considered that the non-coding areas were predominantly 
screened with SSCP/HA, which is less sensitive than DNA sequencing, the method employed to screen 
exon 11.   
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Since only exon 10 of the CHEK2 gene was screened and the CHEK2*1100delC mutation was not 
detected in the study population, no deductions can be made as to the role this or any other CHEK2 
variant has in the pathogenesis of breast cancer in South African women and men. 
 
 
 
   
 
 
CHAPTER FIVE              DISCUSSION 
___________________________________________________________________________________ 
 
5.  DISCUSSION 
 
The primary objectives of this study were to determine the BRCA1 and BRCA2 mutation spectrum in 
South African breast cancer probands and to ascertain whether South African breast cancer patients are 
carriers of the CHEK2*1100delC mutation.  Forty-eight South African breast cancer patients were 
screened for BRCA1 and BRCA2 mutations using SSCP/HA analysis and DNA sequencing.  
Deleterious BRCA1 mutations were identified in three patients (6.3%) and BRCA2 mutations in five 
patients (10.4%), together accounting for 16.7% of breast cancer in the study population.  In addition, a 
number of benign polymorphisms and variants of unknown functional significance were identified.  
Our findings do not suggest the presence of the CHEK2 mutation in South African breast cancer 
patients.    
 
Variants have been divided into different categories, firstly depending on whether it has been reported 
in the BIC database (Breast Cancer Information Core http://research.nhgri.nih.gov/projects/bic), 
thereafter as non-coding (nucleotide changes within intronic and in 5’- or 3’-untranslated regions), 
benign polymorphisms, unclassified variants or as pathogenic mutations.  Although located in 
noncoding regions, critical sequences in the untranslated regions do influence stability of mRNA and 
therefore phenotype (Sachs 1993).  Synonymous polymorphisms in both coding and non-coding 
regions can still affect gene function by altering the stability and splicing of the mRNA.  Duan et al. 
(2003) demonstrated that certain combinations of synonymous mutations in the human dopamine 
receptor (DRD2) gene have functional consequences, namely decreasing mRNA stability and 
translation.   
 
Missense mutations are generally assessed for possible pathogenicity according to the following criteria 
(Greenman et al. 1998): (1) segregation with the disease; (2) absence in ethnically matched controls; 
(3) nonconservative amino acid substitutions; (4) residues conserved in mammalian homologues of the 
BRCA1 and BRCA2 genes (e.g. murine and canine); or (5) occurrence within a conserved and possibly 
functional motif.  Since no functional, case-control or family studies have been done for this study, 
pathogenicity of unclassified variants can only be inferred theoretically by means of (3), (4) and (5).  
Functional in vitro studies, utilizing mammalian cell line, can also be done to determine expression 
levels and to determine if the protein retains its various functions.  For most variants which have been 
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reported in the BIC database, various entries exist.  If in at least one of these entries a variant is 
classified as a benign polymorphism, it will be treated as such and it will be assumed that these claims 
can be substantiated by the respective research groups who submitted their data to the database.   
 
The BIC database does not cross-reference to published studies.  A literature search was therefore done 
in the NCBI PubMed database (www.ncbi.nlm.nih.gov/) for variants which have been reported.  
Available references for the first reports in the literature of these variants were included in the 
discussion which follows.       
 
5.1  VARIANTS IDENTIFIED IN THE BRCA1 GENE 
 
5.1.1  Non-coding variants 
 
Seven non-coding variants were identified in the BRCA1 gene, including five single nucleotide changes 
and two one base pair deletions (Table 4.1).  Two of these were reported as polymorphisms, 
5271+85delT and 5525+8T>C (Futreal et al. 1994), and two were reported as unclassified variants, 
5271+66G>A and 3’UTR36C>G (Newman et al. 1998).  The 5271+66G>A variant was previously 
shown to be a frequent polymorphism (Futreal et al. 1994; Durocher et al. 1996; Malone et al. 1998) 
and was detected in four patients in our study population (8.3%).  This polymorphism was initially 
designated PM5 by Futreal et al. (1994).  The 5525+8T>C variant was identified in two of our patients 
(4.2%) and it was reported to be a benign polymorphism (Arena et al. 1996).  A functional role for the 
unclassified variants has not been excluded.  Three variants, 5451+88T>C, 5526-76delT and 5587-
55C>G, have not been reported before.  None of the non-coding variants are suspected to be involved 
in splicing as they are deep within the adjacent intronic regions.  It should also be noted that the novel 
variants were detected in all the samples that were sequenced (five to eight samples in each instance), 
which is consistent with the theory of a frequent polymorphism rather than that of a rare mutation in the 
study population. 
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5.1.2  Coding variants 
 
5.1.2.1  Benign polymorphisms 
 
Seven single base pair substitutions were detected in the coding regions which are classified in the BIC 
database, classified as benign polymorphisms.  Three of these do not cause an amino acid change, 
S694S, L771L (Friedman et al. 1994) and P938P (Newman et al. 1998), and are therefore not expected 
to effect the functions of the protein.  The following polymorphisms do change the amino acid 
sequence, but have been shown by other research groups not to be functional, as they were also 
detected in control chromosomes: D693N (Durocher et al. 1996), P871L, K1183G (Miki et al. 1994) 
and E1038G (Friedman et al. 1994).  P871L, K1183 (originally designated PM6 and PM7 by Miki et 
al. 1994) and E1038G have been shown to be frequent polymorphisms.  The E1038G polymorphism 
was identified in three patients (6.3%) and the K1183G polymorphism in five patients (10.4%) from 
our study group.  These variants have been detected at a much higher frequency by another research 
group in Canadian and American breast cancer patients (Durocher et al. 1996).  They reported the 
E1038G polymorphism in 34% and the K1183G polymorphism in 31% of their patients.  The proline 
allele of the P871L variant was present at a frequency of 0.37 in our Caucasian study population, which 
is in agreement with Durocher’s study.  They calculated the allele frequency in various population 
groups to be between 0.21 and 0.42.  We did not detect the proline allele in the Mixed Ancestry 
population.   
 
The following variants are under the BRCA1 top 20 missense or synonymous mutations in the BIC 
database: S694S, L771L, P938P, K1183G and E1038G.   
 
5.1.2.2  Pathogenic mutations 
 
Three disease causing mutations have previously been identified in this study population.  These results 
have been presented at a national congress (Appendix C, Scholtz et al. 2003).  One of these mutations, 
1623_1627delTTAAA, creates a stop codon at position 503, shortening the protein to only 26% of its 
full length (1863 amino acids).  This mutation has been reported in the BIC database.  The deletion has 
been identified in a female patient from Mixed Ancestry, diagnosed at 53 years of age.  She reported 
one first degree relative with breast cancer.  Another mutation, E881X, which has been associated with 
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Afrikaner ancestry (Reeves et al. 2004), is a single base pair substitution converting glutamic acid to a 
stop codon.  To date, the mutation has not been submitted to the BIC database.  E881X was detected in 
a female patient of Mixed Ancestry, contracting breast cancer at 40 years of age.  This patient has three 
third degree relatives diagnosed with breast cancer.  Kotze et al. (1995) showed in another study that a 
familial hypercholesterolemia (FH) Afrikaner founder mutation in the low-density lipoprotein receptor 
(LDLR) gene is also common in the Mixed Ancestry population.  This suggests that the South African 
Caucasian and Mixed Ancestry populations may also share BRCA1 and BRCA2 variants.  It is therefore 
plausible that the BRCA1 Afrikaner mutation E881X was detected in a patient of Mixed Ancestry.   
 
The third mutation, 5313delC, is in exon 20.  The one base pair deletion causes a frameshift, 
introducing a stop codon in exon 21 at position 1764 and therefore deleting the C-terminal 5% of the 
protein.  This deletion was identified in a female Caucasian patient diagnosed at age 52, reporting one 
second degree relative with breast cancer.  This mutation is regarded as novel as it has not been 
reported in the BIC database. 
   
5.1.2.3  Unclassified variants 
 
Five variants that occur in coding regions or exons were detected, which have been reported to the BIC 
database as unclassified variants.  These single nucleotide changes have therefore, to date, not been 
excluded as breast cancer susceptibility alleles.  All of these are located in exon 11, which contains the 
binding domain for RAD51 (amino acids 158 to 1064), an interaction that is essential in the double-
strand break repair function of the BRCA1 protein (Welcsh et al. 2000).  One variant, T703T, is 
described in the database as an unclassified variant, but it does not result in an amino acid change and 
is therefore likely to be a benign polymorphism.  This synonymous variant is also listed in the database 
as one of the 20 most common BRCA1 mutations, which is another reason to consider T703T a benign 
polymorphism. 
 
In N723D the change is from asparagine, an amide which is highly hydrophilic, to its acid, aspartate, 
which is also hydrophilic, but carries a negative charge and would therefore change the charge on the 
protein.  This amino acid is, however, conserved in canine and murine species, suggesting functional 
significance of asparagine at this position.  This is the only BRCA1 unclassified variant detected in this 
study which is conserved across all three species (human, dog and mouse) (Table 4.2).  Asparagine at 
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this position, however, does not seem to be part of a highly conserved motif and neither do any of the 
other novel unclassified variants. 
 
In S1040N the change is from serine, a non-polar amino acid with an alcohol group, to the very 
hydrophilic asparagine, which is polar.  This putative missense mutation was first described by Castilla 
et al. (1994) as a polymorphism. It was found not to segregate with the disease and was also detected in 
control chromosomes.  In the report of Friedman et al. (1994), however, this alteration did segregate 
with the disease in the family in which it was identified and was absent in control chromosomes, 
therefore qualifying the variant as a missense mutation.  Thus, the functional significance of the 
S1040N variant is questionable.  The variant was only detected in one patient from our study 
population.   
 
In S1140G the change is from serine to glycine.  Both are small, non-polar aliphatic molecules.  This 
variant has been detected in African American breast cancer cases and controls (Newman et al. 1998; 
Panguluri et al. 1999).  In T1349M the change is from threonine, a non-polar amino acid with an 
alcohol group, to methionine, which contains a sulfur atom and is highly hydrophobic.  The sulfide 
molecule present in methionine could cross-link with cysteine residues in other peptide chains and 
cause aggregations or clumping (Horton et al. 1996).  The functional significance of both these variants 
is therefore not clear.      
 
Three novel synonymous variants have been discovered.  G677G and H1822H are postulated not to be 
pathogenic mutations, as they do not change the amino acid sequence.  But, as mentioned before, they 
could have an impact on the mRNA level.  H1822H cannot be detected with SSCP/HA, but has been 
detected in all samples sequenced (allele frequency of 0.1).  It is therefore possible that this variant is a 
silent polymorphism that occurs at a relatively high frequency in the study population.   
 
The third novel variant, K168T, has been identified in a previous study in our study population 
(Appendix C, Scholtz et al. 2003).  This single base substitution cause an amino acid change, from 
lysine, a large highly hydrophilic, positively charged base to threonine, a small weakly polar amino 
acid with an alcohol group.  Hydropathy, the relative hydrophobicity or hydrophilicity of each amino 
acid, is an important determinant of protein-chain folding.  Lysine and threonine have very different 
properties and could therefore affect the three-dimensional structure as well as the binding properties of 
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the BRCA1 protein.  The variant, which is in exon 8 of the gene, falls just outside the N-terminal RING 
finger of the protein, amino acids 1-112 (Miki et al. 1994), which interacts with BARD1 and BAP1.  
This complex is subsequently involved in the ubiquitination of other proteins.  Without functional, 
case-control or family studies, this variant should be considered an unclassified variant which could 
possibly have a functional role.  K168T has been found in a female patient of Mixed Ancestry, who 
contracted breast cancer at the age of 68 years.  She reported only one second degree relative with 
breast cancer.  Unfortunately family members of this individual was not available for further 
investigation of this variant.  However, 50 control individuals from an ethnically-matched population 
(Mixed Ancestry) were genotyped for this variant.  The absence of the variant in this group supports a 
disease causing role for the K168T variant.   
  
5.2  VARIANTS IDENTIFIED IN THE BRCA2 GENE 
 
5.2.1  Non-coding variants 
 
In total, six variants were identified in non-coding regions of the BRCA2 gene, of which two have been 
described in the BIC database (8035-15T>C and 9486-17T>C (Friedman et al. 1997)).  Two of the 
novel variants occur in the 5’-untranslated region (5’UTR199T>G and 5’UTR212G>A), while one 
variant is 5’ to exon 14 (in intron thirteen) (7236-27A>T) and another 5’ to exon four (in intron three) 
(549-26C>T).  Although the variant in intron three is not found in the database, it has been described 
by Wagner et al. (1999). 
 
5.2.2 Coding variants 
 
5.2.2.1  Benign polymorphisms 
 
Eight known synonymous variants, H743H, V1269V and S2414S (Tavtigian et al. 1996), Q961Q, 
K1132K, L1521L and V2171V (Wagner et al. 1999) and L1356L were detected in the study 
population.  Each of these only appeared in one, two or three patients, with the exception of K1132K 
and V1269V, which were found at a relatively high frequency (refer to Table 4.6 for genotype 
frequencies).  The following variants are under the BRCA2 top 20 synonymous mutations in the BIC 
database: H743H, S2414S, Q961Q and K1132K.   
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Six known amino acid altering polymorphisms were identified, all of which are single base 
substitutions.  These are N289H (Couch et al. 1996a), N372H (according to the reference sequence, 
GenBank accession number U43746, the C allele is the wild-type but in the literature the 
polymorphism is commonly referred to as N372H, implying that 1342A is the wild-type genotype), 
N991D (Tavtigian et al. 1996), T1915M (Couch et al. 1996a), N1805S (Wagner et al. 1999) and 
V2138F.  Of these variants, only two of the implicated amino acid residues (N289H and N1805S) are 
conserved in other mammalian species (dog and mouse) (see table 4.5). 
 
The BRCA2 N372H non-conservative amino acid substitution falls within a region of BRCA2 
(residues 290-453) that has been shown to interact with a histone acetyltransferase (P/CAF), needed for 
transcriptional activation of other genes (Fuks et al. 1998).  Healey et al. (2000) found this 
polymorphism to be associated with an increased risk for developing breast cancer.  Associations with 
this polymorphism were subsequently assessed in four other European population-based case-control 
series.  Odds ratio (OR) estimates for individuals with the HH genotype were consistently elevated, 
ranging from 1.1 to 1.8 with the combined analysis yielding an OR of 1.3, explaining 2% of breast 
cancers occurring in those populations.  Results from a large Australian population-based study 
(Spurdle et al. 2002) supported these findings.  They found the HH genotype to be associated with a 
1.4 to 1.5 fold increased risk for developing breast cancer.  A comparison of genotypes among 
spontaneous abortions and live births suggested in utero selection against female fetuses with the HH 
genotype (Healey et al. 2000).  Newborn females have an excess of heterozygotes and a deficit of 
homozygotes, whereas the opposite was observed in newborn males.  The HH genotype was not absent 
in our female population, but occurred at a low frequency (4.35%).  The study population demonstrated 
Hardy-Weinberg equilibrium, including (P=0.1013) and excluding (P=0.1723) the two male patients.  
Whether the variant has a direct causative role or is in linkage disequilibrium with a deleterious variant 
in BRCA2 or another nearby gene, is not known yet (Goode et al. 2002). 
 
5.2.2.2  Pathogenic mutations 
 
Two deleterious mutations were detected, of which one is novel.  The previously described mutation 
8162delG (Gayther et al. 1997) is a frameshift mutation in exon 17.  It introduces a stop codon at 
position 2647, therefore truncating the protein to ~77% of its full length (3418 amino acids).  This 
would delete the nuclear localization signals (NLSs), rendering the protein cytoplasmic and ruling out 
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any interaction with the RAD51 complex (Spain et al. 1999).  The mutation occurred in three patients, 
two Caucasian males and one female of Mixed Ancestry at a frequency of 6.1% in our study 
population.  The male patients were diagnosed at age 53 years and 63 years respectively.  The older 
male reported breast cancer in one first degree female relative.  The female patient was diagnosed at 
age 46 years, but could not recall any family history of breast or ovarian cancer.   
  
A novel mutation, 6677_6678insTA (can also be designated as 6675_6676dupTA), was identified in 
two female patients of Mixed Ancestry, one diagnosed at the age of 57 years and the other diagnosed at 
the age of 64 years.  Neither reported a family history of breast cancer.  This is another frameshift 
mutation, truncating the protein at amino acid residue 2167 (at ~63% of its full length).  The truncation 
occurs in exon 11, which contains the important BRC repeats needed for RAD51 to be able to bind to 
the BRCA2 protein.  This variant can therefore be classified as a disease causing mutation with relative 
certainty.  This mutation is located 3’ of the ovarian cancer cluster region (OCCR) in exon 11 (between 
nucleotides 3035 and 6629) (Gayther et al. 1997). 
 
5.2.2.3  Unclassified variants 
 
Three variants were found which have been reported in the BIC database as unclassified variants 
(M1149V, I3412V and K1285del).  The M1149V variant was only identified in one patient (allele 
frequency of 0.01).  Methionine and valine have similar characteristics, as both are large non-polar 
amino acids that are highly hydrophobic.  However, methionine contains sulfur, which could create an 
illegal disulfide bond with another peptide.  I3412V in exon 27 has first been reported by Teng et al. 
1996 and is regarded as a rare sequence variant.  Another group (Vehmanen et al. 1997) confirmed this 
as they could not detect the variant in control chromosomes.  The functional status of this sequence 
change has not been elucidated to date.  Isoleucine and valine have similar properties, as they are both 
aliphatic amino acids that are highly hydrophobic.  Neither of the above mentioned substitutions occurs 
at conserved positions in canine and murine species.  K1285del has initially been reported by Wagner 
et al. (1999).  Although lysine is conserved in canine and murine species, it does not form part of a 
conserved motif (Table 4.5).  K1285del and I3412V are in the BIC BRCA2 top 20 lists for in frame 
deletions and missense mutations respectively. 
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Four variants were identified which are not listed in the BIC database.  Of these, L775L and D3341D 
do not alter the amino acid sequence of the protein and will therefore not alter the structure of BRCA2.  
In addition to this, variants were detected which will change the primary structure of the protein.  Two 
novel sequence variations were identified, N2447D and N1600del, of which the functional 
consequences are not known. The novel point mutation, N2447D, is caused by a A>G transition 
converting codon 2447 encoding the hydrophilic amide asparagine into aspartic acid or aspartate, its 
conjugated base (as the amino acid is found under most physiological conditions (Amino acids and the 
primary structure of proteins 1996)), which is also hydrophilic.  The amino acids involved have similar 
properties and may therefore not have a major effect on the protein structure or function.  Asparagine is 
also not conserved in either the dog or the mouse, which provides further reason to classify this variant 
as a benign polymorphism.  N1600del is an in frame deletion, removing the residue aspartic acid from 
the peptide.  Aspartic acid is neither conserved in canine, nor in murine species.  Fifty control 
individuals from the Mixed Ancestry population were genotyped for this variant.  The variant was not 
detected in any of these individuals.  A functional consequence of this deletion can therefore not be 
excluded.  
 
5.3  CONTRIBUTION OF BRCA1 AND BRCA2 MUTATIONS TO BREAST CANCER IN   
        SOUTH AFRICAN FAMILIES 
 
Due to the small sample size, this investigation should be considered a pilot study.  A larger patient 
population need to be investigated to determine if the mutations identified, especially the novel 
mutations (BRCA1 5313delC and BRCA2 6677insTA), occur at an increased frequency in South 
African women with familial breast cancer.  Apart from the E881X mutation, that has previously been 
shown to be a common mutation in the South African population (Reeves et al. 2004), the two 
mutations identified in the BRCA2 gene, 8162delG and 6677insTA, had been identified in more than 
one patient each.  Haplotype studies would indicate whether these patients had a common ancestor, or 
whether these are recurrent mutations.  This was, however, not within the scope of this study. 
 
Many unclassified variants have been identified in BRCA1 and BRCA2, both known and novel.  
Functional implications for these variants cannot be ruled out, unless functional, family or case-control 
studies have been done.  BRCA1 exon 11 comprise 82.8% of the total coding area screened in this study 
and 92.9% (13/14) of the coding variants were detected in this exon.  This does not include the variants 
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detected with melt-MADGE and not with SSCP/HA.  The difference between the observed and 
expected number of variants is not significant if a homogenous distribution of mutations across the 
gene is expected.  BRCA2 exon 11 comprised 48.1% of the total coding area screened and 69.6% 
(16/23) of the coding variants were detected in this exon.  The much higher frequency of exon 11 
mutations in relation to the remainder of the gene could possibly be explained by the different 
screening methods used (SSCP/HA versus DS).  
 
Deleterious BRCA1 and BRCA2 mutations have been detected in eight individuals.  Only two of these 
individuals were diagnosed before the age of 50 years.  None reported a family history of ovarian 
cancer or male breast cancer.  Two patients had a one first or second degree relative with breast cancer; 
the other patients had a family history of breast cancer in more distant relatives.  It is evident from 
these findings that early-onset breast cancer and a strong family history are not essential for identifying 
a BRCA1 or BRCA2 mutation.  The accuracy and completeness of family history data, should however, 
be taken into account.  A person may be unaware of relatives affected with cancer.  In addition, small 
family sizes and premature deaths may limit the information obtained from a family history.  In the 
case of breast cancer, cancer on the paternal side of the family usually involves more distant relatives 
than on the maternal side (due to the higher penetrance of BRCA1 and BRCA2 mutations in females 
relative to males) and thus may be more difficult to obtain.  It is evident from population-based breast 
cancer studies that most women with a family history of breast cancer are not members of high-risk 
families, but instead have one, or perhaps two family members affected with breast cancer (Claus et al. 
1998).  Therefore, the extent to which a positive family history of breast cancer remains a factor in the 
prediction of breast cancer risk outside high-risk families remains an important issue.  Our study 
population conforms to the profile for women (and men) at moderate risk of developing breast cancer.  
After determining the contribution of BRCA1 and BRCA2 mutations to breast cancer in this group of 
patients, one can now assess the appropriateness of predictive or diagnostic DNA testing in the clinical 
setting.     
   
It has been shown in larger studies that BRCA1 mutation carriers have a younger age of onset of breast 
cancer than BRCA2 mutation carriers (Ford et al. 1998).  More than 70% of our familial group have 
been diagnosed with late-onset (>50 years of age) breast cancer (see Table 3.1).  This could explain the 
lower preponderance of BRCA1 versus BRCA2 mutations in our study population, despite the higher 
contribution of BRCA1 mutations in the general population (Krainer et al. 1997).  Aretini et al. (2003) 
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suggests that less stringent eligibility criteria (moderate family history of breast cancer with little or no 
reported cases of ovarian cancer and later age at onset of breast cancer) would lead to a higher 
percentage of BRCA2 mutations detected.   The sensitivity of the screening method should also be 
taken into account.  A large area of BRCA2 (exon 11) was screened with a more sensitive technique 
(DS) than was the same area for BRCA1 (exon 11, SSCP/HA).   
 
In this study SSCP/HA has predominantly been used for mutation screening and SSCP is also the 
technique most often employed by other research groups for screening of the smaller BRCA1 and 
BRCA2 exons (refer to Table 2.3).  The protein truncation test (PTT) is the most popular technique 
used to analyse the larger exons, namely BRCA1 exon 11 and BRCA2 exons ten and 11 (refer to Table 
2.3).  In addition to SSCP/HA, BRCA1 exon 11 was screened with melt-MADGE.  This technique 
proved to be less sensitive than SSCP/HA, as 60% of the exon 11 variants identified in our study group 
could not be detected with melt-MADGE analysis.  This re-emphasises the fact that no method will be 
able to detect all the variants present in genes as large as BRCA1 and BRCA2. 
   
The variants detected may therefore not represent the full spectrum of mutations in the South African 
population, as the mutation detection technique used is not 100% sensitive.  Large genomic 
rearrangements and mutations in regulatory regions have also not been screened for in this study.  
Since the Caucasian South Africans are of European ancestry and therefore also from The Netherlands, 
it is possible that the Dutch founder mutations, i.e. large deletions, will be present in the South African 
population.  However, Reeves et al. (2004) did not detect any of these in their study population of 
South African breast/ovarian cancer families.    
 
Deleterious BRCA1 mutations have been identified in 6.3% and BRCA2 mutations in 10.4% of patients 
from our study population.  Only considering female patients, deleterious BRCA2 mutations were only 
identified in 6.5% of the female study group.  BRCA1 mutations were identified in 5.9% female 
Caucasian patients.  No BRCA2 mutations have been found in female Caucasian patients, but BRCA2 
mutations have been identified in 100% of male breast cancer patients.  BRCA1 mutations were 
identified in 6.9% and BRCA2 mutations in 10.3% of female Mixed Ancestry patients.  Our populations 
of patients are mostly representative of cases who are of moderate risk for hereditary susceptibility, but 
who do not meet the stringent criteria of autosomal-dominant predisposition.  The results of this study 
are in agreement with those from other populations, indicating that less than 20% of breast cancers that 
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occur in individuals with a modest risk for developing breast cancer are due to BRCA1 and BRCA2 
mutations (refer to Table 2.3).   
 
5.4  THE CHEK2*1100DELC VARIANT AND THE SOUTH AFRICAN POPULATION 
 
Although the CHEK2*1100delC mutation has a stronger association with familial breast cancer, it has 
been reported to contribute to breast cancer risk in patients with sporadic disease (The CHEK2 Breast 
Cancer Case-Control Consortium 2004).  We screened both familial (n=48) and sporadic (n=53) breast 
cancer patients, but the CHEK2 mutation was not detected in our study population.  Unfortunately we 
were not able to obtain a positive control for the mutation and no restriction enzyme sites are created or 
abolished by this variant.  Two different SSCP/HA electrophoresis systems were therefore used to 
screen the patients.  However, the detection technique is not 100% sensitive, and mutation positive 
individuals in the South African study population could have been missed.  The sample size of 101 
individuals was also relatively small, considering that the mutation have only been reported at a 
frequency of 2-6% in other populations (Meijers-Heijboer and The CHEK2-Breast Cancer Consortium 
2002; Vahteristo et al. 2002; Walsh et al. 2002). The CHEK2*1100delC mutation can therefore not be 
excluded as a low-penetrance breast cancer susceptibility allele in the two population groups screened.   
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6.  CONCLUSION 
 
Much of what is known about the frequency and distribution of germline BRCA1 and BRCA2 mutations 
derives from studies in those rare families that have large numbers of affected women and many living 
family members available for sampling.  While detailed analysis of these mapping families has proven 
invaluable in studies aimed at determining the initial mutation spectrum, additional studies are now 
needed to elucidate the role of germline BRCA mutations outside the selected venue of high-risk 
families.  Individuals with a modest breast cancer family history present the biggest challenge for the 
development of testing strategies in women from the general population.  This will be further 
complicated by the intricate array of functions of the BRCA proteins and the uncertainty regarding 
most rare missense mutations and unclassified variants. 
 
Overall, mutations in BRCA1 and BRCA2 are uncommon in the general population and account for a 
small proportion of all cases of hereditary breast cancer.  This is evident from the results we obtained 
for our group of breast cancer patients with a moderate family history of the disease.  Unselected 
screening for mutations is not feasible.  It is therefore important to identify patients who have a high 
pre-test probability of carrying a mutation to justify genetic testing.  Initial reports of breast cancer risk 
were overestimates since they depended in part on results obtained from high-risk families suitable for 
linkage analysis.  Most of these studies have focused on women who were deliberately selected 
because they were members of large multiple member families with breast and ovarian cancer.  Such 
women represent only a fraction of the spectrum of patients who seek advice in the clinical setting.  
Population specific risk estimates will aid in the selection and screening process.  Our study is different 
in that we have characterized the BRCA1 and BRCA2 mutation spectrum in a population group unique 
to South Africa, namely the Mixed Ancestry population.  In addition, we screened patients of European 
descent.  None of the published European founder mutations have been detected in these patients (or 
the patients from Mixed Ancestry), suggesting a unique mutation spectrum for the people of South 
Africa.  This observation emphasizes that we cannot only rely on data obtained from studies done in 
European, American or even British populations, but should conduct our own investigations using 
South African families as our study populations.   
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Two deleterious BRCA2 mutations, 8162delG and 6677_6678insTA, have been identified in three and 
two patients respectively.  A future prospect would be to establish if these mutations are recurrent 
mutations in the South African population or if the patients with these alleles have a common ancestor.  
Furthermore, the potential functional significance of both the known and novel BRCA1 and BRCA2 
unclassified variants has to be assessed by screening control chromosomes.  In addition to this, the 
CHEK2*1100delC needs to be screened for in a larger group of breast cancer patients.  Although this 
mutation was not detected in this study, it cannot be excluded as a low-penetrance breast cancer 
susceptibility allele, as the mutation has been identified in various populations and other research 
groups have established its functional significance. 
     
The first recorded case of hereditary breast cancer dates back to 1757; a 19-year-old nun believed that 
“her blood was corrupted by a cancerous ferment natural to her family” (Le Dran 1757, as cited by 
Eisinger et al. 1998).  Centuries later, the hereditary component have been calculated relatively 
accurately even before the identification of the BRCA1 and BRCA2 genes in the 1990s.  It is, however, 
well recognized that there exists residual heritable risk that cannot be explained by mutations in these 
highly penetrant genes.  The literature is currently mushrooming with small studies suggesting low 
penetrance gene effects that are then subsequently discounted by follow-up studies.  An increasing 
number of studies are investigating the interaction between probable low penetrance alleles and 
environmental risk factors.  These studies are vital since breast cancer is a complex disease, with a 
genetic and an environmental component.  It is therefore comprehensible that, despite much research 
directed at understanding, preventing and treating breast cancer, it persists as a major health burden.  
To a certain extend, we can control and manipulate our environment, but we cannot change the genes 
and the genetic predisposition to disease that we have inherited.  The challenge remains to identify and 
characterize our genetic inheritance to be able to ultimately implement cancer intervention programs.   
 
 
“But remember throughout, that no external cause is efficient without a predisposition of the body 
itself.  Otherwise, external causes which affect one would affect all.”   Galen, 200 A.D. 
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APPENDIX A 
Patient consent form 
SUBJECT INFORMATION AND CONSENT FORM 
 
TITLE OF PROJECT: 
The genetics of breast cancer 
 
DECLARATION BY OR ON BEHALF OF PARTICIPANT 
 
I, THE UNDERSIGNED, ………………..…………………………………….. (name) 
[ID No: ……….……………] the participant/*in my capacity as ……………………...……. of  
the participant [ID No: ………..……………...] of  …………………………………………. 
……………...………………………………………………………………… (address). 
 
 
A. I declare that: 
 
1. I/*The patient was invited to participate in the above mentioned research project which is 
being undertaken by the Department of Genetics, University of Stellenbosch, in collaboration 
with the Division of Human Genetics, University of Stellenbosch. 
 
 
2.  It has been explained to me that 
 
2.1 the project is being undertaken to investigate the role of BRCA1 and BRCA2 mutations as a 
cause of cancer in the South African population. 
 
2.2 if I/*The patient participate(s) in the project, only 10 ml (2 teaspoons) of blood will be 
collected from the arm. DNA and RNA will be extracted from the blood and used in genetic 
tests. 
 
2.3 a blood sample will be required from both affected and unaffected family members. The 
project should not take more than 2 years.  One blood sample per patient should be sufficient. 
 
2.4 The research may provide important insights to our understanding of cancer.  DNA diagnosis 
of breast cancer will assist in the overall management and counseling of familial cases and 
may contribute to our understanding of the role of BRCA1 and 2 in isolated cases of cancer. 
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3. I/*The patient have/has been warned that the drawing of blood may result in slight discomfort, 
which can be coupled with bleeding where the needle pierces the skin. 
 
 
4. it has been explained to me/*the patient that participation in this project will result in the 
broadening of medical knowledge. The development of an accurate diagnostic DNA test for 
the condition(s) might lead to early detection and better counseling of affected individuals. 
 
 
5. I/*The patient have/has been informed that all information collected will be treated 
confidentially. The results will be used for publication in scientific journals/theses, without 
revealing the identity of any individual. 
 
 
6. I/*The patient may, during or on completion of the project, request the results of the tests 
without any conditions attached thereto, since the results could be advantageous to me/*the 
patient and my/*his or her family. Genetic counseling will be provided with this information. 
 
 
7. I/*The patient have/has been told that participation is voluntary and that I/*the patient may 
refuse to participate in this project and that I/*the patient may also at any time withdraw 
my/*his or her participation from the project. Refusal or withdrawal from the project will in no 
way affect my/*his or her present or future treatment at this institution. I/*the patient also 
understand that the researcher may withdraw me/*him or her from the project if he/*she 
considers it in my/*the patient’s best interest. 
 
 
8. the information above has been explained to me/the patient by 
..................................................................(name) in *English/Afrikaans/Xhosa, 
...................................................(other), and that I/*the patient am/is fully conversant in this 
language. I/*the patient was given the opportunity to ask questions which were answered to 
my/*the patient’s satisfaction. 
 
9. I/*the patient was not pressurized to participate in this project and I/*the patient know that 
I/*the patient may at any time withdraw from this project without penalization. 
 
10. participation in this project will not result in unnecessary expenses for me/*the patient. 
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B. I/*the patient voluntarily agree(s) to participate in the above mentioned project 
 
 
 SIGNED/AFFIRMED AT….............................. ON …....................................... 20....... 
 
 
 
 
 
 
 ...................................................   ............................................... 
 Signature or right thumb print of     Witness 
 patient/representative of patient 
 
 
 
 
DECLARATION BY OR ON BEHALF OF THE RESEARCHER 
 
 
I, ............................………………………………..(name) declare that I  
 
1. have explained the information in this document to the patient, 
.....................................……………(name) and/or his/*her representative. 
 
2. requested *him/her/them to ask questions where anything was unclear. 
 
3. this conversation was conducted in *English/Afrikaans/Xhosa, ...........................       (other)  
*and no translator was used/that this conversation was translated into ............................ 
...........................................by Dr/Mr/Ms ..................................................(name) 
 
 
 SIGNED AT……........................ ON ..................................................20............ 
 
 
 
 ....................................................   ................................................. 
 Researcher/Research representative    Witness 
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DECLARATION OF TRANSLATOR 
 
I, ...................................................……………………………..(name) declare that I 
 
1. translated the contents of this document from *English/Afrikaans/Xhosa/.............................. 
(other) into ................................. to the patient/*representative of the patient as well as the 
questions put to ...............................(name of researcher) by the patient/*patient’s 
representative and translated this person’s answers. 
 
2. information translated by me is a factual account of what was conveyed to me 
 
 SIGNED AT ........................................... ON ................................................. 20........... 
 
 
 .................................................   ......................................... 
  Translator’s signature     Witness 
 
 
* Delete where not applicable 
 
 
 
IMPORTANT INFORMATION 
 
Dear Patient/Representative of the patient 
 
Thank you for participating in this project. If at any time during the course of the project  
 
1. you require further information regarding the project, or 
 
3. if any of the following occurs, please contact Prof Louise Warnich at telephone number:
 (021) 8085888 
 
- a participant changes address and/ or telephone number. 
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APPENDIX B 
Patient questionnaire form: English 
Study Group Number MA   Control Group Number  
Date of Interview:  //  Interviewer:……………………………………. 
Diagnosis (clinical):  ………………………………………….………  Stage:  ……………………..…….… 
Breast Cancer Questionnaire for Patients 
Personal Information 
Name:   
Date of Birth:  //  Age:    Sex:  M   F    
Race:  Coloured  White  Black  Indian  Other (please specify) .....…............………………... 
Ethinicity:  …………………………………………………………………………………………………….. 
Place of Birth:  ………………………………………………………………………………………………... 
 
Disease States   
Do you suffer from any other disease?  Yes  No  If yes, indicate disease  …….................….……….. 
When were you diagnosed with breast cancer?  (year/month/day) // 
How old were you when you were diagnosed?   
Do you have unilateral or bilateral tumours?  …………………………………………….…………………. 
If contralateral breast cancer has been diagnosed:   
Date of diagnosis (year/month/day) //           Age at diagnosis  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Have you received treatment for your breast cancer?  Yes  No   
 Name of drug Response Negative side effects 
1    
2    
3    
4    
5    
 
Do you suffer from ovarian cancer?  Yes  No   
Has any blood relative had cancer?  Yes  No   
 Relative 1 Relative 2 Relative 3 Relative 4 
Relationship (eg 
aunt, sister) 
    
Type of cancer     
Age at diagnosis     
If breast cancer, 
was it unilateral 
or bilateral 
    
Age at diagnosis 
of each 
    
Relative’s current 
age 
    
Deceased from 
the cancer? 
    
Age of death     
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Risk Factors 
Menarche, pregnancy and breast feeding 
How old were you at menarche?  years months 
Have you ever been pregnant?  Yes  No   
How old were you when you first fell pregnant?  years months 
How old were you when you had your first live birth?  years months 
How many times have you been pregnant?   
How many  
Live births Miscarriages Still births Abortions 
    
How long did you breast feed your children (average)?  years months days 
 
Contraceptive Use 
Have you ever taken contraceptives?  Yes  No   
 
Family Tree 
APPENDIX B  PATIENT QUESTIONNAIRE – ENGLISH 
___________________________________________________________________________________ 
 
 145
Please indicate the name of the contraceptives.  ……………………………………………….…………….. 
………………...….…………………………………………………………………………………………… 
How old were you when you started taking contraceptives?  years months 
How old were you when you last used contraceptives?  years months 
How long in total did you take contraceptives?  years months 
Why did you stop taking them?  …………………………………………………………………….………... 
………………………………………………………………………………………………………………… 
 
Hormone Replacement Therapy and Menopause 
Have you been through menopause?  Yes  No   
If yes, how old were you when you experienced it?  years months 
Have you been on hormone replacement therapy (HRT)?  Yes  No   
What kind of HRT? 
Oestrogen alone  Progesterone alone  Combination:  sequence  non-sequenced  
Name of drug:  …………………………………………………………………………………………….. 
How long did you receive HRT?  years months 
 
Other 
Have you had a hysterectomy?  Yes  No  At what age did you have it?  years 
Were your ovaries left in?  Yes  No  Unsure 
Have you previously had breast irradiation?  Yes  No   
Do you take any other drugs/medication on a regular basis?  Yes  No  If yes, please specify.  
………………………………………………………………………………………………………………. 
Do you donate blood on a regular basis?  Yes  No     
Do you take vitamin/iron supplements on a regular basis?  Yes  No  If yes, please specify.  
………………………………………………………………………………………………………………. 
 
Smoking 
Do/did you smoke?  Yes  No   
Age started?  years      Age stopped?  years 
Average number smoked per day:   
What did you smoke?   Cigarettes   Pipe   Hand-rolled cigarettes    
Other (please specify)  ……………………………………………………… 
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How long did you smoke regularly?  years months 
Number of pack years smoked:   
Side-stream smoke 
Did anyone smoke in your house/room?  Yes  No   
Do people smoke around you in your workplace?  Yes  No   
Have you ever lived or worked in a smoky environment?  Yes  No    
When?  (year/month/day) //    
 
Alcohol 
Do/did you drink alcohol?  Yes  No   
What did you drink?   Beer   Wine   Spirits 
Other (please specify)  ……………………………………………………… 
How long did you drink regularly?  years months 
On average, how many drinks would you have per sitting?  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Patient questionnaire form: Afrikaans 
Studiegroep Nommer MA   Kontrolegroep Nommer  
Onderhoud Datum:  //  Onderhoudvoerder:……………………………………. 
Diagnose (klinies):  ………………………………………….……  Stadium:  ……………………..…….… 
Borskanker Vraelys vir Pasiënte 
Persoonlike Inligting 
Naam:   
Geboortedatum:  //         Ouderdom:   Geslag:  M   V    
Ras:   Kleurling  Blank   Swart   Indiër   
          Ander (spesifiseer asb.) .....…............……………….……….. 
Etniese Agtergrond: ….……………………………………………………………………………………….. 
Geboorteplek:  ………………………………………………………………………………………………... 
 
Siekte Status   
Lei u aan enige ander siekte(s)?  Ja  Nee   Indien ja, spesifiseer asb …….…….................….……….. 
Wanner is u gediagnoseer met borskanker?    (jaar/maand/dag) // 
Op watter ouderdom is u gediagnoseer?   
Het u unilaterale of bilaterale gewasse?  …………………………………………….…………………. 
Indien kontralaterale borskanker gediagnoseer is:   
Datum van diagnose (jaar/maand/dag) //     Ouderdom met diagnose  jaar 
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Het u behandeling ontvang vir borskanker?  Ja  Nee    
 Naam van behandeling Reaksie Newe effekte 
1    
2    
3    
4    
5    
 
Het u ovariale kanker?  Ja  Nee    
Het enige bloedverwante familie kanker gehad?  Ja  Nee    
 Familielid 1 Familielid 2 Familielid 3 Familielid 4 
Verwantskap (bv. 
tante, suster) 
    
Tipe kanker     
Ouderdom met 
diagnose 
    
Indien borskanker, 
was dit unilateraal 
of bilateraal? 
    
Ouderdom met 
diagnose 
    
Familielid se 
huidige ouderdom 
    
Oorlede aan 
kanker? 
    
Ouderdom met 
afsterwe 
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Risiko Faktore 
Menarche, swangerskap en borsvoeding 
Ouderdom met menarche?  jaar maande 
Was u ooit swanger?  Ja  Nee    
Wat was u ouderdom met u eerste swangerskap?  jaar maande 
Op watter ouderdom het u u eerste lewende geboorte gehad?  jaar maande 
Hoeveel keer was u swanger?   
Hoeveel 
Lewende geboortes Miskrame Stil geboortes Aborsies 
    
Vir hoe lank het u u kinders geborsvoed (gemiddeld)?  jaar maande dae 
 
Voorbehoedmiddel gebruik 
Het u ooit voorbehoedmiddels gebruik?  Ja  Nee    
Dui asb. die naam van die middel(s) aan:  ……………………………………………….…………….. 
Familie 
stamboom 
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………………...….…………………………………………………………………………………………… 
Op watter ouderdom het u voorbehoedmiddels begin gebruik?  jaar maande 
Op watter ouderdom het u laas voorbehoedmiddels gebruik?  jaar maande 
Vir hoe lank in totaal het u voorbehoedmiddels gebruik?  jaar maande 
Waarom het u opgehou om dit te gebruik?  …………………………………………………………………….………... 
………………………………………………………………………………………………………………… 
 
Hormoonvervangingsterapie en Menopause 
Het u reeds menopause ondergaan?  Ja  Nee    
Indien ja, op watter ouderdom het u dit ondervind?  jaar maande 
Was / is u op hormoonvervangingsterapie (HVT)?  Ja  Nee    
Watter soort HVT? 
Estrogeen alleen  Progesteroon alleen  Kombinasie:  sekwens  nie-sekwens  
Naam van middel: …………………………………………………………………………………………….. 
Vir hoe lank het u HVT ontvang?  jaar maande 
 
Ander 
Het u ‘n histerektomie gehad?  Ja  Nee   Op watter ouderdom?  jaar 
Is u ovaria ook verwyder?  Ja  Nee   Onserker 
Het u voorheed bestraling van die bors gehad?  Ja  Nee    
Neem u enige ander medikasie op ‘n gereelde basis?  Ja  Nee   Indien ja, spesifiseer asb.  
………………………………………………………………………………………………………………. 
Skenk u gereeld bloed?  Ja  Nee      
Neem u gereeld vitamien / minerale aanvullings?  Ja  Nee   Indien ja, spesifiseer asb.  
………………………………………………………………………………………………………………. 
 
Rook 
Rook of het u gerook?  Ja  Nee    
Ouderdom waarop begin?  jaar     Ouderdom opgehou?  jaar 
Gemiddelde aantal gerook per dag:   
Wat het u gerook?   Sigarette   Pyp   Handgerolde sigarette    
Ander (spesifiseer asb.)  ……………………………………………………… 
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Vir hoe lank het u gereeld gerook?  jaar maande 
Aantal jare gerook x pakkies per dag:   
Sekondêre rook 
Rook iemand in u huis / kamer?  Ja  Nee    
Rook mense rondom u by die werk?  Ja  Nee    
Het u ooit gewoon of gewerk in ‘n rokerige omgewing?  Ja  Nee     
Wanneer?  (jaar/maand/dag) //    
 
Alkohol 
Drink of het u alkohol gedrink?  Ja  Nee    
Wat het u gedrink?   Bier   Wyn   Spiritualeë 
Ander (spesifiseer asb.)  ……………………………………………………… 
Vir hoe lank het u gereeld gedrink?  jaar maande 
Gemiddeld hoeveel drankies het u per geleentheid gehad?  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APPENDIX C 
Conferences at which research was presented 
Results have been presented at the following national conferences.  The presenting author’s name is 
underlined. 
  
ORAL PRESENTATIONS 
10th BIENNIAL CONGRESS OF THE SOUTHERN AFRICAN SOCIETY OF HUMAN 
GENETICS:  Durban, South Africa, May 2003.  Scholtz CL, Agenbag GM, Du Plessis L, Thiart R, 
De Villiers JNP, Bouwens CSH, Warnich L, Apffelstaedt J, Kotze MJ.  Molecular-genetic analysis of 
South African patients with breast cancer:  Identification of novel mutations in the BRCA1 gene.  
 
POSTER PRESENTATIONS 
18th CONGRESS OF THE SOUTH AFRICAN GENETICS SOCIETY: Stellenbosch, South Africa, 
April 2004.  Agenbag GM, Scholtz CL, Apffelstaedt J, Warnich L, Kotze MJ.  Molecular-genetic 
analysis of the BRCA1 gene in South African breast cancer patients.   
11th BIENNIAL CONGRESS OF THE SOUTHERN AFRICAN SOCIETY OF HUMAN 
GENETICS: Muldersdrift, South Africa, March 2005.  Agenbag GM, Kotze MJ, Apffelstaedt J, 
Warnich L.  Molecular-genetic analysis of the BRCA2 gene in South African breast cancer patients. 
 
 
